PATENTTI- JA REKISTERIHALLITUS
NATIONAL BOARD OF PATENTS AND REGISTRATION

PCT/FI2004/000011

10/541677

Helsinki 25.2.2004

RECEIVED
18 MAR 2004
WIPO PCT

E T U O I K E U S T O D I S T U S
P R I O R I T Y D O C U M E N T

BEST AVAILABLE COPY

Hakija Applicant	Orion Corporation Espoo
Patenttihakemus nro Patent application no	20030030
Tekemispäivä Filing date	09.01.2003
Kansainvälinen luokka International class	C07D
Keksinnön nimitys Title of invention	"New Compounds" (Uusia yhdisteitä)

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

Täten todistetaan, että oheiset asiakirjat ovat tarkkoja jäljennöksiä Patentti- ja rekisterihallitukselle alkuaan annetuista selityksestä, patenttivaatimuksista, tiivistelmästä ja piirustuksista.

This is to certify that the annexed documents are true copies of the description, claims, abstract and drawings originally filed with the Finnish Patent Office.

Marketta Tehikoski
Apulaistarkastaja

Maksu 50 EUR
Fee 50 EUR

Maksu perustuu kauppa- ja teollisuusministeriön antamaan asetukseen 1027/2001 Patentti- ja rekisterihallituksen maksullisista suoritteista muutoksineen.

The fee is based on the Decree with amendments of the Ministry of Trade and Industry No. 1027/2001 concerning the chargeable services of the National Board of Patents and Registration of Finland.

Osoite: Arkadiankatu 6 A
P.O.Box 1160
FIN-00101 Helsinki, FINLAND
Puhelin: 09 6939 500
Telephone: + 358 9 6939 500
Telefax: 09 6939 5328
Telefax: + 358 9 6939 5328

L4

NEW COMPOUNDS

Technical field

The present invention relates to new therapeutically active compounds and pharmaceutically acceptable salts and esters thereof. The invention also relates to pharmaceutical compositions containing these compounds as active ingredients. The compounds of the invention are potent inhibitors of Na^+/Ca^{2+} exchange mechanism.

Background of the invention

Na^+/Ca^{2+} exchange mechanism is one of the ion transport mechanisms that regulate the concentration of sodium and calcium ions in the cells. Compounds which selectively inhibit Na^+/Ca^{2+} exchange mechanism and thereby prevent overload of Ca^{2+} in cells are regarded useful in preventing the cell injury mechanism of cardiac muscle and the like after ischemia and reperfusion. Such compounds are useful e.g. in the treatment of ischemic diseases such as heart diseases, ischemic cerebral diseases, ischemic renal diseases and in the protection of cells during thrombolytic therapy, angioplasty, bypass operation of coronary artery or organ transplantation and arrhythmias.

Compounds capable of inhibiting Na^+/Ca^{2+} exchange system have been described earlier e.g. in patent publications WO 97/09306, EP 0978506, EP 1031556, JP 11049752 and JP 11302235.

Summary of the invention

It has now been found that compounds of formula (I) or (II) are particularly potent inhibitors of Na^+/Ca^{2+} exchange mechanism and are particularly useful in the treatment of arrhythmias.

The compounds of the present invention have a structure represented by formula (I) or (II):



wherein

X is -O-, $-CH_2-$ or -C(O)-;

Z is $-CHR_{12}-$ or a valence bond;

Y is $-CH_2-$, -C(O)-, $CH(OR_{13})-$, -O-, -S-;

provided that in case Z is a valence bond, Y is not C(O);

the dashed line represents an optional double bond in which case Z is $-CR_{12}-$ and Y is

$-CH_2-$, -C(O)- or $CH(OR_{10})-$ (in formula II) or

-CH- (in formula I);

R_2 and R_3 are independently H, lower alkyl, lower alkoxy, $-NO_2$, halogen, $-CF_3$, -OH, benzyloxy or a group of formula (IIIa)



(IIIa)

R_1 is H, CN, halogen, $-CONH_2$, -COOH, $-CH_2NH_2$, $-NHC(O)R_5$, $-NHC(NH)NHCH_3$ or, in case the compound is of formula (II) wherein the optional double bond exists or in case R_2 or R_3 is benzyloxy or a group of formula (IIIa), R_1 can also be $-NO_2$ or $-NR_{16}R_{17}$;

R_4 is H, $-NO_2$, CN, halogen, $-CONH_2$, -COOH, $-CH_2NH_2$, $-NR_{16}R_{17}$, $-NHC(O)R_5$ or $-NHC(NH)NHCH_3$;

R_5 is lower halogenalkyl, lower carboxylalkyl, $-CHR_6NR_7R_8$, or one of the following groups



W is N or CH;

Q is CHR_{14}, NR_9, S or O;

R_6 is H or lower alkyl;

R_7 and R_8 are independently H, acyl, lower alkyl or lower hydroxyalkyl;

R_9 is H, lower alkyl or phenyl;

R_{10} and R_{11} are independently H or lower alkyl;

R_{12} is H or lower alkyl;

R_{13} is H, alkylsulfonyl or acyl;

R_{14} is H, -OH, $-COOR_{15}$;

R_{15} is H or lower alkyl;

R_{16} and R_{17} are independently H, acyl, alkylsulfonyl, $-C(S)NHR_{18}$ or $-C(O)NHR_{18}$;

R_{18} is H or lower alkyl

and pharmaceutically acceptable salts and esters thereof.

In one class of preferred compounds and pharmaceutically acceptable salts and esters thereof are compounds of formula (Ib) or (IIb), wherein R1, R2, R3, X, Y and Z are as defined above.



(Ib)



(IIb)

In a subclass of preferred compounds and pharmaceutically acceptable salts and esters thereof are compounds of formula (Ic) or (IIc), wherein R1, R2, R3, X, Y and Z are as defined above.



(Ic)



(IIc)

In another class of preferred compounds and pharmaceutically acceptable salts and esters thereof are compounds of formula (I) or (II) wherein R1 is $-NHC(O)R_5$, X is O, Y is CH_2 and Z is CHR_{12}. In one subclass of preferred compounds and pharmaceutically acceptable salts and esters thereof are compounds of formula (I) or (II) wherein R1 is $-NHC(O)R_5$, X is O, Y is CH_2, Z is CH2 and R5 is $-CHR_6NR_7R_8$ or one of the following groups:



In other class of preferred compounds and pharmaceutically acceptable salts and esters thereof are compounds wherein R2 or R3 is a benzyloxy or a group of formula (IIIa)



(IIIa)

In one subclass of preferred compounds and pharmaceutically acceptable salts and esters thereof are compounds wherein R4 and R1 are NO_2.

The present invention also provides a pharmaceutical composition comprising a compound of formula (I) or (II) together with a pharmaceutically acceptable carrier.

The present invention further provides a method for inhibiting Na^+/Ca^{2+} exchange mechanism in a cell, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or (II).

The present invention further provides a method for preventing overload of Ca^{2+} ions in cells, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or (II).

The present invention further provides a method for treating arrhythmias, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I) or (II).

Brief description of the drawings

FIG. 1 shows the effects of the compounds of Examples 76, 61, 80 and 83 on the start time of fast rise of ouabain-induced aftercontractions in guinea-pig papillary muscles.

FIG. 2 shows the effects of the compounds of Examples 76, 61, 80 and 83 on the maximum heights of ouabain-induced aftercontractions in guinea-pig papillary muscles.

FIG. 3 shows the effects of the compounds of Examples 76, 61, 80 and 83 on the time to maximum heights of ouabain-induced aftercontractions in guinea-pig papillary muscles.

Detailed description of the invention

The compounds of the invention can be prepared from corresponding phenol derivatives (III), wherein R_2, R_3, X, Z and Y are the same as defined above.



(III)

The syntheses are shown in Scheme 1, wherein formula (III) is abbreviated as Ar-OH (II). Pyridin-2-yloxy derivatives (1) are obtained by reactions with suitable 2-chloropyridines (2) where R_1 can be hydrogen, nitro, cyano or halogen. The nitropyridine derivatives are reduced to corresponding amines (3).



SCHEME 1.

The aminopyridine derivatives (3) are reacted with suitable amino acids and other carboxylic acid derivatives using 1-(dimethylaminopropyl)-3-ethylacarbodiimide hydrochloride as an coupling agent to result in amide derivatives (5) as shown in the following Scheme 2 wherein R_5 is as defined above. Optionally the amide derivatives of (5) can be obtained by well-known acylation methods. Protecting groups are removed if needed.



SCHEME 2.

4-(4-methylpiperazin-1-ylmethyl)benzoic acid (9) is obtained as described in the following Scheme 3. 4-Chloromethylbenzoic acid (6) is first esterified to a methyl ester to protect an acid group in the following reaction. 4-Chloromethylbenzoic acid methyl ester (7) is then allowed to react with 1-methylpiperazine to give 4-(4-methylpiperazin-1-ylmethyl)benzoic acid methyl ester (8). Methyl ester is cleaved by heating with potassium hydroxide in methanol. 4-(4-methylpiperazin-1-ylmethyl)benzoic acid is reacted as described above in Scheme 2 with aminopyridine derivatives (3) to result in *N*-4-(4-methylpiperazin-1-ylmethyl)benzamide derivatives

of (5). By a similar manner other *N*-4-(piperazin-1-ylmethyl)benzamide derivatives of (5) can be prepared.



SCHEME 3

The 2-chloroacetamide derivatives (5') where R_5 is CH_2Cl are reacted with sodium azide to result in azide derivatives (10) which in turn are reduced to corresponding 2-aminoacetamide derivatives (11) as shown in the following Scheme 4 wherein R_7 and R_8 are as defined above. The acetamide derivatives (12) are obtained from 2-chloroacetamide derivatives (5) by reaction with various amines.



SCHEME 4

As shown in the following Scheme 5, wherein R_2 and R_3 are the same as defined above, 6- and 7-hydroxyflavane derivatives (14) are obtained from corresponding flavanones (13) by Clemmensen reduction. 6- and 7-hydroxyflavanones (13) are commercially available or can be synthesised by methods described in the literature, e.g. *J. Org Chem.*, 1960, 25, 1247-9 and *J. Org. Chem.*, 1958, 23, 1159-61 or as described later in Scheme 7.



SCHEME 5.

The following Scheme 6, wherein R_2 and R_3 are the same as defined above, describes the synthesis of 2-phenyl indan-5-ols (21). Condensation of *p*-anisaldehyde (15) with substituted phenyl acetic acid (16) gives mixture of *cis*-and *trans*-isomers of the corresponding acrylic acid (17). After hydrogenation and intramolecular Friedel-Crafts reaction carbonyl functionality of 1-indanones (19) can be reduced by Clemmensen reduction. Finally methoxy indane (20) is refluxed in concentrated hydrobromic acid to obtain 2-phenyl indan-5-ols (21).



SCHEME 6

6-Hydroxyflavanone derivatives can be synthesised as shown in Scheme 7 wherein R_{12} is as defined above. 2',5'-Dihydroxyacetophenone or corresponding propiophenone (22) is condensed with appropriate benzaldehyde (23) resulting in a mixture of desired 6-hydroxyflavanone (25) and the corresponding chalcone (24). The chalcone can be cyclised to flavanone.



SCHEME 7

2-Phenylchroman-4,6-diol derivatives (26) are obtained from corresponding 6-hydroxyflavanones (25) by reduction as shown in Scheme 8 wherein R_{12} is as defined above. These diol derivatives can be reduced further into 6-hydroxyflavanes (27).



SCHEME 8

The following Scheme 9, wherein R_2 and R_3 are the same as defined above, describes the synthesis of 7-hydroxyisoflavones (32) and 7-hydroxyisoflavans (33). Acylation of 3-methoxyphenol with substituted phenyl acetic acids gives the corresponding 2-hydroxydeoxybenzoins (30) which can be cyclised with triethyl-orthoformate to yield isoflavones (31). Deprotection with hydrobromic acid and catalytic hydrogenation gives 7-hydroxyisoflavans (33).



SCHEME 9

The following Scheme 10 describes the synthesis of 2-phenyl-2,3-dihydro-benzo[1,4]oxathiin-6-ol (37). The reaction of 2-mercaptobenzene-1,4-diol with styrene epoxide in the presence of base gives sulphide (36). The ring closure with an acid ion exchanger affords 2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-ol (37).



SCHEME 10.

The following Scheme 11 describes the synthesis of 6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-ol (42) and 6-hydroxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one (41). Pd-catalyzed α-arylation of 6-methoxy-1-tetralone (38) gives 6-methoxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one (40) which after demethylation leads to the phenolic compound (41). Reduction with triethylsilane gives 6-phenyl-5,6,7,8-tetrahydronaphthalen-2-ol (42).



SCHEME 11

The following Scheme 12, wherein R_2 and R_3 are as defined above and R is an appropiate protecting group, describes the synthesis of 2,3-dihydro-2-phenyl-benzo[1,4]dioxin-6-ols (47). After the protecting hydroxyl groups of 2,5-dihydroxy-acetophenone are removed, this ketone rearranges with peracids and gives a phenol (43) after hydrolysis. The phenol is condensed with a haloketone and after reduction and removal of protection groups the hydroxyphenol (46) is cyclised to a 2,3-dihydro-2-phenyl-benzo[1,4]-dioxin-6-ol (47).



SCHEME 12

Dihydroxyflavane derivatives (48) can be reacted with 2-chloropyridine-derivatives in a similar manner as described for compound (1) in Scheme 1. 4-Chromanol derivative of (49) where R' is OH can be reduced to corresponding flavane with triethylsilane in acidic media. 5-nitropyridine derivatives (49) are reduced to corresponding 2-aminoderivatives (50), which in turn can be acylated or mesylated or reacted with various aminoacid- or carboxylic acid derivatives as described in Scheme 2 for compound (5).



SCHEME 13

When the nitrogroup in the benzyloxyderivative (52) is reduced by hydrogenation using palladium as catalyst there are obtained [6-(5-aminopyridin-2-yloxy)-chroman-2-yl]phenol derivatives which in turn can acylated or mesylated. These phenol derivatives (56) can then be reacted with 2-chloropyridine derivatives 2 to result in derivatives like (57) as shown in the following Scheme 14. The reduction with zinc leads to amines like (53) which in turn can be acylated, mesylated or reacted with various aminoacid- or carboxylic acid derivatives as described in Scheme 2 for structure (5).



SCHEME 14

Salts and esters of the compounds, when applicable, may be prepared by known methods. Physiologically acceptable salts are useful as active medicaments. Examples are the salts with inorganic acids such as hydrochloric acid, hydrobromic acid or nitric acid, and salts with organic acids such as methanesulfonic acid, citric acid or tartaric acid. Physiologically acceptable esters are also useful as active medicaments. Examples are the esters with aliphatic or aromatic acids such as acetic acid or with aliphatic or aromatic alcohols.

The term "alkyl" as employed herein by itself or as part of another group includes both straight, branched and cyclized chain radicals of up to 18 carbon atoms,

preferably 1 to 7 carbon atoms, most preferably 1 to 4 carbon atoms. The term "lower alkyl" as employed herein by itself or as part of another group includes straight, branched and cyclized chain radicals of 1 to 7, preferably 1 to 4, most preferably 1 or 2 carbon atoms. Specific examples for the alkyl and lower alkyl residues, respectively, are methyl, ethyl, propyl, isopropyl, butyl, tert. butyl, pentyl, cyclopentyl, hexyl, cyclohexyl, octyl, decyl and dodecyl including the various branched chain isomers thereof.

The term "alkoxy" as employed herein by itself or as part of another group includes an alkyl group as defined above linked to an oxygen atom.

The term "acyl" as employed herein by itself or as part of another group refers to an alkylcarbonyl or alkenylcarbonyl group, the alkyl and alkenyl groups being defined above.

Compounds of the invention may be administered to a patient in therapeutically effective amounts which range usually from about 0.05 to 200 mg, preferably 0.1 to 100 mg, more preferably 0.5 to 50, mg per day depending on the age, weight, condition of the patient, administration route and the Na^+/Ca^{2+} exchange inhibitor used. The compounds of the invention can be formulated into dosage forms using the principles known in the art. It can be given to a patient as such or in combination with suitable pharmaceutical excipients in the form of tablets, granules, capsules, suppositories, emulsions, suspensions or solutions. Choosing suitable ingredients for the composition is a routine for those of ordinary skill in the art. It is evident that suitable carriers, solvents, gel forming ingredients, dispersion forming ingredients, antioxidants, colours, sweeteners, wetting compounds and other ingredients normally used in this field of technology may be also used. The compositions containing the active compound can be given enterally or parenterally, the oral route being the preferred way. The contents of the active compound in the composition is from about 0.5 to 100 %, preferably from about 0.5 to about 20 %, per weight of the total composition.

EXPERIMENTS

The effects of the compounds of the invention were tested on ouabain-induced arrhythmias in guinea-pig papillary muscles.

Methods

Guinea-pig papillary muscles were mounted into horizontal muscle cuvette. A hook connected to force transducer was attached to another end of the muscle. Muscle preparations were electrically paced at 1 Hz with field stimulation via platinum electrodes. Modified Tyrode solution was used for superfusion of muscle preparations. The composition of the Tyrode solution was the following (mM): NaCl 135, $MgCl_2$ x $6H_2O$ 1, KCl 5, $CaCl_2$ x $2H_2O$ 2, $NaHCO_3$ 15, Na_2HPO_4 x $2H_2O$ 1, and glucose 10. The Tyrode solution was gassed with carbogen (95% O_2, 5% CO_2) to set pH at 7.4. Experiments were carried out at 37 °C. Acquisition and analysis of twitch tensions with Action Potential and Force Measurement System (ACFO v1.0, Fision Ltd, Finland).

Inhibition of ouabain-induced arrhythmias

Ouabain by blocking of sodium-potassium ATPase increase intracellular sodium which is changed for calcium via NCX. Increased intracellular calcium is leading to overload of sarcoplasmic reticulum (SR) and spontaneous calcium release from SR inducing delayed afterpolarizations (DADs). Equivalence for DADs in force signal is aftercontractions (ACs) which are seen as spontaneous twitches after the pacing controlled twitch.

The antiarrhythmic effects of the title compounds of Examples 76, 61, 80 and 83 were examined. The results are shown in Figures 1 to 3. Figure 1 shows the effects of the compounds on the start time of fast rise of ouabain-induced aftercontractions. Figure 2 shows the effects of the compounds on the maximum heights of ouabain-induced aftercontractions in guinea-pig papillary muscles. Figure 3 shows the effects of the compounds on the time to maximum heights of ouabain-induced aftercontractions in guinea-pig papillary muscles.

In general, the compounds of the invention delayed appearance and decreased the amplitude of aftercontractions. The title compound of Example 61, at 10 μM concentration, was able to inhibit completely the emergency of ouabain-induced second aftercontraction.

EXAMPLES:

Examples 1 to 32 and 34 to 52 generally describe the preparation of intermediates of the compounds of the invention. The preparation of the compounds of the invention is generally described in Example 33 and from Example 53 onwards.

Example 1:

5-Nitro-2-(2-phenylchroman-6-yloxy)pyridine

a) 2-phenylchroman-6-ol

Zinc (5,4 g, 83,2 mmol), mercury (II) chloride (340 mg), concentrated hydrogen chloride (0,2 ml) and water were mixed at room temperature for 15 minutes and the mixture was decanted. 6-Hydroxyflavanone (1,0 g) was added as a suspension in a mixture of acetic acid (25 ml), concentrated hydrogen chloride (5,2 ml) and water (2 ml). The reaction mixture was refluxed for 1½ hours. After cooling into room temperature, the reaction mixture was filtered and the filtrate was extracted with ethyl acetate. The combined organic layers were washed with saturated $NaHCO_3$-solution, then with water and dried with Na_2SO_4. The 2-phenylchroman-6-ol was purified by column chromatography using heptane-ethyl acetate (2:1) as an eluant. ^1H NMR (400 MHz, d_6-DMSO) δ: 8.78 (s, 1H), 7.43-7.31 (m, 5H), 6.63 (d, 1H, J 8.6 Hz) 6.51 (dd, 1H, J 8.6, 2.9 Hz), 6.48 (d, 1H, J 2.9 Hz), 4.98 (dd, 1H, J, 9.9, 2.2 Hz), 2.89 (ddd, 1H, J –16.7, 11.3, 6.1 Hz), 2.63 (ddd, 1H, J –16.7, 5.5, 3.3 Hz) 2.10 (m, 1H), 1.94 (m, 1H).

b) 5-Nitro-2-(2-phenylchroman-6-yloxy)pyridine

Potassium fluoride (225 mg) was added into a solution of 2-phenylchroman-6-ol (300 mg) in dry DMF (3 ml). After stirring the resulting mixture at 120°C for 30 minutes 2-chloro-5-nitropyridine (195 mg) was added. The reaction mixture was stirred for a further 6½ hours at 120°C. After cooling into room temperature 1 M

HCl-solution was added and the mixture was extracted with ethyl acetate. The combined organic layers were washed with water then with saturated NaCl-solution and dried with Na_2SO_4. 5-Nitro-2-(2-phenylchroman-6-yloxy)-pyridine was recrystallised from acetone- 2-propanol (1:5). ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.00 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.2, 2.9 Hz), 7.47-7.32 (m, 5H), 7.20 (d, 1H, J 9.2 Hz), 7.00-6.89 (m, 3H), 5.15 (dd, 1H, J 10.1, 2.2 Hz), 2.99 (ddd, 1H, J –16.8, 11.3, 6.2 Hz), 2.75 (ddd, 1H, J –16.8, 5.4, 3.3 Hz) 2.18 (m, 1H), 2.02 (m, 1H).

Example 2:

2-[2-(4-Fluorophenyl)chroman-6-yloxyl-5-nitropyridine

a) 6-Hydroxy-2-(4-fluorophenyl)chroman-4-one

2',5'-Dihydroxyacetophenone (3,0 g) was dissolved in warm glacial acetic acid (40 ml). 4-Fluorobenzaldehyde (2,4 ml) and ammonium acetate (1,97 g) were added. The reaction mixture was refluxed for 8 hours. It was allowed to cool to room temperature and poured in ice. The precipitate formed was filtered resulting in 4,23 g of a mixture of 2-(4-fluorophenyl)-6-hydroxychroman-4-one and 1-(2,5-dihydroxy-phenyl)-3-(4-fluorophenyl)propenone. The obtained mixture was dissolved in ethanol (75 ml) and sodium acetate (3,4 g) was added. The reaction mixture was refluxed for 5 hours. It was then allowed to cool to room temperature and diluted with water and filtered. The 2-(4-fluorophenyl)-6-hydroxychroman-4-one was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.59 (m, 2H), 7.27 (m, 2H), 7.14 (d, 1H, J 3.1 Hz), 7.05 (dd, 1H, J 8.9, 3.1 Hz), 6.96 (d, 1H, J 8.9 Hz), 5.56 (dd, 1H, J 13.2, 2.8 Hz), 3.18 (dd, 1H, J –16.9, 13.2 Hz), 2.77 (dd, 1H, J –16.9, 2.8 Hz).

b) 2-(4-Fluorophenyl)chroman-4,6-diol

Into a suspension of 2-(4-fluorophenyl)-6-hydroxychroman-4-one (3,4 g) in dry THF (34 ml) was added dropwise a solution of borane-THF complex (20 ml, 1.0 M in THF) under nitrogen. The reaction mixture was refluxed for 1 hour. After cooling to the room temperature it was poured into an ice-2 M HCl-solution. 2-(4-Fluorophenyl)chroman-4,6-diol was filtered. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.84 (s, 1H), 7.48 (m, 2H), 7.21 (m, 2H), 6.89 (d, 1H, J 2.7 Hz), 6.59 (d, 1H, J 8.7 Hz), 6.54 (dd, 1H, J 8.7, 2.7 Hz), 5.42 (bs, 1H), 5.12 (d, 1H, J 10.7 Hz), 4.87 (m, 1H), 2.25 (m, 1H), 1.89 (m, 1H).

c) 2-(4-Fluorophenyl)chroman-6-ol

Triethylsilane (14 ml) was added slowly into a solution of 2-(4-fluorophenyl)chroman-4,6-diol (2,9 g) in dichloromethane (58 ml) . Trifluoroacetic acid (27 ml) was then added dropwise into a reaction mixture and it was stirred at room temperature for 1 hour. The reaction mixture was poured on ice-water and extracted with dichloromethane. The residue was evaporated under reduced pressure with toluene to obtain 2-(4-fluorophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.38 (m, 2H), 7.06 (m, 2H), 6.77 (d, 1H, J 8.6 Hz), 6.61 (dd, 1H, J 8.6, 2.9 Hz) 6.57 (d, 1H, 8.6 Hz), 4.97 (dd, 1H, J 10.2, 2.4 Hz), 2.95 (ddd, 1H, J –16.8, 11.4, 6.2 Hz), 2.74 (ddd, 1H, J –16.8, 5.3, 3.1 Hz), 2.15 (m, 1H), 2.05 (m, 1H).

d) 2-[2-(4-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(4-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 160 mg of 2-(4-fluorophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (dd, 1H, J 2.9, 0.4 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 7.51 (m, 2H), 7.24 (m, 1H), 7.20 (dd, 1H, J 9.1, 0.4 Hz), 7.01 (d, 1H, J 2.8 Hz), 6.96 (dd, 1H, J 8.7, 2.8 Hz) 6.91 (d, 1H, 8.7 Hz), 5.15 (dd, 1H, J 10.3, 2.2 Hz), 2.94 (m, 1H), 2.76 (m, 1H) 2.17 (m, 1H), 2.01 (m, 1H).

Example 3:

2-[2-(3-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(3-Fluorophenyl)-6-hydroxychroman-4-one

2-(3-Fluorophenyl)-6-hydroxychroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a) starting from 2',5'-dihydroxyacetophenone (1.50 g) and 3-fluorobenzaldehyde (1.35 g). The 2-(3-fluorophenyl)-6-hydroxychroman-4-one was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.45 (s, 1H), 7.47 (m, 1H), 7.40-7.37 (m, 2H), 7.22 (m, 1H), 7.12 (d, 1H, J 3.0 Hz), 7.05 (dd, 1H, J 8.8, 3.0 Hz), 6.98 (d, 1H, J 8.8 Hz), 5.59 (dd, 1H, J 13.0, 2.9 Hz), 3.21 (dd, 1H, J –16.9, 13.0 Hz), 2.82 (dd, 1H, J –16.9, 2.9 Hz).

b) 2-(3-Fluorophenyl)chroman-4,6-diol

2-(3-Fluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 220 mg of 2-(3-fluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 7.45 (m, 1H), 7.30-7.25 (m, 2H), 7.15 (m, 1H), 6.88 (d, 1H, J 2.8 Hz), 6.62 (d, 1H, J 8.7 Hz), 6.55 (dd, 1H, J 8.7, 2.8 Hz), 5.44 (d, 1H, J 7.0 Hz), 5.15 (d, 1H, J 10.7 Hz), 4.86 (m, 1H), 2.29 (m, 1H), 1.86 (m, 1H).

c) 2-(3-Fluorophenyl)chroman-6-ol

2-(3-Fluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(b) starting from 195 mg of 2-(3-fluorophenyl)-chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.78 (s, 1H), 7.43 (m, 1H), 7.28-7.25 (m, 2H), 7.14 (m, 1H), 6.66 (d, 1H, J 8.5 Hz) 6.52 (dd, 1H, J 8.5, 2.7 Hz), 6.49 (d, 1H, J 2.7 Hz), 5.03 (dd, 1H, J 9.9, 2.1 Hz), 2.86 (m, 1H), 2.63 (m, 1H) 2.13 (m, 1H), 1.93 (m, 1H).

d) 2-[2-(3-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 210 mg of 2-(3-fluorophenyl)chroman-6-ol. The product was recrystallised from 2-propanol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.07 (d, 1H, J 2.8 Hz), 8.46 (dd, 1H, J 9.0, 2.8 Hz), 7.36 (m, 1H), 7.21-7.15 (m, 2H), 7.03 (m, 1H), 7.01 (d, 1H, J 9.0 Hz), 6.98 (d, 1H, J 8.6 Hz) 6.92 (dd, 1H, J 8.6, 2.7 Hz), 6.90 (d, 1H, J 2.7 Hz), 5.09 (dd, 1H, J 10.3, 2.4 Hz), 3.01 (ddd, 1H, J –16.9, 11.4, 6.0 Hz), 2.82 (ddd, 1H, J – 16.9, 5.1, 3.2 Hz) 2.24 (m, 1H), 2.09 (m, 1H).

Example 4:

2-[2-(2-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(2-Fluorophenyl)-6-hydroxychroman-4-one

2-(2-Fluorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 2.0 g of

2',5'-dihydroxyacetophenone and 1.4 ml of 2-fluorobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.45 (s, 1H), 7.67 (m, 1H), 7.47 (m, 1H), 7.32-7.25 (m, 2H), 7.14 (d, 1H, J 3.0 Hz), 7.04 (dd, 1H, J 8.9, 3.0 Hz), 6.95 (d, 1H, J 8.9 Hz), 5.77 (dd, 1H, J 13.5, 2.8 Hz), 3.26 (dd, 1H, J –16.9, 13.5 Hz), 2.76 (dd, 1H, J –16.9, 2.8 Hz).

b) 2-(2-Fluorophenyl)chroman-4,6-diol

2-(2-Fluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1.19 g of 2-(2-fluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 7.56 (m, 1H), 7.40 (m, 1H), 7.28-7.21 (m, 2H), 6.89 (d, 1H, J 2.9 Hz), 6.60 (d, 1H, J 8.7 Hz), 6.54 (dd, 1H, J 8.7, 2.8 Hz), 5.46 (d, 1H, J 6.9 Hz), 5.35 (d, 1H, J 10.6 Hz), 4.89 (m, 1H), 2.26 (m, 1H), 1.98 (m, 1H).

c) 2-(2-Fluorophenyl)chroman-6-ol

2-(2-Fluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 800 mg of 2-(2-fluorophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 7.50 (m, 1H), 7.39 (m, 1H), 7.26-7.19 (m, 2H), 6.63 (m, 1H) 6.53-6.50 (m, 2H), 5.21 (dd, 1H, J, 10.2, 2.3 Hz), 2.98 (ddd, 1H, J -16.9, 11.2, 6.0 Hz), 2.66 (ddd, 1H, J –16.9, 5.0, 2.9 Hz) 2.11 (m, 1H), 1.99 (m, 1H).

d) 2-[2-(2-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2-Fluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 390 mg of 2-(2-fluorophenyl)chroman-6-ol. The product was purified by column chromatography using heptane- ethyl acetate (4:1) as an eluant. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.04 (d, 1H, J 2.8 Hz), 8.60 (dd, 1H, J 9.1, 2.8 Hz), 7.56 (m, 1H), 7.43 (m, 1H), 7.30-7.22 (m, 2H), 7.20 (d, 1H, J 9.1 Hz), 7.02 (d, 1H, J 2.8 Hz) 6.98 (dd, 1H, J 8.7, 2.8 Hz), 6.91 (d, 1H, J 8.7 Hz), 5.37 (dd, 1H, J 10.4, 2.3 Hz), 3.04 (ddd, 1H, J –17.0, 11.5, 6.0 Hz), 2.82 (ddd, 1H, J –17.0, 5.1, 2.8 Hz) 2.18 (m, 1H), 2.08 (m, 1H).

Example 5:

2-[2-(2,3-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(2,3-Difluorophenyl)-6-hydroxychroman-4-one

2-(2,3-Difluorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 2.6 ml of 2,3-difluorobenzaldehyde. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.51 (s, 1H), 7.53-7.46 (m, 2H), 7.31 (m, 1H), 7.14 (d, 1H, J 3.0 Hz), 7.05 (dd, 1H, J 8.8, 3.0 Hz), 6.96 (d, 1H, J 8.8 Hz), 5.82 (dd, 1H, J 13.4, 2.8 Hz), 3.26 (dd, 1H, J –16.9, 13.4 Hz), 2.79 (dd, 1H, J –16.9, 2.8 Hz).

b) 2-(2,3-Difluorophenyl)chroman-4,6-diol

2-(2,3-Difluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluoro)phenylchroman-4,6-diol in Example 2(b) starting from 2.91 g of 2-(2,3-difluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.88 (s, 1H), 7.45-7.36 (m, 2H), 7.28 (m, 1H), 6.89 (d, 1H, J 2.8 Hz), 6.61 (d, 1H, J 8.7 Hz), 6.55 (dd, 1H, J 8.7, 2.8 Hz), 5.49 (bs, 1H), 5.40 (dd, 1H, J 11.8, 1.4 Hz), 4.90 (m, 1H), 2.28 (m, 1H), 1.99 (m, 1H).

c) 2-(2,3-Difluorophenyl)chroman-6-ol

2-(2,3-Difluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 1.5 g of 2-(2,3-difluorophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 7.41 (m, 1H), 7.33 (m, 1H), 7.26 (m, 1H), 6.64 (dd, 1H, 9.0, 2.8 Hz), 6.54-6.51 (m, 2H), 5.25 (dd, 1H, J 10.2, 2.2 Hz), 2.93 (m, 1H), 2.66 (m, 1H), 2.14 (m, 1H), 2.01 (m, 1H).

d) 2-[2-(2,3-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2,3-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 1.88 g of 2-(2,3-difluorophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 3.0 Hz), 8.60 (dd, 1H, J 9.1, 3.0 Hz), 7.45 (m, 1H), 7.38 (m, 1H), 7.30 (m, 1H), 7.21 (d, 1H, 9.1Hz), 7.03 (d, 1H, J 2.7 Hz), 6.98 (dd, 1H, J 8.8, 2.7

Hz), 6.92 (d, 1H, 8.8 Hz), 5.42 (dd, 1H, J 10.4, 2.3 Hz), 3.04 (m, 1H), 2.79 (m, 1H) 2.21 (m, 1H), 2.08 (m, 1H).

Example 6:

2-[2-(2,4-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(2,4-Difluorophenyl)-6-hydroxychroman-4-one

2-(2,4-Difluorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 1,6 ml of 2,4-difluorobenzaldehyde. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.46 (s, 1H), 7.73 (m, 1H), 7.34 (m, 1H), 7.19 (m, 1H), 7.13 (d, 1H, J 2.9 Hz), 7.04 (dd, 1H, J 8.8, 2.9 Hz), 6.95 (d, 1H, J 8.8 Hz), 5.74 (dd, 1H, J 13.5, 2.8 Hz), 3.28 (dd, 1H, J –16.9, 13.5 Hz), 2.74 (dd, 1H, J –16.9, 2.8 Hz).

b) 2-(2,4-Difluorophenyl)chroman-4,6-diol

2-(2,4-Difluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1,47 g of 2-(2,4-difluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.86 (s, 1H), 7.61 (m, 1H), 7.28 (m, 1H), 7.14 (m, 1H), 6.88 (d, 1H, J 2.7 Hz), 6.59 (d, 1H, J 8.9 Hz), 6.54 (dd, 1H, J 8.9, 2.7 Hz), 5.46 (s, 1H), 5.32 (dd, 1H, J 11.9, 1.4 Hz), 4.88 (m, 1H), 2.24 (m, 1H), 1.99 (m, 1H).

c) 2-(2,4-Difluorophenyl)chroman-6-ol

2-(2,4-Difluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 800 mg of 2-(2,4-difluorophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.83 (s, 1H), 7.56 (m, 1H), 7.28 (m, 1H), 7.13 (m, 1H), 6.63 (m, 1H), 6.53-6.50 (m, 2H), 5.17 (dd, 1H, J 10.3, 2.3 Hz), 2.92 (ddd, 1H, J –17.0, 11.5, 5.8 Hz), 2.66 (ddd, 1H, J –17.0, 5.0, 2.7 Hz), 2.09 (m, 1H), 1.98 (m, 1H).

d) 2-[2-(2,4-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2,4-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 720 mg of 2-(2,4-difluorophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6 - DMSO) δ: 9.04 (d, 1H, J 3.0 Hz), 8.60 (dd, 1H, J 9.0, 3.0 Hz), 7.61 (m, 1H), 7.31 (m, 1H), 7.21 (d, 1H, 9.0Hz), 7.17 (m, 1H) 7.02 (d, 1H, J 2.9 Hz), 6.97 (dd, 1H, J 8.9, 2.9 Hz), 6.91 (d, 1H, 8.9 Hz), 5.34 (dd, 1H, J 9.9, 2.0 Hz), 3.03 (m, 1H), 2.78 (m, 1H) 2.17 (m, 1H), 2.07 (m, 1H).

Example 7:

2-[2-(2,5-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(2,5-Difluorophenyl)-6-hydroxychroman-4-one

2-(2,5-Difluorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 2.57 ml of 2,5-difluorobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.46 (s, 1H), 7.53 (m, 1H), 7.36-7.30 (m, 2H), 7.14 (d, 1H, J 3.0 Hz), 7.05 (dd, 1H, J 8.8, 3.0 Hz), 6.97 (d, 1H, J 8.8 Hz), 5.76 (dd, 1H, J 13.6, 2.7 Hz), 3.26 (dd, 1H, J –16.8, 13.6 Hz), 2.76 (dd, 1H, J –16.8, 2.7 Hz).

b) 2-(2,5-Difluorophenyl)chroman-4,6-diol

2-(2,5-Difluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1.0 g of 2-(2,5-difluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.87 (s, 1H), 7.39-7.22 (m, 3H), 6.89 (d, 1H, J 2.8 Hz), 6.63 (d, 1H, J 8.7 Hz), 6.56 (dd, 1H, J 8.7, 2.8 Hz), 5.50 (d, 1H, J 6.8 Hz), 5.35 (d, 1H, J 11.2 Hz), 4.89 (m, 1H), 2.28 (m, 1H), 1.95 (m, 1H).

c) 2-(2,5-Difluorophenyl)chroman-6-ol

2-(2,5-Difluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 420 mg of 2-(2,5-difluorophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.82 (s, 1H),

7.34-7.22 (m, 3H), 6.71-6.51 (m, 3H), 5.20 (m, 1H), 2.93 (m, 1H,), 2.68 (m, 1H), 2.11 (m, 1H), 1.98 (m, 1H).

d) 2-[2-(2,5-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2,5-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 100 mg of 2-(2,5-difluorophenyl)chroman-6-ol. The product was recrystallised from 2-propanol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.07 (dd, 1H, J 2.8, 0.4 Hz), 8.47 (dd, 1H, J 9.1, 2.8 Hz), 7.26 (m, 1H), 7.05-6.91 (m, 6H), 5.35 (dd, 1H, J 10.3, 1.5 Hz), 3.04 (ddd, 1H, J –16.9, 11.7, 6.0 Hz), 2.82 (ddd, 1H, J –16.9, 5.2, 3.0 Hz) 2.29 (m, 1H), 2.01 (m, 1H).

Example 8:

2-[2-(2,6-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 6-Hydroxy-2-(2,6-difluorophenyl)chroman-4-one

6-Hydroxy-2-(2,6-Difluorophenyl)chroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 2.6 ml of 2,6-difluorobenzaldehyde. The product was triturated from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.55 (m, 1H) 7.22-7.18 (m, 2H), 7.14 (d, 1H, J 3.0 Hz), 7.03 (dd, 1H, J 8.9, 3.0 Hz), 6.93 (d, 1H, J 8.9 Hz), 5.84 (dd, 1H, J 14.0, 3.0 Hz), 3.38 (dd, 1H, J –17.0, 14.0 Hz), 2.80 (dd, 1H, J –17.0, 3.0 Hz).

b) 2-(2,6-Difluorophenyl)chroman-4,6-diol

2-(2,6-Difluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 4.45 g of 2-(2,6-difluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.87 (s, 1H), 7.48 (m, 1H), 7.17-7.13 (m, 2H), 6.90 (d, 1H, J 2.9 Hz), 6.55-6.54 (m, 2H), 5.46 (dd, 1H, J 12.2, 1.8 Hz), 4.87 (m, 1H), 2.37 (m, 1H), 2.23 (m, 1H).

c) 2-(2,6-Difluorophenyl)chroman-6-ol

2-(2,6-Difluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 1,5 g of 2-(2,6-difluorophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 7.41 (m, 1H), 7.33 (m, 1h), 7.26 (m, 1H), 6.64 (dd, 1H, J 9.0, 2.8 Hz), 6.54-6.51 (m, 2H), 5.25 (dd, 1H, J 10.2, 2.2 Hz), 2.93 (m, 1H,), 2.66 (m, 1H), 2.14 (m, 1H), 2.01 (m, 1H).

d) 2-[2-(2,6-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2,6-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 1,8 g of 2-(2,6-difluorophenyl)chroman-6-ol. The product was recrystallised from 2-propanol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.04 (d, 1H, J 3.0 Hz), 8.60 (dd, 1H, J 9.1, 3.0 Hz), 7.45 (m, 1H), 7.38 (m, 1H), 7.30 (m, 1H), 7.21 (d, 1H, J 9.1 Hz), 7.03 (d, 1H, J 2.7 Hz), 6.98 (dd, 1H, J 8.8, 2.7 Hz) 6.92 (d, 1H, J 8.8 Hz), 5.42 (dd, 1H, J 10.4, 2.3 Hz), 3.04 (m, 1H), 2.79 (m, 1H) 2.21 (m, 1H), 2.08 (m, 1H).

Example 9:

2-[2-(3,5-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(3,5-Difluorophenyl)-6-hydroxychroman-4-one

2-(3,5-Difluorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 1.0 g of 2',5'-dihydroxyacetophenone and 1.12 g of 3,5-difluorobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.47 (s, 1H), 7.30-7.23 (m, 3H), 7.12 (d, 1H, J 2.9 Hz), 7.06 (dd, 1H, J 8.8, 2.9 Hz), 7.00 (d, 1H, J 8.8 Hz), 5.60 (dd, 1H, J 13.1, 2.8 Hz), 3.15 (dd, 1H, J –16.8, 13.1 Hz), 2.85 (dd, 1H, J –16.8, 2.8 Hz).

b) 2-(3,5-Difluorophenyl)chroman-4,6-diol

2-(3,5-Difluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 800 mg of 2-(3,5-difluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.87 (s, 1H), 7.21-7.17 (m, 3H), 6.88 (d, 1H, J 2.4 Hz), 6.64 (d, 1H, J 8.7 Hz), 6.55 (dd,

1H, J 2.4, 8.7 Hz), 5.47 (d, 1H, J 7.0 Hz), 5.17 (d, 1H, J 10.5 Hz), 4.86 (m, 1H), 2.32 (m, 1H), 1.85 (m, 1H).

c) 2-(3,5-Difluorophenyl)chroman-6-ol

2-(3,5-Difluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 500 mg of 2-(3,5-difluorophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.82 (s, 1H), 7.20-7.14 (m, 3H), 6.68 (d, 1H, J 8.6 Hz), 6.53 (d, 1H, J 2.9 Hz), 6.50 (dd, 1H, J 8.6, 2.9 Hz), 5.05 (dd, 1H, J 9.8, 2.2 Hz), 2.88 (ddd, 1H, J -16.7, 10.8, 5.9 Hz), 2.62 (ddd, 1H, J -16.7, 8.9, 5.0 Hz), 2.15 (m, 1H), 1.93 (m, 1H).

d) 2-[2-(3,5-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3,5-Difluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 340 mg of 2-(3,5-difluorophenyl)chroman-6-ol. The product was purified on preparative TLC-plate covered with silica gel using toluene - ethyl acetate as an eluant and then crystallised from 2-propanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 7.23-7.19 (m, 4H), 7.01-6.95 (m, 3H), 5.18 (dd, 1H, J 10.0, 2.1 Hz), 2.97 (ddd, 1H, J –16.9, 10.9, 5.7 Hz), 2.76 (ddd, 1H, J –16.9, 8.4, 4.7 Hz) 2.22 (m, 1H), 1.99 (m, 1H).

Example 10:

5-Nitro-2-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridine

a) 6-Hydroxy-2-(2-trifluoromethylphenyl)chroman-4-one

6-Hydroxy-2-(2-trifluoromethylphenyl)chroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 3.0 ml of 2-trifluoromethylbenzaldehyde. The product was triturated from ethanol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.48 (s, 1H), 8.07 (m, 1H,) 7.86-7.79 (m, 2H), 7.66 (m, 1H), 7.15 (d, 1H, J 3.0 Hz), 7.06 (dd, 1H, J 8.8, 3.0 Hz), 6.95 (d, 1H, J 8.8 Hz), 5.70 (dd, 1H, J 13.8, 2.4 Hz), 3.38 (dd, 1H, J –16.9, 13.8 Hz), 2.66 (dd, 1H, J –16.9, 3.0 Hz).

b) 2-(2-Trifluoromethylphenyl)chroman-4,6-diol

2-(2-Trifluoromethylophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1.43 g of 2-(2-trifluoromethylphenyl)-6-hydroxychroman-4-one. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.89 (s, 1H), 7.83 (m, 1H), 7.79-7.74 (m, 2H), 7.58 (m, 1H), 6.90 (d, 1H, J 2.7 Hz), 6.61 (d, 1H, J 8.9 Hz), 6.56 (dd, 1H, J 8.7, 2.7 Hz), 5.51 (d, 1H, J 6.5 Hz), 5.34 (d, 1H, J 11.6 Hz), 4.88 (m, 1H), 2.21 (m, 1H), 1.95 (m, 1H).

c) 2-(2-Trifluoromethylphenyl)chroman-6-ol

2-(2-Trifluoromethyl phenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 800 mg of 2-(2-trifluoromethylphenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.86 (s, 1H), 7.81-7.75 (m, 3H), 7.57 (m, 1H), 6.674 (dd, 1H, J 7.1, 2.1 Hz), 6.54-6.51 (m, 2H), 5.14 (d, 1H, J 10.5 Hz), 2.95 (m, 1H), 2.72 (m, 1H), 2.05 (m, 1H), 1.96 (m, 1H).

d) 2-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 680 mg of 2-(2-trifluoromethylphenyl)chroman-6-ol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.2, 2.9 Hz), 7.86-7.76 (m, 3H), 7.60 (m, 1H), 7.22 (d, 1H, J 9.2 Hz) 7.05 (d, 1H, J 2.7 Hz), 6.99 (dd, 1H, J 8.7, 2.7 Hz), 6.91 (d, 1H, 8.7 Hz), 5.30 (d, 1H, J 10.0, Hz), 3.05 (m, 1H), 2.84 (m, 1H) 2.16-2.00 (m, 2H),.

Example 11:

5-Nitro-2-[2-(4-trifluoromethylphenyl)chroman-6-yloxylpyridine

a) 6-Hydroxy-2-(4-trifluoromethylphenyl)chroman-4-one

6-Hydroxy-2-(4-trifluoromethylphenyl)chroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 2,0 g of 2',5'-dihydroxyacetophenone and 2,1 ml of 4-trifluoromethylbenzaldehyde. The product was purified by column chromatography using heptane-ethyl acetate

(2:1) as an eluant. Further purification was carried out by column chromatography using toluene-ethyl acetate (4:1) as an eluant. Finally the product was crystallised from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.47 (s, 1H), 7.82-7.76 (m, 4H), 7.13 (d, 1H, J 3.0 Hz), 7.06 (dd, 1H, J 8.8, 3.0 Hz), 6.99 (d, 1H, J 8.8 Hz), 5.70 (dd, 1H, J 12.9, 2.9 Hz), 3.16 (dd, 1H, J –16.9, 12.9 Hz), 2.86 (dd, 1H, J –16.9, 2.9 Hz).

b) 2-(4-Trifluoromethylphenyl)chroman-4,6-diol

2-(4-Trifluoromethylphenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 860 mg of 2-(4-trifluoromethylphenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.86 (s, 1H), 7.77 (d, 2H, J 8.3 Hz), 7.68 (d, 2H, J 8.3 Hz), 6.89 (d, 1H, J 2.9 Hz), 6.63 (d, 1H, J 8.7 Hz), 6.56 (dd, 1H, J 8.7, 2.9 Hz), 5.45 (d, 1H, J 7.0 Hz), 5.26 (d, 1H, J 11.2 Hz), 4.90 (m, 1H), 2.32 (m, 1H), 1.85 (m, 1H).

c) 2-(4-Trifluoromethylphenyl)chroman-6-ol

2-(4-Trifluoromethyl phenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 730 mg of 2-(4-trifluoromethylphenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.82 (s, 1H), 7.75 (d, 2H, J 8.3 Hz), 7.65 (d, 2H, J 8.3 Hz), 6.67 (d, 1H, J 8.6 Hz), 6.53 (d, 1H, J 2.9 Hz) 6.51 (dd, 1H, 8.6, 2.9 Hz), 5.12 (d, 1H, J 8.3 Hz), 2.90 (m, 1H), 2.63 (m, 1H), 2.16 (m, 1H), 1.92 (m, 1H).

d) 2-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 605 mg of 2-(4-trifluoromethylphenyl)chroman-6-ol. The product was purified column chromatography using 1,5 % ethyl acetate in toluene as an eluant and then crystallised from a mixture of 2-propanol and acetone. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 7.79 (d, 2H, J 8.2 Hz), 7.70 (d, 1H, J 8.2 Hz), 7.21 (d, 1H, J 9.1 Hz) 7.01 (dd, 1H, J 8.7, 2.7 Hz) 6.98 (d, 1H, J 2.7 Hz), 6.95 (d, 1H, 8.7 Hz), 5.29 (dd, 1H, J 10.1, 2.0 Hz), 3.00 (ddd, 1H, J –16.9, 10.1, 5.8 Hz), 2.4 (ddd, 1H, J –16.9, 8.4, 4.5 Hz) 2.24 (m, 1H), 1.99 (m, 1H).

Example 12:

2-[2-(3-Chloro-4-fluorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(3-Chloro-4-fluorophenyl)-6-hydroxychroman-4-one

2-(3-Chloro-4-fluorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 3.8 g of 3-chloro-4-fluorobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.45 (s, 1H), 7.53 (m, 1H), 7.36-7.31 (m, 2H), 7.13 (d, 1H, J 3.0 Hz), 7.05 (dd, 1H, J 8.9, 3.0 Hz), 6.96 (d, 1H, J 8.9 Hz), 5.76 (dd, 1H, J 13.5, 2.7 Hz), 3.26 (dd, 1H, J –16.9, 13.5 Hz), 2.75 (dd, 1H, J –16.9, 2.7 Hz).

b) 2-(3-Chloro-4-fluorophenyl)chroman-4,6-diol

2-(3-Chloro-4-fluorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 5.5 g of 2-(3-chloro-4-fluorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.88 (s, 1H), 7.39-7.24 (m, 3H), 6.88 (d, 1H, J 2.8 Hz), 6.63 (d, 1H, J 8.7 Hz), 6.55 (dd, 1H, J 8.7, 2.8 Hz), 5.49 (d, 1H, J 6.8 Hz), 5.35 (d, 1H, J 11.3 Hz), 4.89 (m, 1H), 2.39 (m, 1H), 1.97 (m, 1H).

c) 2-(3-Chloro-4-fluorophenyl)chroman-6-ol

2-(3-Chloro-4-fluorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 5.0g of 2-(3-Chloro-4-fluorophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.84 (s, 1H), 7.33-7.21 (m, 3H), 6.66 (d, 1H, J 8.3 Hz) 6.54-6.51 (m, 2H), 5.19 (d, 1H, J, 8.8 Hz), 2.92 (m, 1H), 2.66 (m, 1H) 2.12 (m, 1H), 1.96 (m, 1H).

d) 2-[2-(3-Chloro-4-fluorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3-Chloro-4-fluorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 5.0 g of 2-(3-chloro-4-fluorophenyl)chroman-6-ol. The product was purified by passing through silica gel column using heptane- ethyl acetate (1:2)

as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 7.40-7.27 (m, 3H), 7.21 (d, 1H, J 9.1 Hz), 7.03 (d, 1H, J 2.7 Hz) 6.98 (dd, 1H, J 8.8, 2.7 Hz), 6.94 (d, 1H, J 8.8 Hz), 5.36 (dd, 1H, J 10.7, 2.1 Hz), 3.04 (m, 1H), 2.80 (m, 1H) 2.18 (m, 1H), 1.99 (m, 1H).

Example 13:

2-[2-(2-Chlorophenyl)chroman-6-yloxyl-5-nitropyridine

a) 2-(2-Chlorophenyl)-6-hydroxychroman-4-one

2-(2-Chlorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 2.8 g of 2-chlorobenzaldehyde. The product was passed though silica gel using heptane - ethyl acetate as an eluant and then triturated with ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.49 (s, 1H), 7.77 (dd, 1H, J 7.7, 2.0 Hz), 7.53 (dd, 1H, J 7.6, 1.8 Hz), 7.49-7.41 (m, 2H), 7.14 (d, 1H, J 2.9 Hz), 7.06 (dd, 1H, J 8.8, 2.9 Hz), 6.93 (d, 1H, J 8.8 Hz), 5.78 (dd, 1H, J 13.6, 2.6 Hz), 3.19 (dd, 1H, J –16.9, 13.6 Hz), 2.78 (dd, 1H, J –16.9, 2.6 Hz).

b) 2-(2-Chlorophenyl)chroman-4,6-diol

2-(2-Chlorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1.12 g of 2-(2-chlorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.63 (dd, 1H, J 7.7, 1.8 Hz), 7.49 (dd, 1H, J 7.8, 1.4 Hz), 7.45-7.36 (m, 2H), 6.89 (d, 1H, J 2.9 Hz), 6.63 (d, 1H, J 8.8 Hz), 6.56 (dd, 1H, J 8.9, 2.9 Hz), 5.39 (dd, 1H, J 11.7, 1.5 Hz), 4.90 (m, 1H), 2.33 (m, 1H), 1.82 (m, 1H).

c) 2-(2-Chlorophenyl)chroman-6-ol

2-(2-Chlorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 500 mg of 2-(2-chlorophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 7.58-7.36 (m, 4H), 6.66 (m, 1H), 6.55-6.51 (m, 2H), 5.23 (dd, 1H, J 10.1, 2.1 Hz), 2.92 (m, 1H), 2.68 (m, 1H), 2.17 (m, 1H), 1.87 (m, 1H).

d) 2-[2-(2-Chlorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2-Chlorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 485 mg of 2-(2-chlorophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9, 0.5 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 7.62 (dd, 1H, J 7.5, 1.8 Hz), 7.51 (dd, 1H, J 7.6, 1.7 Hz), 7.45-7.40 (m, 2H), 7.21 (dd, 1H, J 9.1, 0.5 Hz), 7.04 (d, 1H, J 2.7 Hz), 6.99 (dd, 1H, J 8.8, 2.7 Hz), 6.94 (d, 1H, 8.8 Hz), 5.40 (dd, 1H, J 10.4, 2.1 Hz), 3.04 (m, 1H), 2.80 (m, 1H) 2.24 (m, 1H), 1.95 (m, 1H).

Example 14:

2-[2-(3-Chlorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(3-Chlorophenyl)-6-hydroxychroman-4-one

2-(3-Chlorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 2.0 g of 2',5'-dihydroxyacetophenone and 1.85 g of 3-chlorobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.47 (s, 1H), 7.62 (s, 1H), 7.51-7.45 (m, 3H), 7.12 (d, 1H, J 3.0 Hz), 7.05 (dd, 1H, J 8.8, 3.0 Hz), 6.98 (d, 1H, J 8.8 Hz), 5.58 (dd, 1H, J 13.1, 2.9 Hz), 3.18 (dd, 1H, J –16.9, 13.1 Hz), 2.81 (dd, 1H, J –16.9, 2.9 Hz).

b) 2-(3-Chlorophenyl)chroman-4,6-diol

2-(3-Chlorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 730 mg of 2-(3-chlorophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 7.50 (d, 1H, J 1.7 Hz), 7.46-7.38 (m, 3H), 6.88 (d, 1H, J 2.5 Hz), 6.62 (d, 1H, J 8.6 Hz), 6.55 (dd, 1H, J 8.6, 2.5 Hz), 5.44 (d, 1H, J 6.6 Hz), 5.15 (dd, 1H, J 11.8, 1.4 Hz), 4.87 (m, 1H), 2.29 (m, 1H), 1.85 (m, 1H).

c) 2-(3-Chlorophenyl)chroman-6-ol

2-(3-Chlorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 635 mg of 2-(3-

chlorophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.79 (s, 1H), 7.48 (d, 1H, J 0.7 Hz), 7.42-7.37 (m, 3H), 6.71-6.49 (m, 3H), 5.04 (m, 1H), 2.91 (m, 1H), 2.65 (m, 1H), 2.12 (m, 1H), 1.93 (m, 1H).

d) 2-[2-(3-Chlorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3-Chlorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 590 mg of 2-(3-chlorophenyl)chroman-6-ol. The product was recrystallised from a 3:1 mixture of 2-propanol and ethyl acetate. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.0, 2.9 Hz), 7.53 (s, 1H), 7.46-7.42 (m, 3H), 7.20 (d, 1H, J 9.0 Hz) 7.00 (dd, 1H, J 8.7, 2.7 Hz), 6.97 (d, 1H, J 2.7 Hz), 6.94 (d, 1H, J 8.7 Hz), 5.18 (dd, 1H, J 10.2, 2.2 Hz), 2.97 (ddd, 1H, J –17.0, 11.5, 5.9 Hz), 2.83 (ddd, 1H, J –17.0, 8.1, 4.5 Hz) 2.21 (m, 1H), 2.00 (m, 1H).

Example 15:

2-[2-(2,4-Dichlorophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(2,4-Dichlorophenyl)-6-hydroxychroman-4-one

2-(2,4-Dichlorophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 1.0 g of 2',5'-dihydroxyacetophenone and 1.4 g of 2,4-dichlorobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.49 (s, 1H), 7.78 (d, 1H, J 8.5 Hz), 7.71(d, 1H, J 2.0 Hz)), 7.57 (dd, 1H, J 8.5, 2.0 Hz), 7.14 (d, 1H, J 3.0 Hz), 7.06 (dd, 1H, J 8.8, 3.0 Hz), 6.97 (d, 1H, J 8.8 Hz), 5.77 (dd, 1H, J 13.5, 2.7 Hz), 3.18 (dd, 1H, J –16.9, 13.5 Hz), 2.78 (dd, 1H, J –16.9, 2.7 Hz).

b) 2-(2,4-Dichlorophenyl)chroman-4,6-diol

2-(2,4-Dichlorophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1.2 g of 2-(2,4-dichlorophenyl)-6-hydroxychroman-4-one. The product was purified by column chromatography using heptane - ethyl acetate (2:1) as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.89 (s, 1H), 7.66 (d, 1H, J 2.1 Hz), 7.64 (d, 1H, J 8.5 Hz), 7.51 (dd, 1H, J 2.1, 8.5 Hz), 6.89 (d, 1H, J 2.7 Hz), 6.63 (d, 1H, J 8.7 Hz), 6.56 (dd, 1H, J 2.7,

8.7 Hz), 5.50 (d, 1H, J 6.8 Hz), 5.37 (d, 1H, J 10.4 Hz), 4.90 (m, 1H), 2.32 (m, 1H), 1.80 (m, 1H).

c) 2-(2,4-Dichlorophenyl)chroman-6-ol

2-(2,4-Dichlorophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 625 mg of 2-(2,4-dichlorophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 7.65 (d, 1H, J 2.2 Hz), 7.57 (d, 1H, J 8.4 Hz), 7.49 (dd, 1H, J 8.4, 2.2 Hz), 6.67-6.51 (m, 3H), 5.21 (dd, 1H, J 10.3, 2.1 Hz), 2.91 (m, 1H), 2.69 (m, 1H), 2.16 (m, 1H), 1.85 (m, 1H).

d) 2-[2-(2,4-Dichlorophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 530 mg of 2-(2,4-dichlorophenyl)chroman-6-ol. The product was purified on preparative TLC-plate covered with silica gel using heptane - ethyl acetate (3:1) as an eluant. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.06 (d, 1H, J 2.7 Hz), 8.47 (dd, 1H, J 9.0, 2.7 Hz), 7.56 (d, 1H, J 8.4 Hz), 7.41 (d, 1H, J 2.0 Hz), 7.33 (dd, 1H, J 8.4, 2.0 Hz) 7.02 (d, 1H, J 9.0 Hz) 6.99-6.92 (m, 3H), 5.39 (dd, 1H, J 10.4, 2.2 Hz), 3.06 (ddd, 1H, J –16.9, 11.9, 6.0 Hz), 2.83 (ddd, 1H, J –16.9, 5.3, 2.7 Hz) 2.34 (m, 1H), 1.89 (m, 1H).

Example 16:

2-[2-(3-Bromophenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(3-Bromophenyl)-6-hydroxychroman-4-one

2-(3-Bromophenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 3.0 g of 2',5'-dihydroxyacetophenone and 2.3 ml of 3-bromobenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.41 (s, 1H), 7.50 (m, 1H), 7.59-7.53 (m, 2H), 7.39 (m, 1H) 7.12 (d, 1H, J 2.9 Hz), 7.05 (dd, 1H, J 8.8, 2.9 Hz), 6.98 (d, 1H, J 8.8 Hz), 5.57 (dd, 1H, J 13.0, 2.9 Hz), 3.12 (dd, 1H, J –16.9, 13.0 Hz), 2.81 (dd, 1H, J –16.9, 2.9 Hz).

b) 2-(3-Bromo-phenyl)-chroman-4,6-diol

2-(3-Bromophenyl)-chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 1.0 g of 2-(3-bromophenyl)-6-hydroxychroman-4-one. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.83 (s, 1H), 7.63 (m, 1H) 7.53 (m, 1H) 7.46 (m, 1H) 7.37 (m, 1H), 6.88 (d, 1H, J 2.9 Hz), 6.62 (d, 1H, J 8.7 Hz), 6.55 (dd, 1H, J 8.7, 2.9 Hz), 5.42 (d, 1H, J 7.0 Hz), 5.14 (d, 1H, J 10.5 Hz), 4.86 (m, 1H), 2.29 (m, 1H), 1.84 (m, 1H).

c) 2-(3-Bromophenyl)chroman-6-ol

2-(3-Bromophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 700 mg of 2-(3-bromophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.81 (s, 1H), 7.61 (m, 1H), 7.51 (m, 1H), 7.43 (m, 1H), 7.35 (m, 1H) 6.67-6.48 (m, 3H), 5.01 (m, 1H), 2.87 (m, 1H,), 2.63 (m, 1H), 2.12 (m, 1H), 1.92 (m, 1H).

d) 2-[2-(3-Bromophenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3-Bromophenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 339 mg of 2-(3-bromophenyl)chroman-6-ol. The product was filtered through silica gel using toluene - ethyl acetate as an eluant and then crystallised from 2-propanol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.2, 2.9 Hz), 7.66 (bs, 1H), 7.55 (m, 1H), 7.48 (m, 1H), 7.39 (m, 1H) 7.20 (d, 1H, J 9.2 Hz) 7.01-6.93 (m, 3H), 5.17 (dd, 1H, J 10.1, 2.2 Hz), 2.97 (m, 1H), 2.72 (m, 1H) 2.20 (m, 1H), 2.00 (m, 1H).

Example 17:

2-[2-(4-Ethylphenyl)chroman-6-yloxy]-5-nitropyridine

a) 2-(4-Ethylphenyl)-6-hydroxychroman-4-one

2-(4-Ethylphenyl)-6-hydroxychroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 1.0 g of

2',5'-dihydroxyacetophenone and 0.8 ml of 4-ethylbenzaldehyde. The product was recrystallised from acetic acid. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.43 (d, 2H, J 8.1 Hz), 7.25 (d, 2H, J 8.1 Hz), 7.11 (d, 1H, J 3.1 Hz), 7.03 (dd, 1H, J 8.9, 3.1 Hz), 6.93 (d, 1H, J 8.9 Hz), 5.51 (dd, 1H, J 13.0, 2.9 Hz), 3.15 (dd, 1H, J –16.9, 13.0 Hz), 2.75 (dd, 1H, J –16.9, 2.9 Hz), 2.62 (q, 2H, J 7.5 Hz), 1.18 (t, 3H, J 7.5 Hz).

b) 2-(4-Ethylphenyl)chroman-4,6-diol

2-(4-Ethylphenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 474 mg of 2-(4-ethylphenyl)-6-hydroxychroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.81 (s, 1H), 7.34 (d, 2H, J 8.0 Hz) 7.22 (d, 2H, J 8.0 Hz), 6.88 (d, 1H, J 2.8 Hz), 6.57 (d, 1H, J 8.6 Hz), 6.53 (dd, 1H, J 8.6, 2.8 Hz), 5.39 (d, 1H, J 7.1 Hz), 5.06 (d, 1H, J 10.7 Hz), 4.86 (m, 1H), 2.61 (q, 2H, J 7.6 Hz), 2.29 (m, 1H), 1.84 (m, 1H), 1.19 (t, 3H, J 7.6 Hz).

c) 2-(4-Ethylphenyl)chroman-6-ol

2-(4-Ethylphenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 425 mg of 2-(4-ethylphenyl)chroman-4,6-diol. The product was purified using heptane - ethyl acetate (3:1) as an eluant. ^{1}H NMR (400 MHz, CD_3OD) δ: 7.26 (d, 2H, J 8.2 Hz) 7.13 (d, 2H, J 8.2 Hz), 6.65 (d, 1H, J 8.6 Hz), 6.55 (dd, 1H, J 8.6, 2.8 Hz), 6.51 (d, 1H, J 2.8 Hz),, 4.83 (dd, 1H, J 10.1, 2.3 Hz), 2.84 (m, 1H,), 2.62 (m, 1H), 2.59 (q, 2H, J 7.6 Hz) 2.03 (m, 1H), 1.93 (m, 1H), 1.19 (t, 3H, J 7.6 Hz).

d) 2-[2-(4-Ethylphenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(4-Ethylphenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 205 mg of 2-(4-ethylphenyl)chroman-6-ol. The product was recrystallised from a mixture of 2-propanol and acetone. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.04 (d, 1H, J 2.8 Hz), 8.60 (dd, 1H, J 9.1, 2.8 Hz), 7.36 (d, 2H, J 8.1 Hz) 7.24 (d, 2H, J 8.1 Hz), 7.20 (d, 1H, J 9.1 Hz), 7.00 (d, 1H, J 2.7 Hz) 6.96 (dd, 1H, J 8.8, 2.7 Hz), 6.89 (d, 1H, J 2.7 Hz), 5.11 (dd, 1H, J 10.1, 2.2 Hz), 2.98 (m, 1H), 2.75 (m, 1H), 2.62 (q, 2H, J 7.5 Hz) 2.16 (m, 1H), 2.01 (m, 1H), 1.19 (t, 3H, J 7.5 Hz).

Example 18:

5-Nitro-2-[2-(2-nitrophenyl)chroman-6-yloxy]pyridine

a) 6-Hydroxy-2-(2-nitrophenyl)chroman-4-one

6-Hydroxy-2-(2-nitrophenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a). ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.49 (s, 1H), 8.05-8.06 (m, 1H), 7.96-7.98 (m, 1H), 7.83-7.87 (m, 1H), 7.65-7.69 (m, 1H), 7.14 (d, 1H, J 3.1 Hz), 7.05 (dd, 1H, J 8.8, 3.1 Hz), 6.91 (d, 1H, J 8.8 Hz), 5.69 (dd, 1H, J 13.0, 2.6 Hz), 3.22 (dd, 1H, J 16.8, 13.0 Hz), 2.98 (dd, 1H, J 16.8, 2.6 Hz).

b) 2-(2-Nitrophenyl)chroman-4,6-diol

2-(2-Nitrophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 6-hydroxy-2-(2-nitrophenyl)-chroman-4-one. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.87 (s, 1H), 7.99-8.02 (m, 1H), 7.77-7.86 (m, 2H), 7.59-7.64 (m, 1H), 6.89 (d, 1H, J 2.4 Hz), 6.56-6.57 (m, 2H), 5.51-5.55 (m, 2H), 4.85-4.92 (m, 1H), 2.42-2.47 (m, 1H), 1.85-1.96 (m, 1H).

c) 2-(2-Nitrophenyl)chroman-6-ol

2-(2-Nitrophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 2-(2-nitrophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.85 (s, 1H), 8.00 (d, 1H, J 8.0 Hz), 7.79-7.80 (m, 2H), 7.59-7.63 (m, 1H), 6.59-6.62 (m, 1H), 6.50-6.53 (m, 2H), 5.36 (dd, 1H, J 10.2, 2.0 Hz), 2.89-2.93 (m, 1H), 2.67-2.73 (m, 1H), 2.26-2.31 (m, 1H), 1.90-1.95 (m, 1H).

d) 5-Nitro-2-[2-(2-nitrophenyl)chroman-6-yloxy]pyridine

5-Nitro-2-[2-(2-nitrophenyl)chroman-6-yloxy]pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 2-(2-nitrophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 8.03 (d, 1H, J 7.9 Hz), 7.80-7.85 (m, 2H), 7.62-7.66 (m, 1H), 7.22 (d, 1H, J 9.1 Hz), 7.04 (d, 1H, J 2.8 Hz), 6.98 (dd, 1H, J 8.8,

2.8 Hz), 6.88 (d, 1H, J 8.8 Hz), 5.52 (dd, 1H, J 10.3, 2.0 Hz), 2.99-3.31 (m, 1H), 2.80-2.85 (m, 1H), 2.35-2.40 (m, 1H), 1.99-2.04 (m, 1H).

Example 19:

5-Nitro-2-[2-(3-nitrophenyl)chroman-6-yloxy]pyridine

a) 6-Hydroxy-2-(3-nitrophenyl)chroman-4-one

6-Hydroxy-2-(3-nitrophenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a). The product was recrystallised from ethanol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.40 (s, 1H), 8.24 (dd, 1H, J 8.2, 2.3 Hz), 8.01 (d, 1H, J 7.9 Hz), 7.74 (t, 1H, J 15.9, 7.9 Hz), 7.13 (d, 1H, J 2.9 Hz), 7.07 (dd, 1H, J 8.8, 2.9 Hz), 7.00 (d, 1H, 8.8 Hz), 5.75 (dd, 1H, J 13.1, 2.9 Hz), 3.21 (dd, 1H, J 16.8, 13.1 Hz), 2.88 (dd, 1H, J 16.8, 2.9 Hz).

b) 2-(3-Nitrophenyl)chroman-4,6-diol

2-(3-Nitrophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 6-hydroxy-2-(3-nitrophenyl)-chroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.89 (br s, 1H), 8.29 (s, 1H), 8.20 (dd, 1H, J 8.2, 2.3 Hz), 7.93 (d, 1H, J 7.9 Hz), 7.71 (t, 1H, J 15.9, 7.9 Hz), 6.89 (d, 1H, J 2.8 Hz), 6.66 (d, 1H, J 8.7 Hz), 6.57 (dd, 1H, J 8.7, 2.9 Hz), 5.47 (br s, 1H), 5.33 (d, 1H, J 10.7 Hz), 4.88-4.92 (m, 1H), 2.33-2.39 (m, 1H), 1.83-1.92 (m, 1H).

c) 2-(3-Nitrophenyl)chroman-6-ol

2-(3-Nitrophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 2-(3-nitrophenyl)chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.80 (s, 1H), 8.26 (s, 1H), 8.19 (dd, 1H, J 8.1, 2.3 Hz), 7.90 (d, 1H, J 7.9 Hz), 7.70 (t, 1H, J 15.9, 7.9 Hz), 6.70 (d, 1H, J 8.4 Hz), 6.51-6.55 (m, 2H), 5.19 (dd, 1H, J 10.0, 2.0), 2.86-2.91 (m, 1H), 2.61-2.68 (m, 1H), 2.17-2.23 (m, 1H), 1.91-1.97 (m, 1H).

d) 5-Nitro-2-[2-(3-nitrophenyl)chroman-6-yloxy]pyridine

5-Nitro-2-[2-(3-nitrophenyl)chroman-6-yloxy]pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 2-(3-nitrophenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.0, 2.9 Hz), 8.32 (s, 1H), 8.23 (d, 1H, J 8.3 Hz), 7.95 (d, 1H, J 7.9 Hz), 7.74 (t, 1H, J 15.8, 7.9 Hz), 7.21 (d, 1H, J 9.0 Hz), 6.96-7.03 (m, 3H), 5.35 (d, 1H, J 8.7 Hz), 2.98-3.06 (m, 1H), 2.72-2.79 (m, 1H), 2.26-2.33 (m, 1H), 1.99-2.06 (m, 1H).

Example 20:

5-Nitro-2-[2-(4-nitrophenyl)chroman-6-yloxy]pyridine

a) 6-Hydroxy-2-(4-nitrophenyl)chroman-4-one

6-Hydroxy-2-(4-nitrophenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a). The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.48 (s, 1H), 8.29 (d, 2H, J 6.9 Hz), 7.83 (d, 2H, J 6.9 Hz), 7.13 (d, 1H J 2.9 Hz), 7.06 (dd, 1H, J 8.8, 2.9 Hz), 7.01 (d, 1H, J 8.8 Hz), 5.77 (dd, 1H, J 13.0, 3.0 Hz), 3.15 (dd, 1H, J 16.8, 13.0 Hz), 2.89 (dd, 1H, J 16.8, 3.0 Hz).

b) 2-(4-Nitrophenyl)chroman-4,6-diol

2-(4-Nitrophenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 6-hydroxy-2-(4-nitrophenyl)chroman-4-one. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.86 (s, 1H), 8.26 (d, 2H, J 6.9 Hz), 7.74 (d, 2H, J 6.9 Hz), 6.89 (d, 1H J 2.8 Hz), 6.65 (d, 1H, J 8.6 Hz), 6.56 (dd, 1H, J 8.6, 2.8 Hz), 5.46 (d, 1H, J 6.9 Hz), 5.32 (d, 1H, J 10.5 Hz), 4.86-4.94 (m, 1H), 2.31-2.38 (m, 1H), 1.78-1.89 (m, 1H).

c) 2-(4-Nitrophenyl)chroman-6-ol

2-(4-Nitrophenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 2-(4-nitrophenyl)chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.84 (s, 1H), 8.26 (d, 2H, J 6.9 Hz), 7.71 (d, 2H, J 6.9 Hz), 6.69 (d, 1H, J 8.6 Hz), 6.53 (dd, 1H, J 8.6, 2.8 Hz), 6.50 (d, 1H, J 2.8

Hz), 5.19 (dd, 1H, J 9.9, 2.2 Hz), 2.87-2.91 (m, 1H), 2.61-2.66 (m, 1H), 2.16-2.21 (m, 1H), 1.89-1.93 (m, 1H).

d) 5-Nitro-2-[2-(4-nitrophenyl)chroman-6-yloxy]pyridine

5-Nitro-2-[2-(4-nitrophenyl)chroman-6-yloxy]pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 2-(4-nitrophenyl)chroman-6-ol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 8.29 (d, 2H, J 6.9 Hz), 7.76 (d, 2H, J 6.9 Hz), 7.21 (d, 1H, J 9.1 Hz), 6.98-7.02 (m, 3H), 5.35 (dd, 1H, J 9.9, 2.2 Hz), 2.96-3.05 (m, 1H), 2.73-2.78 (m, 1H), 2.24-2.29 (m, 1H), 1.96-2.04 (m, 1H).

Example 21:

2-[2-(3-Methoxyphenyl)chroman-6-yloxy]-5-nitropyridine

a) 6-Hydroxy-2-(3-methoxyphenyl)chroman-4-one

6-Hydroxy-2-(3-methoxyphenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a). The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.42 (s, 1H), 7.33 (t, 1H, J 15.8, 8.3 Hz), 7.12 (d, 1H, J 3.0 Hz), 7.10 (s, 1H), 7.09 (d, 1H, J 8.3 Hz), 7.04 (dd, 1H, J 8.8, 3.0 Hz), 6.96 (d, 1H, 8.8 Hz), 6.93 (dd, 1H, J 8.0, 2.5 Hz), 5.52 (dd, 1H, J 12.9, 2.9 Hz), 3.77 (s, 3H), 3.17 (dd, 1H, J 16.9, 12.9 Hz), 2.77 (dd, 1H, J 16.9, 2.9 Hz).

b) 2-(3-methoxyphenyl)chroman-4,6-diol

2-(3-Methoxyphenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 6-hydroxy-2-(3-methoxyphenyl)chroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.82 (s, 1H), 7.31 (t, 1H, J 15.7, 7.9 Hz), 6.99-7.02 (m, 2H), 6.88-6.90 (m, 2H), 6.59 (d, 1H, J 8.7 Hz), 6.54 (dd, 1H, J 8.7, 2.8 Hz), 5.40 (d, 1H, J 7.0 Hz), 5.08 (d, 1H, J 11.5 Hz), 4.83-4.89 (m, 1H), 3.77 (s, 3H), 2.23-2.28 (m, 1H), 1.83-1.92 (m, 1H).

c) 2-(3-Methoxyphenyl)chroman-6-ol

2-(3-Methoxyphenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 2-(3-methoxyphenyl)-chroman-4,6-diol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.75 (s, 1H), 7.28 (t, 1H, J 15.7, 7.9 Hz), 6.96-6.99 (m, 2H), 6.87 (dd, 1H, J 7.9, 2.5 Hz), 6.63 (d, 1H, J 8.3 Hz), 6.52 (d, 1H, J 2.9 Hz), 6.48 (s, 1H), 4.95 (dd, 1H, J 9.8, 2.2 Hz), 3.75 (s, 3H), 2.82-2.89 (m, 1H), 2.57-2.66 (m, 1H), 2.06-2.13 (m, 1H), 1.89-1.97 (m, 1H).

d) 2-[2-(3-Methoxyphenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3-Methoxyphenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 2-(3-methoxyphenyl)chroman-6-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.60 (dd, 1H, J 9.1, 2.9 Hz), 7.32 (t, 1H, J 15.7, 7.9 Hz), 7.20 (d, 1H, J 9.1 Hz), 7.03 (d, 1H, J 8.4 Hz), 7.01 (s, 1H), 7.00 (d, 1H, J 2.8 Hz), 6.96 (dd, 1H, J 8.7, 2.8 Hz), 6.92 (d, 1H, J 8.7 Hz), 6.90 (dd, 1H, J 8.4, 2.6 Hz), 5.12 (dd, 1H, J 10.0, 2.3 Hz), 3.77 (s, 3H), 2.93-2.97 (m, 1H), 2.71-2.77 (m, 1H), 2.15-2.20 (m, 1H), 1.99-2.05 (m, 1H).

Example 22:

2-(3-Methyl-2-phenylchroman-6-yloxy)-5-nitropyridine

a) 6-Hydroxy-3-methyl-2-phenylchroman-4-one

6-Hydroxy-3-methyl-2-phenylchroman-4-one was prepared as described for 2-(4-fluorophenyl)-6-hydroxychroman-4-one in Example 2(a) starting from 2.0 g of 2,5-dihydroxypropiophenone and 1.63 ml of benzaldehyde. The product was purified by column chromatography using heptane - ethyl acetate (3:1) as an eluant. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.37 (s, 1H), 7.53 (m, 2H), 7.47-7.39 (m, 3H), 7.13 (d, 1H, J 3.1 Hz), 7.02 (dd, 1H, J 8.9, 3.1 Hz), 6.89(d, 1H, J 8.9 Hz), 5.17 (d, 1H, J 12.3), 3.18 (dq, 1H, J 12.3, 6.9 Hz), 0.84 (d, 3H, J 6.9 Hz).

b) 3-Methyl-2-phenylchroman-4,6-diol

3-Methyl-2-phenylchroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 474 mg of 6-hydroxy-3-methyl-2-phenylchroman-4-one. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.79 (s, 1H),

7.42-7.33 (m, 5H), 6.88 (bs, 1H,), 6.53 (m, 2H), 5.37 (d, 1H, J 8.0 Hz), 4.70 (d, 1H, J 10.6 Hz), 1.94 (m, 1H), 0.73 (d, 3H, J 6.7 Hz).

c) 3-Methyl-2-phenylchroman-6-ol

3-Methyl-2-phenylchroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 605 mg of 3-methyl-2-phenylchroman-4,6-diol. ^{1}H NMR (400 MHz, CD_3OD) δ: 8.77 (s, 1H), 7.41-7.33 (m, 5H), 6.59-6.48 (m, 3H), 4.56 (d, 1H, J 9.2 Hz), 2.73 (dd, 1H, J -16.5, 5.0 Hz), 2.54 (dd, 1H, J -16.5, 5.8 Hz), 2.11 (m, 1H), 0.72 (d, 3H, J 6.6 Hz).

d) 2-(3-Methyl-2-phenylchroman-6-yloxy)-5-nitropyridine

2-(3-Methyl-2-phenylchroman-6-yloxy)-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 600 mg of 3-methyl-2-phenylchroman-6-ol. The product was purified by column chromatography using heptane - 2-propanol (20:1) as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.8 Hz), 8.59 (dd, 1H, J 9.1, 2.8 Hz), 7.43-7.36 (m, 5H), 7.19 (d, 1H, J 9.1 Hz), 7.00 (d, 1H, J 2.6 Hz) 6.95 (dd, 1H, J 8.7, 2.6 Hz), 6.86 (d, 1H, J 8.7 Hz), 4.73 (d, 1H, J 9.3 Hz), 2.85 (dd, 1H, J -16.7, 5.0 Hz), 2.64 (dd, 1H, J -16.5, 10.9 Hz), 2.18 (m, 1H), 0.77 (d, 3H, J 6.7 Hz).

Example 23:

5-Nitro-2-(2-phenylchroman-7-yloxy)pyridine

a) 2-Phenylchroman-7-ol

2-Phenyl-chroman-7-ol was prepared as described for 5-nitro-2-(2-phenyl-chroman-6-yloxy)pyridine in Example 1(a) starting from 1.0 g of 7-hydroxy-flavanone. The product was purified by column chromatography using heptane-ethyl acetate (2:1) as an eluant. ^{1}H NMR (400 MHz, CD_3OD) δ: 7.41-7.28 (m, 5H), 6.86 (d, 1H, J 8.2 Hz) 6.32 (dd, 1H, J 8.2, 2.4 Hz), 6.29 (d, 1H, J 2.4 Hz), 5.00 (dd, 1H, J 9.9, 2.4 Hz), 2.84 (m, 1H), 2.64 (m, 1H) 2.15 (m, 1H), 1.99 (m, 1H).

b) 5-Nitro-2-(2-phenylchroman-7-yloxy)pyridine

5-Nitro-2-(2-phenylchroman-7-yloxy)pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 115 mg of 2-phenyl-chroman-7-ol. The product was purified on preparative TLC-plate covered with silica gel using toluene - ethyl acetate (15:1) as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.8 Hz), 8.60 (dd, 1H, J 9.1, 2.8 Hz), 7.46-7.32 (m, 5H), 7.22 (d, 1H, J 9.1 Hz), 7.20 (d, 1H, J 8.9 Hz) 6.72 (dd, 1H, J 8.9, 2.3 Hz), 6.72 (d, 1H, J 2.3 Hz), 5.16 (dd, 1H, J 10.1, 2.1 Hz), 2.97 (ddd, 1H, J –16.7, 11.3, 5.9 Hz), 2.77 (ddd, 1H, J –16.7, 8.1, 4.5 Hz) 2.20 (m, 1H), 2.02 (m, 1H).

Example 24:

6-(5-Nitropyridin-2-yloxy)-2-phenylchroman-4-one

6-(5-Nitropyridin-2-yloxy)-2-phenylchroman-4-one was prepared as described for 5-Nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) using 200 mg of 6-hydroxyflavanone. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.03 (bs, 1H), 8.64 (d, 1H, J 9.0 Hz), 7.59-7.41 (m, 7H), 7.31 (d, 1H, J 9.0 Hz), 7.23 (d, 1H, 8.8 Hz), 5.75 (dd, 1H, J 12.3, 2.9 Hz), 3.30 (dd, 1H, -16.3, 12.3 Hz), 2.87 (dd, 1H, -16.3, 2.9 Hz).

Example 25:

7-(5-Nitropyridin-2-yloxy)-2-phenylchroman-4-one

7-(5-Nitropyridin-2-yloxy)-2-phenylchroman-4-one was prepared as described for 5-Nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) using 150 mg of 7-hydroxyflavanone. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.07 (d, 1H, J 2.8 Hz), 8.67 (dd, 1H, J 9.0, 2.8 Hz), 7.89 (d, 1H, 8.6 Hz), 7.60-7.35 (m, 6H), 7.04 (d, 1H, 2.1 Hz), 6.97 (dd, 1 H, 8.6, 2.1 HZ), 5.75 (dd, 1H, J 13.0, 2.7 Hz), 3.32 (dd, 1H, 16.9, 13.0 Hz), 2.85 (d, -16.9, 2.7 Hz).

Example 26:

3-Methyl-6-(5-nitropyridin-2-yloxy)-2-phenylchroman-4-one

Methyl-6-(5-nitropyridin-2-yloxy)-2-phenylchroman-4-one was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 200 mg of 6-hydroxy-3-methyl-2-phenylchroman-4-one. The product was purified by column chromatography using heptane - ethyl acetate (2:1) as an eluant and then crystallised from a mixture of 2-propanol and acetone. ^{1}H NMR (400 MHz,

d_6-DMSO) δ: 9.03 (d, 1H, J 2.9 Hz), 8.64 (dd, 1H, J 9.1, 2.9 Hz), 7.59-7.56 (m, 3H), 7.50-7.32 (m, 4H) 7.30 (d, 1H, J 9.1 Hz), 7.18 (d, 1H, J 8.9 Hz), 5.38 (d, 1H, J 12.5 Hz), 3.36 (dd, 1H, J 12.5, 6.9 Hz), 0.86 (d, 3H, J 6.9 Hz).

Example 27:
2-(2,3-Dihydro-2-phenyl-benzo[1,4]dioxin-6-yloxy)-5-nitropyridine

a) 1-[2,5-Bis(benzyloxy)phenyl]ethanone

A mixture of 1-(2,5-dihydroxyphenyl)ethanone (3.16 g), benzyl chloride (7.04 g), potassium carbonate (12.4 g) and 18-Crown-6 (30 mg) in 2-butanone (50 ml) was heated under reflux for 5 hrs. After cooling the precipitate was filtered off. The filtrate was evaporated to dryness under reduced pressure and ether (50 ml) was added to it. The solution was washed twice with dilute sodium hydroxide solution, twice with dilute hydrochloric acid, dried over sodium sulphate and substantially evaporated to dryness under reduced pressure. The residue was triturated with cold n-heptane (30 ml), and the precipitate was filtered off with suction filtration giving after drying 2.85 g of 1-[2,5-Bis(benzyloxy)phenyl]ethanone. ^{1}H NMR (400 MHz, DMSO-d_6) δ: 2.50 (s, 3H), 5.08 (s, 2H), 5.18 (s, 2H), 7.20-7.50 (m, 13H).

b) Acetic acid 2,5-bis(benzyloxy)phenyl ester

A solution of 1-[2,5-bis(benzyloxy)phenyl]ethanone (2.25 g) and peracetic acid 40% (1.63 ml) in acetic acid (5.4 ml) was stirred at 60 °C for 1 h. After cooling to room temperature the precipitated product was collected by filtration, washed with cold ether and dried under reduced pressure. Acetic acid 2,5-bis(benzyloxy)phenyl ester was recrystallized from 2-propanol. Yield is 1.87 g. ^{1}H NMR (DMSO-d_6) δ: 2.23 (s, 1H), 5.03 (s, 2H), 5.05 (s, 2H), 6.84-7.44 (m, 13H).

c) 2,5-Bis(benzyloxy)phenol

A solution of acetic acid 2,5-bis(benzyloxy)phenyl ester (1.85 g) and 5M sodium hydroxide solution (10.6ml) in ethanol (11 ml) was heated under reflux for 6.5 hrs. After ethanol was evaporated under reduced pressure the clear solution was made acidic with diluted hydrochloric acid. The precipitated product was collected by filtration, washed with cold water and dried under reduced pressure. Yield is 0.56

g. ^{1}H NMR (DMSO-d_6) δ: 4.97 (s, 2H), 5.01 (s, 2H), 6.34 (dd, J 3.1, 8.8 Hz, 1H), 6.49(d, J 3.1 Hz, 1H), 6.85 (d, J 8.8 Hz, 1H), 7.28-7.46 (m, 10H), 9.1 (br s, 1H).

d) 2-[2,5-Bis(benzyloxy)phenoxy]-1-phenylethanone

A mixture of 2,5-bis(benzyloxy)phenol (0.28 g), 2-bromoacetophenone (0.22 g), potassium hydrogen-carbonate (0.25 g) and 18-Crown-6 (3 mg) in acetonitrile (4.2 ml) was stirred at 22 °C for one week. The mixture was filtered and evaporated to dryness under reduced pressure. The residue was triturated with the mixture of ether (8.2 ml) and water (1.4 ml) at the ice bath temperature. The product was collected by filtration, washed with cold ether and dried under reduced pressure. Yield is 0.14 g. ^{1}H NMR (DMSO-d_6) δ: 4.98 (s, 2H), 5.06 (s, 2H), 5.58 (s, 2H), 6.51 (dd, J 8.9, 2.3 Hz, 1H), 6.68 (d, J 2.3 Hz, 1H), 6.94 (d, J 8.9 Hz, 1H), 7.28-8.03 (m, 15H).

e) 2-[2,5-Bis(benzyloxy)phenoxy]-1-phenylethanol

To the solution of 2-[2,5-bis(benzyloxy)phenoxy]-1-phenylethanone (0.14 g) in methanol (0.5 ml) and tetrahydrofuran (1.9 ml) was added at the 0 °C temperature sodium borohydride (6.5 mg). The reaction was stirred 15 minutes at 0 °C and 2 hrs at 22 °C temperature. After adding water (5 ml) methanol and tetrahydrofuran were evaporated off. After the residue was stirred at 22 °C 0.5 hr the product was filtered, washed with cold water and dried under reduced pressure. Yield is 0.09 g. ^{1}H NMR (DMSO-d_6) δ: 4.05 (m, 2H), 4.91 (m, 1H), 4.95 (s, 2H), 5.01 (s, 2H), 5.59 (d, J 4.7 Hz, 1H), 6.47 (dd, J 2.8, 8.8 Hz, 1H), 6.68 (d, J 2.8 Hz, 1H), 6.89 (d, J 8.8 Hz, 1H), 7.24-7.45 (m, 15H).

f) 2-(2-Hydroxy-2-phenylethoxy)benzene-1,4-diol

A solution of 2-[2,5-bis(benzyloxy)phenoxy]-1-phenylethanol (3.9 g) in ethanol (175 ml) was hydrogenated in the presence of 10 % palladium on charcoal (100 mg) at 30 psi. The catalyst was removed by filtration and the solvent was evaporated under reduced pressure. The residue was recrystallized from the mixture of toluene-ethyl acetate 8:1 (15 ml). The yield of 2-(2-Hydroxy-2-phenylethoxy)-benzene-1,4-diol is 1.2 g. ^{1}H NMR (DMSO-d_6) δ: 3.79 (dd, J 9.6, 8.3 Hz, 1H), 4.00 (dd, J 9.6, 3.6 Hz, 1H), 4.94 (ddd, J 3.6, 8.3, 3.9 Hz, 1H), 5.66 (d, J 3.9 Hz, 1H), 6.18

(dd, J 8.5, 2.3 Hz, 1H), 6.34 (d, J 2.3, 1H), 6.57 (d, J 8.5, 1H), 7.26-7.47 (m, 5H), 7.97 (s, 1H), 8.66 (s, 1H).

g) 2,3-Dihydro-2-phenyl-benzo[1,4]dioxin-6-ol

A solution of 2-(2-hydroxy-2-phenylethoxy)benzene-1,4-diol (1.2 g) in toluene (75 ml) was heated with Amberlyst 15 catalyst (0.5 g) under reflux for 7 hrs. After filtering the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (toluene/ethyl acetate/acetic acid, 8:1:1). The yield of 2,3-dihydro-2-phenyl-benzo[1,4]dioxin-6-ol is 0.5 g. ^{1}H NMR (DMSO-d_6) δ: 4.02 (dd, J 8.5, 11.4 Hz, 1H), 4.35 (dd, J 2.3, 11.4 Hz, 1H), 5.11 (dd, J 8.5, 2.3 Hz, 1H), 6.29 (dd, J 2.8, 8.5 Hz, 1H), 6.32 (d, J 2.8 Hz, 1H), 6.75 (d, J 8.5 Hz, 1H), 7.36-7.47 (m, 5H), 8.99 (s, 1H).

h) 2-(2,3-Dihydro-2-phenyl-benzo[1,4]dioxin-6-yloxy)-5-nitropyridine

A solution of 2,3-dihydro-2-phenyl-benzo[1,4]dioxin-6-ol (80 mg), 2-chloro-5-nitropyridine (56 mg) and potassium carbonate (52 mg) in dimethylformamide (1.0 ml) was stirred at 120 °C for 2 hrs. After cooling the mixture water (10 ml) was added and the precipitated product was filtered, washed with water and 2-propanol and dried under reduced pressure. Yield is 60 mg and mp 163-170 °C. ^{1}H NMR (DMSO-d_6) δ 4.16 (dd, J 8.5, 11.6 Hz, 1H), 4.47 (dd, J 11.6, 2.6 Hz, 1H), 5.28 (dd, J 2.6, 8.5 Hz, 1H), 6.75 (dd, J 2.6, 8.8 Hz, 1H), 6.88 (d, J 2.6 Hz, 1H), 7.05 (d, J 8.8 Hz, 1H), 7.21 (d, J 9.1 Hz, 1H), 7.39-7.52 (m, 5H), 8.60 (dd, J 2.8, 9.1 Hz, 1H), 9.05 (d, J 2.8 Hz, 1H).

Example 28:

5-Nitro-2-(6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-pyridine

a) 6-Methoxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one

A mixture of palladium(II) acetate (0.57 g), rac-2,2'-bis(diphenylphosphino)-1,1'-binaphtyl (1.91 g) and potassium *tert*-butoxide (4.15 g) in dry toluene was stirred under argon for 10 minutes. Bromobenzene (5.34 g) and 6-methoxy-1-tetralone (3.0 g) solvated in dry toluene were added and the mixture was stirred at 100 °C for 2 h. The reaction mixture was cooled to room temperature and poured into

saturated aqueous ammonium chloride and extracted with ethyl ether. Organic extract was washed with brine, dried and evaporated. The crude product was purified by flash chromatography on silica gel using toluene and toluene-ethyl acetate (9:1) as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.87 (d, 1H, J 7.8 Hz), 7.16-7.33 (m, 5H), 6.91-6.94 (m, 2H), 3.85 (s, 3H), 3.82-3.88 (m, 1H), 3.06-3.14 (m, 1H), 2.92-2.98 (m, 1H), 2.23-2.38 (m, 2H).

b) 6-Hydroxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one

6-Methoxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one (1.0 g) was refluxed with 47 % HBr (20 ml) until disappearance of the starting material. The mixture was poured into water and extracted with ethyl acetate. Ethyl acetate was dried and evaporated. The product was recrystallised from toluene. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 10.35 (s, 1H), 7.79 (d, 1H, J 8.6 Hz), 7.15-7.33 (m, 5H), 6.75 (dd, 1H, J 8.6, 2.4 Hz), 6.68 (d, 1H, J 2.3 Hz), 3.79-3.85 (m, 1H), 2.99-3.06 (m, 1H), 2.83-2.90 (m, 1H), 2.19-2.33 (m, 2H).

c) 6-Phenyl-5,6,7,8-tetrahydro-naphthalen-2-ol

To a solution of 6-hydroxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one (50 mg) in trifluoroacetic acid was added triethylsilane (98 mg). The mixture was heated at 60 °C for 3 h. Solvent was evaporated, water added to the residue and the mixture extracted with ethyl acetate. Organic extract was dried and evaporated. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.02 (s, 1H), 7.18-7.32 (m, 5H), 6.87 (d, 1H, J 7.9), 6.50-6.53 (m, 2H), 2.68-2.92 (m, 5H), 1.94-1.99 (m, 1H), 1.81-1.89 (m, 1H).

d) 5-Nitro-2-(6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-pyridine

6-Phenyl-5,6,7,8-tetrahydro-naphthalen-2-ol (30 mg), 2-chloro-5-nitropyridine (21 mg) and potassium fluoride (23 mg) in dry dimethylformamide were heated at 120 °C until disappearance of the starting material. Water and 1 N HCl were added and the mixture extracted with ethyl acetate. Ethyl acetate was washed with brine and water, dried and evaporated. The product was recrystallised from toluene. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.4 Hz), 8.61 (dd, 1H, J 9.0, 2.5), 7.18-7.35 (m, 7H), 6.95-6.99 (m, 2H), 2.83-3.01 (m, 5H), 1.87-2.04 (m, 2H).

Example 29:

6-(5-Nitro-pyridin-2-yloxy)-2-phenyl-3,4-dihydro-2*H*-naphthalen-1one

6-(5-Nitro-pyridin-2-yloxy)-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one was prepared as described for 5-nitro-2-(6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)-pyridine in Example 28(d) using 50 mg 6-hydroxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one, 33 mg 2-chloro-5-nitropyridine and 37 mg potassium fluoride. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.07 (d, 1H, J 2.8 Hz), 8.68 (dd, 1H, J 9.0, 2.9), 8.01 (d, 1H, J 8.5), 7.37 (d, 1H, J 9.1 Hz), 7.21-7.38 (m, 7H), 3.96-4.04 (m, 1H), 3.15-3.23 (m, 1H), 2.98-3.04 (m, 1H), 2.39-2.48 (m, 1H), 2.25-2.31 (m, 1H).

Example 30:

2-[3-(3-Fluorophenyl)chroman-7-yloxy]-5-nitropyridine

a) 2-(3-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)ethanone

(3-Fluorophenyl)acetic acid (3.7 g) and 3-methoxyphenol (3.0 g) were dissolved into $BF_3{\cdot}Et_2O$ (60 ml, 20 eq) under argon. The mixture was stirred at 60-70°C until disappearance of the starting materials (9 h) and poured into large volume of ice water. After extraction with ethyl acetate the combined organic layers were washed with water, dried and evaporated. The crude product was purified by column chromatography using CH_2Cl_2 as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 12.41 (br s, 1H), 8.02 (d, 1H, J 9.0 Hz), 7.34-7.38 (m, 1H), 7.09-7.13 (m, 3H), 6.56 (dd, 1H, J 9.0, 2.5 Hz), 6.49 (d, 1H, J 2.5 Hz), 4.41 (s, 2H), 3.83 (s, 3H).

b) 3-(3-Fluorophenyl)-7-methoxychromen-4-one

2-(3-Fluorophenyl)-1-(2-hydroxy-4-methoxyphenyl)ethanone (1.76 g) was dissolved in pyridine (88 ml). Piperidine (8.8 ml) and triethylorthoformate (88 ml) were added and the mixture was stirred at 120°C for 3.5 hours. After pouring the mixture into water and acidification with conc. HCl the crude product was filtered. Purification by column chromatography using heptane-ethyl acetate (7:3) as an eluant afforded 3-(3-fluorophenyl)-7-methoxychromen-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.57 (s, 1H), 8.06 (d, 1H, J 8.9 Hz), 7.45-7.50 (m, 3H), 7.21-7.25 (m, 1H), 7.20 (d, 1H, J 2.4 Hz), 7.12 (dd, 1H, J 8.9, 2.4 Hz), 3.92 (s, 3H).

c) 3-(3-Fluorophenyl)-7-hydroxychromen-4-one

3-(3-Fluorophenyl)-7-methoxychromen-4-one (320 mg) was refluxed with 47 % HBr (18 ml) until disappearance of the starting material. The mixture was poured into water and the precipitate was filtrated and dried yielding 3-(3-fluorophenyl)-7-hydroxychromen-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 10.87 (s, 1H), 8.49 (s, 1H), 7.99 (d, 1H, J 8.7 Hz), 7.43-7.49 (m, 3H), 7.20-7.24 (m, 1H), 6.97 (dd, 1H, J 8.7, 2.2 Hz), 6.90 (d, 1H, J 2.2 Hz).

d) 3-(3-Fluorophenyl)chroman-7-ol

3-(3-Fluorophenyl)-7-hydroxychromen-4-one (160 mg) was dissolved in ethanol (40 ml) and 10 % palladium on carbon (400 mg) was added. The reaction mixture was hydrogenated for 6 hours at normal pressure and room temperature. It was then filtered through Celite and washed with ethanol. The solvent was evaporated under reduced pressure to give 3-(3-fluorophenyl)chroman-7-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.19 (br s, 1H), 7.38 (m, 1H), 7.17-7.21 (m, 2H), 7.08 (m, 1H), 6.88 (d, 1H, J 8.2 Hz), 6.30 (dd, 1H, J 8.2, 2.4 Hz), 6.20 (d, 1H, J 2.4 Hz), 4.22 (dd, 1H, J 10.3, 3.6 Hz), 4.02 (t, 1H, 10.3 Hz), 3.20 (m, 1H), 2.90 (m, 2H).'

e) 2-[3-(3-Fluorophenyl)chroman-7-yloxy]-5-nitropyridine

2-[3-(3-Fluorophenyl)chroman-7-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) using 125 mg of 3-(3-fluorophenyl)-chroman-7-ol. The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.07 (d, 1H, J 2.8 Hz), 8.47 (dd, 1H, J 9.0, 2.8 Hz), 7.33 (m, 1H), 7.16 (d, 1H J 8.9 Hz), 6.95-7.06 (m, 4H), 6.69-6.71 (m, 2H), 4.38 (dd, 1H, J 10.6, 4.3 Hz), 4.06 (t, 1H, 10.6 Hz), 3.30 (m, 1H), 3.06 (m, 2H).

Example 31:

5-Nitro-2-(3-phenylchroman-7-yloxy)pyridine

a) 7-Hydroxy-3-phenylchromen-4-one

7-Hydroxy-3-phenylchromen-4-one is commercially available or can be synthesised by methods described for 3-(3-fluorophenyl)-7-hydroxychromen-4-one

(Example 30(a-c)). ^{1}H NMR spectrum as reported in the literature (*Synth. Commun.*, 2000, 30(3), 469-484).

b) 3-Phenylchroman-7-ol

3-Phenylchroman-7-ol was prepared as described for 3-(3-fluorophenyl)-chroman-7-ol in Example 30(d) using 0.5 g of 7-hydroxy-3-phenylchromen-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.18 (br s, 1H), 7.31-7.34 (m, 4H), 7.25-7.27 (m, 1H), 6.88 (d, 1H, J 8.2 Hz), 6.30 (dd, 1H, J 8.2, 2.4 Hz), 6.20 (d, 1H, J 2.4 Hz), 4.21 (dd, 1H, J 10.3, 3.6 Hz), 4.00 (t, 1H, 10.3 Hz), 3.13 (m, 1H), 2.84-2.87 (m, 2H).

c) 5-Nitro-2-(3-phenylchroman-7-yloxy)pyridine

5-Nitro-2-(3-phenylchroman-7-yloxy)pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) using 200 mg of 3-phenylchroman-7-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.05 (d, 1H, J 2.9 Hz), 8.61 (dd, 1H, J 9.1, 2.9 Hz), 7.34-7.38 (m, 4H), 7.27-7.30 (m, 1H), 7.22 (m, 2H), 6.70-6.74 (m, 2H), 4.31 (dd, 1H, J 10.4, 3.5 Hz), 4.12 (t, 1H, 10.4 Hz), 3.24 (m, 1H), 3.01-3.11 (m, 2H).

Example 32:
5-Nitro-2-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridine

a) 2-(2-Hydroxy-1-phenylethylsulfanyl)benzene-1,4-diol

To a stirred solution of 2-mercaptobenzene-1,4-diol (0.5 g) and potassium carbonate (0.49 g) in water (5 ml) was added 2-phenyloxirane (0.40 ml) under argon. The mixture was stirred at room temperature for 2.5 hours and then treated with 2 M HCl and extracted with ethyl acetate. The combined organic layers were washed with water and brine, dried and evaporated. The crude product was purified by column chromatography using heptane-ethyl acetate (1:1) as an eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.94 (br s, 1H), 8.72 (br s, 1H), 7.24-7.37 (m, 5H), 6.62-6.65 (m, 2H), 6.47 (dd, 1H, J 8.6, 2.8 Hz), 4.97 (br s, 1H), 4.34 (m, 1H), 3.72 (m, 2H).

b) 2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-ol

A solution of 2-(2-hydroxy-1-phenylethylsulfanyl)benzene-1,4-diol (0.83 g) in dry toluene (60 ml) was strirred with Amberlyst 15 (0.5 g) at 60 °C until disappearance of the starting material. After the mixture was filtered and solvent evaporated the crude product was purified by column chromatography using heptane-ethyl acetate (1:1) as an eluant. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 7.41 (m, 4H), 7.33-7.40 (m, 1H), 6.81 (d, 1H, J 8.7 Hz), 6.61 (d, 1H, J 3.0 Hz), 6.51 (dd, 1H, J 8.7, 3.0 Hz), 5.10 (dd, 1H, J 9.6, 1.9 Hz), 3.28 (dd, 1H, J 13.0, 9.6 Hz), 3.06 (dd, 1H, J 13.0, 1.9 Hz).

c) 5-Nitro-2-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridine

5-Nitro-2-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) using 269 mg 2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-ol. The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, $CDCl_3$) δ: 9.07 (d, 1H, J 2.8 Hz), 8.47 (dd, 1H, J 9.1, 2.8 Hz), 7.43 (m, 4H), 7.37-7.41 (m, 1H), 7.02 (d, 1H, J 9.1 Hz), 6.99 (d, 1H, J 8.9 Hz), 6.95 (d, 1H, J 2.8 Hz), 6.82 (dd, 1H, J 8.9, 2.8 Hz), 5.21 (dd, 1H, J 9.7, 1.9 Hz), 3.31 (dd, 1H, 13.2, 9.7 Hz), 3.11 (dd, 1H, 13.2, 1.9 Hz).

Example 33:

6-(5-Nitropyridin-2-yloxy)-2-phenylchromen-4-one

6-(5-Nitropyridin-2-yloxy)-2-phenylchromen-4-one was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1(b) starting from 500 mg of 6-hydroxyflavone. The product was recrystallised from a mixture of 2-propanol and acetone. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.04 (d, 1H, J 2.9 Hz), 8.67 (dd, 1H, J 9.0, 2.9 Hz), 8.16-8.13 (m, 2H), 7.95 (d, 1H, J 9.0 Hz), 7.82 (d, 1H, J 2.9 Hz), 7.63 (dd, 1H, J 9.1, 2.9 Hz), 7.64-7.61 (m, 3H), 7.38 (d, 1H, J 9.1 Hz), 7.09 (s, 1H).

Example 34:

5-Nitro-2-(2-phenylindan-5-yloxy) pyridine

a) 3-(4-Methoxyphenyl)-2-phenylacrylic acid

Triethylamine was added to solution of p-anisaldehyde (10 g) and phenylacetic acid (10 g) in acetic anhydride (25 ml). Reaction mixture was stirred at 90°C for 8 h. Reaction mixture was cooled and water (600ml) solution of potassium

carbonate (81 g) was added. After addition reaction mixture was heated at 60°C for an hour. Before neutralising with concentrated hydrochloric acid the reaction mixture was cooled below 10°C. Precipitate was filtered and washed with water. ^{1}H-NMR (400 MHz, d_6-DMSO): 12.6 (bs, 1H), 7.67 (s, 1H), 7.4-7.3 (m, 3H), 7.2-7.1 (m, 2H), 7.0-6.9 (m, 2H), 6.8-6.7 (m, 2H), 3.70 (s, 3H). $(M)^+ = 254$ (100%).

b) 3-(4-Methoxyphenyl)-2-phenylpropionic acid

13 g of 3-(4-methoxyphenyl)-2-phenylacrylic acid was dissolved to 600 ml of ethyl acetate and 2.6 g of 10% palladium on charcoal was added under inert atmosphere. Starting material was hydrogenated at room temperature to give quantitative yield of 3-(4-methoxyphenyl)-2-phenylpropionic acid. ^{1}H-NMR (400 MHz, d_6-DMSO): 12.3 (bs, 1H), 7.32-7.20 (m, 5H), 7.1-7.0 (m, 2H), 6.8-6.7 (m, 2H), 3.79 (dd, 1H, J 6.9, 8.7 Hz), 3.70 (s, 3H), 3.22 (dd, 1H, J 8.7, 13.7 Hz), 2.87 (dd, 1H, J 6.9, 13.7 Hz).

c) 6-Methoxy-2-phenylindan-1-one

To solution of 3-(4-methoxyphenyl)-2-phenylpropionic acid (4.6 g) in dry methylenechloride (26 ml) was added two drops of dry DMF. Thionylchloride (3 ml) was added and reaction mixture was stirred at 40°C for 4 h. Solvent was evaporated under vacuum. Precipitate was dissolved to methylenechloride. Solution was cooled to 0-3°C. This solution and aluminium chloride (2.5g) were mixed slowly over 4 hours keeping temperature under 4°C. After mixing reaction mixture was stirred at room temperature for 2 h. Reaction was quenched by pouring to dilute ice cold hydrochloric acid. Layers were separated and water solution was extracted with methylenechloride. Combined organic layers were washed with water, dried and evaporated. Crude product was triturated to give 2.9 g of 6-Methoxy-2-phenylindan-1-one. ^{1}H-NMR (400 MHz, d_6-DMSO): 7.56 (d, 1H), 7.35-7.23 (m, 4H), 7.18-7.13 (m, 3H), 4.02 (dd, 1H, J 3.9, 8.0 Hz), 3.82 (s, 3H), 3.61 (dd, 1H, J 8.0, 17.2 Hz), 3.11 (dd, 1H, J 3.9, 17.2 Hz).

d) 5-Methoxy-2-phenylindane

5-Methoxy-2-phenylindane was prepared as described for 2-phenylchroman-6-ol in Example 1(a) using 600 mg of 6-methoxy-2-phenylindan-1-one. ^{1}H-NMR

(400 MHz, d_6-DMSO): 7.32-7.27 (m, 4H), 7.21-7.18 (m, 1H), 7.13 (d, 1H, J 8.2 Hz), 6.83 (d, 1H, J 2.4 Hz), 6.72 (dd, 1H, J 2.4, 8.2 Hz), 3.72 (s, 3H), 3.64 (k, 1H, J 8.5 Hz), 3.23 (dt, 2H, J 8.5, 15.9 Hz), 2.92 (m, 2H).

e) 2-Phenylindan-5-ol

Mixture of 5-methoxy-2-phenylindane (200 mg) and concentrated HBr (4 ml) was refluxed for 5.5 h. Reaction mixture was allowed to cool to room temperature and 20 ml of ice water and it was extracted with methylene chloride. The combined organic layers were washed with brine and dried with Na_2SO_4. The solvents were evaporated to give 2-phenylindan-5-ol. ^{1}H-NMR (400 MHz, d_6-DMSO): 9.05 (bs, 1H), 7.3-7.28 (m, 4H), 7.26-7.15 (m, 1H), 7.0 (d, 1H, J 8.1 Hz), 6.64 (d, 1H, J 1.9 Hz), 6.55 (dd, 1H, J 1.9, 8.1 Hz), 3.60 (k, 1H, J 8.6 Hz), 3.18 (m, 2H), 2.86 (dt, 2H, J 8.6, 16 Hz).

f) 5-Nitro-2-(2-phenylindan-5-yloxy) pyridine

5-Nitro-2-(2-phenylindan-5-yloxy) pyridine was prepared as described for 2-phenylchroman-6-yloxy)pyridine in Example 1(b) using 107 mg of 2-phenylindan-5-ol. ^{1}H-NMR (400 MHz, d_6-DMSO): 9.04 (d, 1H, J 2.9 Hz), 8.61 (dd, 1H, J 2.9, 9.1 Hz), 7.38-7.28 (m, 5H), 7.24-7.20 (m, 2H), 7.11 (d, 1H, J 2.2 Hz), 7.00 (dd, 1H, J 2.2, 8.0 Hz), 3.72 (k, 1H, J 8.9 Hz), 3.36-3.28 (m, 2H), 3.01 (dd, 2H, J 8.9, 15.3 Hz).

Example 35:

5-Amino-2-(2-phenylchroman-6-yloxy)pyridine

5-Nitro-2-(2-phenylchroman-6-yloxy)pyridine (2.26g) was dissolved in 350 ml of glacial acetic acid. Zinc powder (8.48g) was added in few portions due to exothermic reaction. The mixture was stirred at room temperature for 2 hours and filtered. The zinc was washed with glacial acetic acid. The acid was evaporated and toluene was added and evaporated again. A product mixture was dissolved in CH_2Cl_2 and washed with 1M NaOH. Water phase was further washed with CH_2Cl_2. Both organic fractions were combined and dried over Na_2SO_4. Product was purified by column chromatography. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 7.52 (d, 1H, J 2.8 Hz), 7.46-7.30 (m, 5H), 7.05 (dd, 1H, J 8.6, 3.0 Hz), 6.82-6.72 (m, 3H), 6.69 (d, 1H, J 8.6

Hz), 5.08 (dd, 1H, J 10.0, 2.1 Hz), 5.00 (s, 2H), 3.00-2.87 (m, 1H), 2.74-2.64 (m, 1H), 2.19-2.10 (m, 1H), 2.05-1.91 (m, 1H).

The title compounds of the following Examples 36-52 were prepared as described for 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in Example 35 but starting from

2-[2-(4-fluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(3-fluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(2-fluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(2,3-difluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(2,4-difluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(2,5-difluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(2,6-difluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(3,5-difluorophenyl)chroman-6-yloxy]-5-nitropyridine,
5-nitro-2-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridine,
2-[2-(2-chlorophenyl)chroman-6-yloxy]-5-nitropyridine,
5-nitro-2-[2-(2-nitrophenyl)chroman-6-yloxy]pyridine,
5-nitro-2-[2-(3-nitrophenyl)chroman-6-yloxy]pyridine,
5-nitro-2-[2-(4-nitrophenyl)chroman-6-yloxy]pyridine,
2-[2-(3-methoxyphenyl)chroman-6-yloxy]-5-nitropyridine,
6-(5-nitropyridin-2-yloxy)-2-phenylchroman-4-one,
5-nitro-2-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridine,
6-(5-nitropyridin-2-yloxy)-2-phenylchromen-4-one, respectively.

Example 36:

6-[2-(4-Fluorophenyl)chroman-6-yloxy]pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.52-7.47 (m, 3H), 7.24 (m, 2H), 7.05 (dd, 1H, J 8.6, 3.0 Hz), 6.84-6.68 (m, 4H), 5.09 (dd, 1H, J 10.2, 2.1 Hz), 5.00 (bs, 2H), 2.93 (m, 1H), 2.69 (m, 1H), 2.13 (m, 1H), 1.98 (m, 1H).

Example 37:

6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.51 (d, 1H, J 3.0 Hz), 7.44 (m, 1H), 7.30-7.25 (m, 2H), 7.16 (m, 1H), 7.05 (dd, 1H, J 8.6, 3.0 Hz), 6.83-6.73 (m, 3H), 6.69 (d, 1H, J 8.6 Hz), 5.13 (dd, 1H, J 10.0, 3.0 Hz), 5.00 (s, 2H), 2.93 (ddd, 1H, -16.8, 10.5, 5.3 Hz), 2.68 (ddd, 1H, J –16.8, 8.0, 4.4 Hz), 2.18 (m, 1H), 1.96 (m, 1H).

Example 38:

6-[2-(2-Fluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.52 (m, 1H), 7.51 (d, 1H, J 3.0 Hz), 7.41 (m, 1H), 7.28-7.24 (m, 2H), 7.05 (dd, 1H, J 8.6, 3.0 Hz), 6.81-6.73 (m, 3H), 6.70 (d, 1H, J 8.6 Hz), 5.31 (dd, 1H, J 10.3, 2.2 Hz), 5.00 (s, 2H), 2.98 (m, 1H), 2.72 (m, 1H), 2.15 (m, 1H), 2.06 (m, 1H).

Example 39:

6-[2-(2,3-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.52 (d, 1H, J 3.0 Hz), 7.45-7.27 (m, 3H), 7.06 (dd, 1H, J 8.6, 3.0 Hz), 6.76-6.69 (m, 4H), 5.36 (dd, 1H, J 10.3, 2.2 Hz), 5.01 (bs, 2H), 2.97 (m, 1H), 2.73 (m, 1H), 2.18 (m, 1H), 2.03 (m, 1H).

Example 40:

6-[2-(2,4-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.58 (m, 1H), 7.51 (d, 1H, J 3.3 Hz), 7.30 (m, 1H), 7.15 (m, 1H), 7.05 (dd, 1H, J 8.3, 3.3 Hz), 6.84-6.73 (m, 3H), 6.70 (d, 1H, J 8.3 Hz), 5.27 (dd, 1H, J 10.3, 2.3 Hz), 5.01 (bs, 2H), 2.97 (m, 1H), 2.73 (m, 1H), 2.13 (m, 1H), 2.03 (m, 1H).

Example 41:

6-[2-(2,5-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (300 MHz, d_6-DMSO) δ: 7.51 (d, 1H, J 2.9 Hz), 7.36-7.25 (m, 3H), 7.05 (dd, 1H, J 8.6, 2.9 Hz), 6.84-6.68 (m, 4H), 5.29 (d, 1H, J 8.6), 4.99 (bs, 2H), 2.96 (m, 1H), 2.72 (m, 1H), 2.14 (m, 1H), 2.01 (m, 1H).

Example 42:

6-[2-(2,6-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.52-7.47 (m, 2H), 7.24 (m, 1H), 7.19-7.14 (m, 3H), 7.07 (dd, 1H, J 8.6, 2.9 Hz), 6.76-6.51 (m, 3H), 5.37 (dd, 1H, J 11.6, 2.0 Hz), 5.00 (bs, 2H), 3.00 (m, 1H), 2.78 (m, 1H), 2.32 (m, 1H), 2.11 (m, 1H).

Example 43:

6-[2-(3,5-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.51 (d, 1H, J 2.9 Hz), 7.22-7.17 (m, 3H), 7.05 (dd, 1H, J 8.6, 2.9 Hz), 6.84 (dd, 1H, J 7.9, 2.0 Hz), 6.76-6.74 (m, 2H), 6.69 (d, 1H, J 8.6 Hz), 5.14 (dd, 1H, J 10.0, 2.2 Hz), 5.01 (bs, 2H), 2.91 (m, 1H), 2.69 (m, 1H), 2.20 (m, 1H), 1.97 (m, 1H).

Example 44:

6-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.78 (d, 2H, J 8.4 Hz), 7.68 (d, 2H, J 8.4 Hz), 7.52 (dd, 1H, J 2.9, 0.5 Hz), 7.06 (dd, 1H, 8.6, 2.9 Hz) 6.84 (m, 1H), 6.77-6.75 (m, 2H), 6.70 (dd, 1H, J 8.6, 0.5 Hz), 5.23 (dd, 1H, J 10.0, 2.0 Hz), 5.01 (bs, 2H), 2.95 (ddd, 1H, -16.8, 11.1, 5.9 Hz), 2.69 (ddd, 1H, J –16.8, 8.5, 4.8 Hz), 2.21 (m, 1H), 1.97 (m, 1H).

Example 45:

6-[2-(2-Chlorophenyl)chroman-6-yloxy]pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.59 (m, 1H), 7.52-7.38 (m, 4H), 7.06 (dd, 1H, J 8.6, 3.0 Hz), 6.87-6.70 (m, 4H), 5.33 (dd, 1H, J 10.3, 2.1 Hz), 5.01 (bs, 2H), 2.97 (m, 1H), 2.74 (m, 1H), 2.20 (m, 1H), 1.93 (m, 1H)

Example 46:

6-[2-(2-Aminophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (300 MHz, d_6-DMSO) δ: 7.51 (d, 1H, J 2.9 Hz), 7.15-7.18 (m, 1H), 7.05 (dd, 1H, J 8.6, 2.9 Hz), 6.98-7.00 (m, 1H), 6.77 (d, 1H, J 8.6 Hz), 6.73-6.75 (m, 2H), 6.66-6.71 (m, 2H), 6.56-6.61 (m, 1H), 5.11 (dd, 1H, J 10.4, 2.0 Hz), 5.01 (s, 2H), 4.99 (s, 2H), 2.94-2.99 (m, 1H), 2.66-2.74 (m, 1H), 2.06-2.13 (m, 1H), 1.88-1.95 (m, 1H).

Example 47:

6-[2-(3-Aminophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (300 MHz, d_6-DMSO) δ: 7.51 (d, 1H, J 2.8 Hz), 7.05 (dd, 1H, J 8.6, 2.8 Hz), 7.01 (t, 1H, J 15.4, 7.7 Hz), 6.70-6.78 (m, 3H), 6.68 (d, 1H, J 8.6 Hz), 6.63 (s, 1H), 6.54 (d, 1H, J 7.7 Hz), 6.50 (d, 1H, J 8.6 Hz), 5.06 (s, 2H), 4.98 (s, 2H), 4.90 (dd, 1H, J 10.0, 2.2 Hz), 2.85-2.96 (m, 1H), 2.62-2.74 (m, 1H), 2.05-2.11 (m, 1H), 1.89-1.95 (m, 1H).

Example 48:

6-[2-(4-Aminophenyl)chroman-6-yloxy]-pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.50 (d, 1H, J 2.9 Hz), 7.07 (d, 2H, 8.4 Hz), 7.04 (dd, 1H, J 8.6, 2.9 Hz), 6.71 (s, 3H), 6.68 (d, 1H, J 8.6 Hz), 6.56 (d, 2H, J 8.4 Hz), 5.07 (s, 2H), 4.99 (s, 2H), 4.84 (dd, 1H, J 9.7, 2.3 Hz), 2.86-2.95 (m, 1H), 2.66-2.71 (m, 1H), 1.95-2.05 (m, 2H).

Example 49:

6-[2-(3-Methoxyphenyl)chroman-6-yloxy]pyridin-3-ylamine

^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.51 (d, 1H, J 3.0 Hz), 7.31 (t, 1H, J 15.8, 7.9 Hz), 7.04 (dd, 1H, J 8.7, 3.0 Hz), 6.99-7.02 (m, 1H), 6.99 (d, 1H, J 2.6 Hz), 6.90 (dd, 1H, J 8.9, 2.6 Hz), 6.79-6.81 (m, 1H), 6.72-6.74 (m, 2H), 6.69 (d, 1H, J 8.9 Hz), 5.06 (dd, 1H, J 9.9, 2.2 Hz), 4.50 (s, 2H), 3.77 (s, 3H), 2.88-2.95 (m, 1H), 2.66-2.71 (m, 1H), 2.12-2.17 (m, 1H), 1.94-2.00 (m, 1H).

Example 50:

6-(5-Aminopyridin2-yloxy)-2-phenylchroman-4-one

^{1}H NMR (400 MHz, CD_3OD) δ: 7.62 (d, 1H, J 3.0 Hz), 7.51-7.49 (m, 2H), 7.42-7.33 (m, 3H), 7.25-7.18 (m, 3H), 7.06 (d, 1H, J 8.8 Hz), 6.76 (d, 1H, J 8.6Hz), 5.50 (dd, 1H, J 13.0, 2.9 Hz), 3.08 (dd, 1H, -17.0, 13.0 Hz), 2.82 (dd, 1H, J –17.0, 2.9 Hz).

Example 51:

6-(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-ylamine hydrochloride

^{1}H NMR (400 MHz, $CDCl_3$) δ: 8.20 (d, 1H, J 2.1 Hz), 7.87 (dd, 1H, J 8.9, 2.1 Hz), 7.41-7.44 (m, 4H), 7.37-7.40 (m, 1H), 6.98 (d, 1H, J 8.9 Hz), 6.97 (d, 1H, J 8.8 Hz), 6.93 (d, 1H, J 2.7 Hz), 6.80 (dd, 1H, J 8.8, 2.7 Hz), 5.20 (dd, 1H, J 9.6, 1.9 Hz), 3.30 (dd, 1H, 13.2, 9.6 Hz), 3.12 (dd, 1H, 13.2, 1.9 Hz).

Example 52:

6-(5-Aminopyridin-2-yloxy)-2-phenylchromen-4-one

^{1}H-NMR (300 MHz; d_6-DMSO) δ: 8.14-8.10 (m, 2H), 7.63-7.51 (m, 5H), 7.42 (d, 1H, J 2.9 Hz) 7.14 (dd, 1H, J 8.6, 2.9 Hz), 7.03 (s, 1H), 6.89 (d, 1H, J 8.6 Hz), 5.19 (s, 2H).

Using the same procedure as described for 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in Example 35 but replacing 5-nitro-2-(2-phenylchroman-6-yloxy)-pyridine by:

2-[2-(3,4-difluorophenyl)chroman-6-yloxy]-5-nitropyridine,
5-nitro-2-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridine,
2-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(3-chlorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(3-bromophenyl)chroman-6-yloxy]-5-nitropyridine,
2-[2-(4-ethylphenyl)chroman-6-yloxy]-5-nitropyridine,
2-(3-methyl-2-phenylchroman-6-yloxy)-5-nitropyridine,
5-nitro-2-(2-phenylchroman-7-yloxy)-pyridine,
7-(5-nitropyridin-2-yloxy)-2-phenylchroman-4-one,
3-methyl-6-(5-nitropyridin-2-yloxy)-2-phenylchroman-4-one,
2-(2,3-dihydro-2-phenyl-benzo[1,4]dioxin-6-yloxy)-5-nitropyridine,
5-nitro-2-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridine,
6-(5-nitropyridin-2-yloxy)-2-phenyl-3,4-dihydro-2*H*-naphthalen-1one,
2-[3-(3-fluorophenyl)chroman-7-yloxy]-5-nitropyridine,
2-(3-phenylchroman-7-yloxy)-5-nitropyridine,
5-nitro-2-(2-phenylindan-5-yloxy) pyridine,
5-Nitro-2-(2-phenylindan-5-yloxy) pyridine

there can be obtained:

6-[2-(3,4-Difluorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-Chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-Chlorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(2,4-Dichlorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-Bromophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(4-Ethylphenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-(3-Methyl-2-phenylchroman-6-yloxy)pyridin-3-ylamine,
5-Amino-2-(2-phenylchroman-7-yloxy)pyridine,
7-(5-Aminopyridin2-yloxy)-2-phenylchroman-4-one,
6-(5-Aminopyridin-2-yloxy)-3-methyl-2-phenylchroman-4-one,
6-(2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-ylamine,
6-(6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-ylamine,

6-(5-Aminopyridin-2-yloxy)-2-phenyl-3,4-dihydro-2H-naphthalen-1-one,
6-[3-(3-Fluorophenyl)chroman-7-yloxy]pyridin-3-ylamine,
6-(3-Phenylchroman-7-yloxy)-pyridin-3-ylamine,
6-(2-Phenylindan-5-yloxy)-pyridin-3-ylamine, respectively.

Example 53:

2-Acetylamino-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide

5-Amino-2-(2-phenylchroman-6-yloxy)-pyridine (500 mg) of Example 35 and N-acetylglycine (275 mg) was dissolved in 35 ml of methylene chloride. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (450 mg) was added. The mixture was stirred at room temperature for 6 hours. Reaction was quenched with addition of water and formed precipitate was filtered. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.1 (s, 1H), 8.30 (d, 1H, J 2.7 Hz), 8.21 (t, 1H, J 5.7 Hz), 8.00 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.30 (m, 5H), 6.95 (d, 1H, J 8.9 Hz), 6.87-6.84 (m, 3H), 5.12 (dd, 1H, J 1.90, 10.0 Hz), 3.86 (d, 2H, J 5.7 Hz), 3.00-2.92 (m, 1H), 2.75-2.70 (m, 1H), 2.19-2.14 (m, 1H), 2.03-1.97 (m, 1H).

Using the same procedure as described for 2-acetylamino-*N*-[6-(2-phenyl-chroman-6-yloxy)-pyridin-3-yl]-acetamide above but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine by:

6-[2-(4-Fluorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine,
6-[2-(2-Fluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine,
6-[2-(2,3-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine,
6-[2-(2,4-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine,
6-[2-(2,5-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine
6-[2-(2,6-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine,
6-[2-(3,4-Difluorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3,5-Difluorophenyl)chroman-6-yloxy]-pyridin-3-ylamine
6-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-Chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(2-Chlorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-Chlorophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(2,4-Dichlorophenyl)chroman-6-yloxy]pyridin-3-ylamine,

6-[2-(3-Bromophenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(4-Ethylphenyl)chroman-6-yloxy]pyridin-3-ylamine,
6-[2-(3-Methoxyphenyl)chroman-6-yloxy]pyridin-3-ylamine
6-(3-Methyl-2-phenylchroman-6-yloxy)pyridin-3-ylamine,
5-Amino-2-(2-phenylchroman-7-yloxy)pyridine,
6-(5-Aminopyridin2-yloxy)-2-phenylchroman-4-one,
7-(5-Aminopyridin2-yloxy)-2-phenylchroman-4-one,
6-(5-Aminopyridin-2-yloxy)-3-methyl-2-phenylchroman-4-one,
6-(2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-ylamine
6-(6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-ylamine,
6-(5-Aminopyridin-2-yloxy)-2-phenyl-3,4-dihydro-2H-naphthalen-1-one,
6-(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-ylamine
6-[3-(3-Fluorophenyl)chroman-7-yloxy]pyridin-3-ylamine,
6-(3-Phenylchroman-7-yloxy)-pyridin-3-ylamine,
6-(5-Aminopyridin-2-yloxy)-2-phenylchromen-4-one,
6-(2-Phenylindan-5-yloxy)-pyridin-3-ylamine,

there is obtained:

2-Acetylamino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,
2-Acetylamino-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide
2-Acetylamino-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide

2-Acetylamino-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-{6-(3-methyl-2-phenylchroman-6-yloxy)pyridin-3-yl}acetamide,

2-Acetylamino-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]-acetamide,

2-Acetylamino-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,

2-Acetylamino-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-*N*-[6-(4-oxo-2-phenyl-4*H*-chromen-6-yloxy)pyridin-3-yl]acetamide,

2-Acetylamino-N-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide, respectively.

Example 54:

Piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide

a) 4-[6-(2-Phenylchroman-6yloxy)pyridin-3-ylcarbamoyl]piperidine-1-carboxylic acid *tert*-butyl ester

5-Amino-2-(2-phenylchroman-6-yloxy)-pyridine (500 mg) and N-(tert-butoxycarbonyl)isonipecotic acid (541 mg) was dissolved in 40 ml of THF. 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (451 mg) was added. The mixture was refluxed for few hours. Reaction was quenched with addition of water and extracted with ethyl acetate. Compined organic layers were washed with water, saturated sodium carbonate solution, dried with Na_2SO_4 and evapotated. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 10.0 (s, 1H), 8.31 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.33 (m, 5H), 6.92 (d, 1H, J 8.8 Hz), 6.87-6.84 (m, 3H), 5.13 (dd, 1H, J 2.2, 10.1 Hz), 4.04-3.96 (m, 2H), 2.99-2.91 (m, 1H), 2.81-2.69 (m, 3H), 2.20-2.12 (m, 2H), 2.08-1.98 (m, 1H), 1.79-1.74 (m, 3H), 1.50-1.35 (m, 11H).

b) Piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide

Mixture of 4-[6-(2-Phenyl-chroman-6-yloxy)-pyridin-3-ylcarbamoyl]-piperidine-1-carboxylic acid tert-butyl ester (860 mg) and of 1 M HCl in diethyl ether (13 ml) was stirred at room temperature for 24 hours. Precipitate was filtered and washed with ether. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 10.3 (s, 1H), 8.97 (bs, 1H), 8.65 (bs, 1H), 8.34 (d, 1H, J 2.7 Hz), 8.04 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.33 (m, 5H), 6.94 (d, 1H, J 8.8 Hz), 6.86-6.84 (m, 3H), 5.11 (dd, 1H, J 2.3, 10.0 Hz), 3.35-3.29

(m, 2H), 2.97-2.89 (m, 3H), 2.74-2.66 (m, 2H), 2.19-2.13 (m, 1H), 2.00-1.74 (m, 5H), 1.50-1.35 (m, 11H).

Using the same procedure as described above for piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide in steps a) and b) but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in step a) by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained:

Piperidine-4-carboxylic acid {6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Piperidine-4-carboxylic acid {6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Piperidine-4-carboxylic acid [6-(3-methyl-2-phenylchroman-6-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(2-phenylchroman-7-yloxy)pyridin-3-yl]-amide,

Piperidine-4-carboxylic acid [6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(5-oxo-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]amide,

Piperidine-4-carboxylic acid {6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl)amide

Piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]-amide,

Piperidine-4-carboxylic acid [6-(4-oxo-2-phenyl-4*H*-chromen-6-yloxy)-pyridin-3-yl]amide,

Piperidine-4-carboxylic acid [6-(2-phenylindan-5-yloxy)pyridin-3-yl]amide, respectively.

Example 55:

2-L-Amino-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]propionamide

a) {1-[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]ethyl}carbamic acid *tert*-butyl ester

{1-[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]ethyl}carbamic acid *tert*-butyl ester was prepared as described for piperidine-4-carboxylic acid [6-(2-phenyl-chroman-6-yloxy)pyridin-3-yl]amide in example 54 (a) starting from *N*-(*tert*-butoxycarbonyl)-L-alanine. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 10.0 (s, 1H), 8.31 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.33 (m, 5H), 6.94 (d, 1H, J 8.9 Hz), 6.87-6.84 (m, 3H), 5.11 (dd, 1H, J 2.0, 10.0 Hz), 4.08 (t, 1H, J 7.1 Hz), 3.00-2.91 (m, 1H), 2.75-2.69 (m, 1H), 2.19-2.04 (m, 1H), 2.02-1.97 (m, 1H), 1.38 (s, 9H), 1.26 (d, 3H, J 7.1 Hz).

b) 2-Amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]propionamide

2-Amino-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]propionamide was prepared as described for piperidine-4-carboxylic acid [6-(2-phenyl-chroman-6-yloxy)-pyridin-3-yl]-amide in example 54 (b) starting from {1-[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]ethyl}carbamic acid *tert*-butyl ester. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.9 (s, 1H), 8.39 (d, 1H, J 2.5 Hz), 8.05 (dd, 1H, J 2.5, 8.8 Hz), 7.46-7.31 (m, 5H), 7.00 (d, 1H, J 8.8 Hz), 6.88-6.85 (m, 3H), 5.12 (d, 1H, J 8.6 Hz), 4.07 (m, 1H) 3.01-2.92 (m, 1H), 2.75-2.70 (m, 1H), 2.19-2.15 (m, 1H), 2.02-1.97 (m, 1H).

Using the same procedure as described above for 2-amino-*N*-[6-(2-phenyl-chroman-6-yloxy)pyridin-3-yl]propionamide in steps a) and b) but replacing *N*-(*tert*-butoxycarbonyl)-L-alanine in step a) by *N*-(*tert*-butoxycarbonyl)-D-alanine or *N*-(*tert*-butoxycarbonyl)-D,L-alanine there can be obtained D- and D,L- form of 2-amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]propionamide, respectively.

Similarly using the same procedure as described above for 2-amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]propionamide in steps a) and b) but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in step a) by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained L-, D- and D,L-forms of:

2-Amino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-(6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]pyridin-3-yl}-propionamide,

2-Amino-*N*-6-[2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(2-phenylchroman-7-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-propionamide,

2-Amino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-propionamide,

2-Amino-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-propionamide,

2-Amino-*N*-[6-(5-Oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}propionamide,

2-Amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(4-oxo-2-phenyl-4*H*-chromen-6-yloxy)pyridin-3-yl]propionamide,

2-Amino-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]propionamide,

respectively.

Example 56:

2-L-Amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide

a) {2-Methyl-1-[6-(2-phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]-propyl}carbamic acid *tert*-butyl ester

{2-Methyl-1-[6-(2-phenyl-chroman-6-yloxy)-pyridin-3-ylcarbamoyl]-propyl}-carbamic acid *tert*-butyl ester was prepared as described for piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]amide in example 54 (a) starting from *N*-(*tert*-butoxycarbonyl)-L-valine. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 10.1 (s,

1H), 8.32 (d, 1H, J 2.7 Hz), 8.04 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.33 (m, 5H), 6.94 (d, 1H, J 8.8 Hz), 6.89-6.84 (m, 3H), 5.11 (dd, 1H, J 2.2, 10.0 Hz), 3.91 (t, 1H, J 6.7 Hz), 3.04-2.91 (m, 1H), 2.78-2.69 (m, 1H), 2.21-2.12 (m, 1H), 2.07-1.92 (m, 2H), 1.39 (s, 9H), 0.9 (d, 6H, J 6.7 Hz).

b) 2-Amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide

2-Amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]butyramide was prepared as described for piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide in example 54 (b) starting from {2-methyl-1-[6-(2-phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]propyl}carbamic acid *tert*-butyl ester. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 10.8 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.31 (bs, 3H), 8.05 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.33 (m, 5H), 7.00 (d, 1H, J 8.9 Hz), 6.98-6.86 (m, 3H), 5.12 (dd, 1H, J 2.2, 10.0 Hz), 3.82-3.78 (m, 1H), 3.08-2.90 (m, 1H), 2.78-2.68 (m, 1H), 2.30-2.10 (m, 2H), 2.07-1.92 (m, 1H), 1.02-0.98 (m, 6H).

Using the same procedure as described above for 2-amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide in steps a) and b) but replacing *N*-(*tert*-butoxycarbonyl)-L-valine by in step a) *N*-(*tert*-butoxycarbonyl)-D-valine or *N*-(*tert*-butoxycarbonyl)-D,L-valine there can be obtained D- and D,L-forms of 2-amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide, respectively.

Similarly using the same procedure as described above for 2-amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide in steps a) and b) but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in step a) by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained L-, D- and D,L-forms of:

2-Amino-3-methyl-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-(6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-6-[2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(2-phenylchroman-7-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-butyramide

2-Amino-3-methyl-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)-pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)-pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}butyramide,

2-Amino-3-methyl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(4-oxo-2-phenyl-4*H*-chromen-6-yloxy)pyridin-3-yl]butyramide,

2-Amino-3-methyl-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]butyramide, respectively.

Example 57:

Pyrrolidine-2-L-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide

a) 2-[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]-L-pyrrolidine-1-carboxylic acid *tert*-butyl ester

2-[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]-L-pyrrolidine-1-carboxylic acid *tert*-butyl ester was prepared as described for piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide in example 54 (a) starting from *N*-(*tert*-butoxycarbonyl)-L-proline. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 10.1 (s, 1H), 8.31 (d, 1H, J 2.4 Hz), 8.03 (dd, 1H, J 2.4, 8.8 Hz), 7.47-7.33 (m, 5H), 6.95 (d, 1H, J 8.8 Hz), 6.87-6.85 (m, 3H), 5.12 (dd, 1H, J 2.1, 9.9 Hz); 4.37-4.13 (m, 1H), 3.5-3.3 (m, 2H), 3.03-2.90 (m, 1H), 2.80-2.68 (m, 1H), 2.29-2.11 (m, 2H), 2.09-1.73 (m, 4H), 1.40-1.29 (m, 9H).

b) Pyrrolidine-2-L-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide

Pyrrolidine-2-L-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide was prepared as described for piperidine-4-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide in example 54 (b) starting from 2-[6-(2-phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]pyrrolidine-1-carboxylic acid *tert*-butyl ester. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 10.9 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.33 (m, 5H), 7.00 (d, 1H, J 8.8 Hz), 6.99-6.85 (m, 3H), 5.12 (dd, 1H, 2.2, 10.1 Hz), 3.32-3.20 (m, 2H), 3.04-2.90 (m, 1H), 2.80-2.68 (m, 1H), 2.49-2.34 (m, 1H), 2.24-2.12 (m, 1H), 2.08-1.90 (m, 4H).

Using the same procedure as described above for pyrrolidine-2-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide steps a) and b) but replacing *N*-(*tert*-butoxycarbonyl)-L-proline in step a) by *N*-(*tert*-butoxycarbonyl)-D-proline or *N*-(*tert*-butoxycarbonyl)-D,L-proline there can be obtained D and D,L forms of pyrrolidine-2-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide, respectively.

Similarly using the same procedure as described above for pyrrolidine-2-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]amide in steps a) and b) but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in step a) by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained L-, D- and D,L-forms of:

Pyrrolidine-2-carboxylic acid {6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid (6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid [2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid [6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(2-phenylchroman-7-yloxy)pyridin-3-yl]-amide,

Pyrrolidine-2-carboxylic acid [6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)-pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(5-oxo-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid [6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid {6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}amide,

Pyrrolidine-2-carboxylic acid [6-(2-phenylchroman-6-yloxy)pyridin-3-yl]-amide,

Pyrrolidine-2-carboxylic acid [6-(4-oxo-2-phenyl-4*H*-chromen-6-yloxy)-pyridin-3-yl]amide,

Pyrrolidine-2-carboxylic acid[6-(2-phenylindan-5-yloxy)pyridin-3-yl]amide, respectively.

Example 58:

N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide

a) 4-Chloromethylbenzoic acid methyl ester

4-Chloromethylbenzoic acid (2.0 g) was dissolved in 300 ml of methanol and 0.5 ml concentrated sulphuric acid was added. The mixture was stirred at room temperature for eight days. Methanol was evaporated and the residue was dissolved in ethyl acetate. The organic layer was washed with saturated $NaHCO_3$-solution, dried with Na_2SO_4 and evaporated to yield 4-chloromethylbenzoic acid methyl ester. ^1H NMR (300 MHz, d_6-DMSO) δ: 3.86 (s, 3H), 4.84 (s, 2H), 7.59 (d, 2H, J 8.2 Hz), 7.97 (d, 2H, J 8.2 Hz).

b) 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid methyl ester

4-Chloromethylbenzoic acid methyl ester (1.66 g), 1-methylpiperazine (1.8 g) and sodium iodide (0.67 g) were added into acetone (50 ml). The reaction mixture was stirred at 60 °C for 9 hours. More 1-methylpiperazine (0.9 g) and sodium iodide

(0.34 g) were added and after stirring additional 1 ½ hours at 60 °C the reaction mixture was allowed to cool into room temperature. The mixture was filtered and acetone was evaporated. The residue was dissolved in ethyl acetate and washed with water. The solvent was dried with $NaSO_4$ and evaporated to yield 4-(4-methyl-piperazin-1-ylmethyl)benzoic acid methyl ester. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 2.18 (s, 3H), 2.37 (bs, 8H), 3.53 (s, 2H), 3.84 (s, 3H), 7.44 (d, 2H, J 8.1 Hz), 7.91 (d, 2H, J 8.2 Hz).

HCl-salt of 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid methyl ester 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid methyl ester was dissolved in ethyl acetate and 1 M HCl-diethyl ether solution was added. The mixture was stirred for 1 hour and precipitated HCl-salt was filtered and washed with diethyl ether. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 2.78 (s, 3H), 3.10-3.75 (m, 8H), 3.87 (s, 3H), 4.35 (bs, 2H), 7.77 (d, 2H, J 7.5 Hz), 8.00 (d, 2H, J 8.1 Hz).

c) 4-(4-Methylpiperazin-1-ylmethyl)benzoic acid

HCl-salt of 4-(4-methylpiperazin-1-ylmethyl)benzoic acid methyl ester (1.25 g) was dissolved in potassium hydroxide-methanol solution (0.93 g KOH in 15 ml methanol). Water (0.75 ml) was added and the mixture was refluxed for 1 hour. The reaction mixture was allowed to cool into room temperature and the pH was tuned to 6 with 2 M HCl. The solvent was evaporated and the residue was dried under vacuum. The residue contained 4-(4-methylpiperazin-1-ylmethyl)benzoic acid and inorganic salts. It was used further without purification and the yield of title compound was assumed to be 100%. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 2.27 (s, 3H), 2.44 (bs, 2H), 3.18-3.95 (m, 8H), 7.41 (d, 2H, J 8.0 Hz), 7.89 (d, 2H, J 8.1 Hz).

d) *N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide

4-(4-Methylpiperazin-1-ylmethyl)benzoic acid (ca 0.19 g), 6-[2-(4-fluoro-phenyl)chroman-6-yloxy]pyridin-3-ylamine (0.18 g) and 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (0.12 g) were added into dichloromethane (12 ml). The mixture was stirred at room temperature and after 4 hours more 4-(4-methylpiperazin-1-ylmethyl)-benzoic acid (ca 0.11 g) and 1-(3-dimethyl-amino-propyl)-3-ethylcarbodiimide hydrochloride (0.0.46 g) were added. Stirring was continued for additional 3 hours. Water and dichloromethane were added and organic

and water phases were separated. Water phase was extracted with dichloromethane. The product was purified by column chromatography using dichloromethane-methanol (9:1) as an eluent to give N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 1.90-2.08 (m, 1H), 2.11-2.21 (m, 1H), 2.18 (s, 3H), 2.38 (bs, 8H), 2.68-2.79 (m, 1H), 2.91-3.05 (m, 1H), 3.54 (s, 2H), 5.13 (dd, 1H, J 2.0, 10.1 Hz), 6.86 (d, 2H, J 1.2 Hz), 6.90 (s, 1H), 6.98 (d, 1H, J 8.8 Hz), 7.19-7.27 (m, 2H), 7.43-7.54 (m, 4H), 7.92 (d, 2H, J 8.2 Hz), 8.18 (dd, 1H, J 2.7, 8.9 Hz), 8.48 (d, 1H, J 2.7 Hz), 10.31 (s, 1H).

Using the same procedure as described above for *N*-{6-[2-(4-fluorophenyl)-chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide, but replacing 6-[2-(4-fluorophenyl)-chroman-6-yloxy]pyridin-3-ylamine by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained:

N-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(2-Fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(2,3-Difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(2,4-Difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(2,5-Difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(2,6-Difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(3,4-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(3,5-Difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(3-Chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(2-Chlorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(3-Chlorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(2,4-Dichlorophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(3-Bromophenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(4-Ethylphenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[2-(3-Methoxyphenyl)chroman-6-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-(3-Methyl-2-phenylchroman-6-yloxy)pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-[6-(2-phenylchroman-7-yloxy)pyridin-3-yl] -4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-[6-(4-Oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-[6-(4-Oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-[6-(3-Methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-(2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-(6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-[6-(5-Oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-[3-(3-Fluorophenyl)chroman-7-yloxy]pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-{6-(3-Phenylchroman-7-yloxy)-pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide,

N-[6-(4-Oxo-2-phenyl-4*H*-chromen-6-yloxy)pyridin-3-yl]-4-(4-methyl-piperazin-1-ylmethyl)benzamide,

N-{6-(2-Phenylindan-5-yioxy)-pyridin-3-yl}-4-(4-methylpiperazin-1-ylmethyl)benzamide.

Example 59:

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid

6-(2-Phenylchroman-6-yloxy)pyridin-3-ylamine (example 35) (270 mg) and succinic acid (151 mg) were dissolved in dichloromethane (16 ml). 1-(3-Dimethyl-aminopropyl)-3-ethylcarbodiimide hydrochloride (245 mg) was added into a reaction mixture and it was stirred at room temperature for 3 hours. Water was added and the mixture was filtered. The precipitate was collected and treated with methanol and filtered again. The methanol-filtrate was evaborated to dryness to yield *N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid. ^{1}H NMR (400 MHz, d_6-DMSO) □: 12.0 (bs, 1H), 10.08 (s, 1H), 8.29 (d, 1H, J 2.4 Hz), 8.01 (dd, 1H, J 8.8, 2.4 Hz), 7.46-7.32 (m, 5H), 6.93 (d, 1H, J 8.8 Hz), 6.86-6.84 (m, 3H), 5.11 (d, 1H, J 8.6 Hz), 2.96 (m, 1H), 2.70 (m, 1H), 2.56-2.52 (m, 4H), 2.16 (m, 1H), 2.00 (m, 1H).

Using the same as procedure as described above for *N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained:

N-{6-[2-(4-Fluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3-Fluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2-Fluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2,3-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2,4-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2,5-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2,6-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3,4-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3,5-Difluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-[6-(3-Methyl-2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(2-phenylchroman-7-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(4-Oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(4-Oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(3-Methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(5-Oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-succinamic acid,

N-[6-(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]succinamic acid,

N-{6-[2-(3-Fluorophenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(4-Oxo-2-phenyl-4*H*-chromen-6-yloxy)pyridin-3-yl]succinamic acid,

N-[6-(2-Phenylindan-5-yloxy)pyridin-3-yl]succinamic acid,

respectively.

Example 60:

2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a cooled solution of 5-amino-2-(2-phenylchroman-6-yloxy)-pyridine (500 mg) in 7.5 ml of methylene chloride was added triethyl amine (437 µl) and chloracetyl chloride (163 µl). The reaction mixture was stirred at room temperature for 3

hours and quenched with addition of water. Water layer was acidified and extracted with methylene chloride. The combined organic layers were dried with Na_2SO_4 and evaporated. The 2-chloro-*N*-[6-(2-phenyl-chroman-6-yloxy)-pyridin-3-yl]-acetamide was purified by column chromatography using 10% methanol in methylene chloride as an eluant. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.4 (s, 1H), 8.30 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.32 (m, 5H), 6.97 (d, 1H, J 8.8 Hz), 6.88-6.85 (m, 3H), 5.12 (dd, 1H, J 2.10, 10.1 Hz), 4.27 (s, 2H), 2.97-2.92 (m, 1H), 2.76-2.70 (m, 1H), 2.19-2.14 (m, 1H), 2.02-1.97 (m, 1H).

Using the same procedure as described above for 2-chloro-*N*-[6-(2-phenyl-chroman-6-yloxy)pyridin-3-yl]acetamide but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained:

2-chloro-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-chloro-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-acetamide,

2-chloro-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-acetamide,

2-chloro-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide

2-chloro-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-chloro-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,

2-chloro-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-chloro-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide,

respectively.

Example 61:

2-Amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

a) 2-Azido-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide (500 mg), sodium azide (445 mg) and acetonitrile were mixed. Reaction mixture was refluxed for 3 hours. After cooling into room temperature, the reaction mixture was filtered and the filtrate was evaporated to the dryness. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.3 (s, 1H), 8.29 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.33 (m, 5H),

6.96 (d, 1H, J 8.8 Hz), 6.88-6.85 (m, 3H), 5.12 (dd, 1H, J 2.20, 10.1 Hz), 4.07 (s, 2H), 3.00-2.92 (m, 1H), 2.76-2.70 (m, 1H), 2.19-2.14 (m, 1H), 2.02-1.97 (m, 1H).

b) 2-Amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

2-Azido-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide (500 mg) was dissolved in methanol (100 ml) and 10 % palladium on charcoal (125 mg) was added. Starting material was hydrogenated for 5 hours at room temperature to give 2-amino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide. The product was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.7 (s, 1H), 8.35 (d, 1H, J 2.6 Hz), 8.17 (bs, 3H), 8.01 (dd, 1H, J 2.6, 8.9 Hz), 7.47-7.32 (m, 5H), 7.00 (d, 1H, J 8.9 Hz), 6.89-6.86 (m, 3H), 5.12 (dd, 1H, J 1.90, 10.1 Hz), 3.79 (q, 2H, J 5.6 Hz), 3.01-2.92 (m, 1H), 2.74-2.70 (m, 1H), 2.20-2.15 (m, 1H), 2.05-1.94 (m, 1H).

Example 62:

2-Amino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide

a) 2-Chloro-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide

To a cooled solution of 6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-ylamine (530 mg) in 8 ml of methylene chloride was added triethyl amine (439 µl) and chloracetyl chloride (163 µl). The reaction mixture was stirred at room temperature for 3 hours and quenched with addition of water. Water layer was acidified and extracted with methylene chloride. The combined organic layers were dried with Na_2SO_4 and evaporated. The 2-Chloro-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-acetamide was purified by column chromatography using 10% methanol in methylene chloride as an eluant. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.4 (s, 1H), 8.29 (d, 1H, J 2.7 Hz), 8.02 (dd, 1H, J 2.7, 8.8 Hz), 7.52-7.48 (m, 2H), 7.25-7.20 (m, 2H), 6.97 (d, 1H, J 8.8 Hz), 6.88-6.84 (m, 3H), 5.12 (dd, 1H, J 1.90, 10.2 Hz), 4.27 (s, 2H), 2.98-2.92 (m, 1H), 2.76-2.69 (m, 1H), 2.18-2.13 (m, 1H), 2.01-1.96 (m, 1H).

b) 2-Azido-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-acetamide

2-Chloro-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-acetamide (434 mg), sodium azide (368 mg) and acetonitrile were mixed. Reaction mixture was refluxed for 3 hours. After cooling into room temperature, the reaction mixture was filtered and the filtrate was evaporated to the dryness. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.3 (s, 1H), 8.30 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.8 Hz), 7.53-7.47 (m, 2H), 7.26-7.19 (m, 2H), 6.96 (d, 1H, J 8.8 Hz), 6.88-6.84 (m, 3H), 5.12 (dd, 1H, J 2.1, 10.1 Hz), 4.07 (s, 2H), 3.00-2.92 (m, 1H), 2.76-2.70 (m, 1H), 2.19-2.14 (m, 1H), 2.02-1.97 (m, 1H).

c) 2-Amino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-acetamide

2-Azido-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-acetamide (420 mg) was dissolved in methanol (80 ml) and 10 % palladium on charcoal (105 mg) was added. Starting material was hydrogenated for 5 hours at room temperature to give 2-amino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-acetamide. Product was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.8 (s, 1H), 8.36 (d, 1H, J 2.7 Hz), 8.21 (bs, 3H), 8.02 (dd, 1H, J 2.7, 8.9 Hz), 7.52-7.47 (m, 2H), 7.26-7.19 (m, 2H), 6.99 (d, 1H, J 8.9 Hz), 6.88-6.85 (m, 3H), 5.14 (dd, 1H, J 1.90, 10.0 Hz), 3.79 (q, 2H, J 5.7 Hz), 2.97-2.91 (m, 1H), 2.74-2.69 (m, 1H), 2.19-2.12 (m, 1H), 2.01-1.91 (m, 1H).

Using the same procedure as described above for 2-amino-*N*-[6-(2-phenyl-chroman-6-yloxy)-pyridin-3-yl]-acetamide and 2-amino-*N*-{6-[2-(4-fluorophenyl)-chroman-6-yloxy]pyridin-3-yl}acetamide but replacing 2-chloro-*N*-[6-(2-phenyl-chroman-6-yloxy)pyridin-3-yl]acetamide or 2-chloro-*N*-{6-[2-(4-fluorophenyl)-chroman-6-yloxy]pyridin-3-yl}acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

2-amino-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-amino-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-amino-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-amino-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-amino-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-amino-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-amino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-amino-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-amino-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide

2-amino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-amino-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,
2-amino-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,
2-amino-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,
2-amino-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide,
respectively.

Example 63:

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-(4-phenylpiperazin-1-yl)acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (500 mg) in acetonitrile was added potassium carbonate (333 mg) and 1-phenylpiperazine (213 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with dichloromethane. Organic extract was dried and evaporated. Product was purified by column chromatography using 10% methanol in dichlomethane as an eluant. *N*-[6-(2-Phenylchroman-6-yloxy)-pyridin-3-yl]-2-(4-phenylpiperazin-1-yl)acetamide was isolated as its dihydrochloride salt ^{1}H NMR (300 MHz, d_4-MeOH) δ: 8.70 (bs, 1H), 8.25 (dd, 1H, J 2.1, 9.1 Hz), 7.46-7.28 (m, 7H), 7.09-6.96 (m, 7H), 5.12 (dd, 1H, J 2.3, 9.8 Hz), 4.32 (s, 2H), 3.73-3.40 (m, 8H), 3.10-2.95 (m, 1H), 2.90-2.76 (m, 1H), 2.33-2.20 (m, 1H), 2.13-2.00 (m, 1H).

Using the same procedure as described above for *N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-2-(4-phenylpiperazin-1-yl)acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,
N-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,
N-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,
N-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,
N-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide,

N-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]-2-(4-phenyl-piperazin-1-yl)acetamide, respectively.

Example 64:

2-(4-Methylpiperazin-1-yl)-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and 1-methylpiperazine (62 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with dichloromethane. Organic extract was dried and evaporated. *N*-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-(4-methylpiperazin-1-yl)acetamide was isolated as its dihydrochloride salt. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 10.7 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.04 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.31 (m, 5H), 6.99 (d, 1H, J 8.8 Hz), 6.88-6.85 (m, 3H), 5.12 (dd, 1H, J 2.0, 10.0 Hz), 3.95 (s, 2H), 3.68-3.42 (m, 4H), 3.42-3.18 (m, 4H), 2.97-2.91 (m, 1H), 2.81 (s, 3H), 2.80-2.73 (m, 1H), 2.25-2.10 (m, 1H), 2.10-1.96 (m, 1H).

Using the same procedure as described above for 2-(4-methylpiperazin-1-yl)-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-(4-methylpiperazin-1-yl)-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide, respectively.

Example 65:

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and 1-methylpiperazine (262 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with dichloromethane.

Organic extract was dried and evaporated. *N*-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-(4-piperazin-1-yl)acetamide was isolated as its dihydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.7 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.33 (m, 5H), 6.99 (d, 1H, J 8.9 Hz), 6.88-6.85 (m, 3H), 5.12 (dd, 1H, J 2.1, 10.1 Hz), 3.5-3.2 (m, 10H), 2.97-2.92 (m, 1H), 2.74-2.70 (m, 1H), 2.20-2.15 (m, 1H), 2.03-1.97 (m, 1H).

Using the same procedure as described above for *N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-2-piperazin-1-yl acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-2 -piperazin-1-yl acetamide,

N-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}-2-piperazin-1-yl acetamide,

N-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]-2 piperazin-1-yl acetamide,

N-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]-2-piperazin-1-yl acetamide, respectively.

Example 66:

2-Morpholin-4-yl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and morpholine (53 mg). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. 2-Morpholin-4-yl-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 11.1 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.32 (m, 5H), 7.01 (d, 1H, J 8.9 Hz), 6.89-6.85 (m, 3H), 5.12 (dd, 1H, J 1.9, 10.0 Hz), 4.23 (s, 2H), 4.02-3.76 (m, 4H), 3.55-3.20 (m, 4H), 3.00-2.92 (m, 1H), 2.75-2.69 (m, 1H), 2.19-2.15 (m, 1H), 2.03-1.98 (m, 1H).

Using the same procedure as described above for 2-morpholin-4-yl-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

2-morpholin-4-yl-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide

2-morpholin-4-yl-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)-pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)-pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,

2-morpholin-4-yl-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-morpholin-4-yl-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide, respectively.

Example 67:

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and thiomarpholine (63 mg). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. *N*-[6-(2-Phenylchroman-6-yloxy)-pyridin-3-yl]-2-thiomorpholin-4-yl-acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 11.0 (s, 1H), 8.37 (d, 1H, J 2.6 Hz), 8.02 (dd, 1H, J 2.6, 8.9 Hz), 7.46-7.32 (m, 5H), 7.01 (d, 1H, J 8.9 Hz), 6.89-6.86 (m, 3H), 5.12 (dd, 1H, J 1.9, 10.1 Hz), 4.20 (bs, 2H), 3.85-2.65 (m, 10H), 2.20-2.15 (m, 1H), 2.05-1.95 (m, 1H).

Using the same procedure as described above for *N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide derivative listed in Example 60, there can be obtained:

N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}-2-thiomorpholin-4-yl acetamide,

N-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide,

N-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]-2-thiomorpholin-4-yl acetamide, respectively.

Example 68:

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-pyrrolidin-1-yl acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and pyrrolidine (51 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. *N*-[6-(2-Phenyl-chroman-6-yloxy) pyridin-3-yl]-2-pyrrolidin-1-yl acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.8 (s, 1H), 8.35 (d, 1H, J 2.7 Hz), 8.02 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.32 (m, 5H), 7.00 (d, 1H, J 8.9 Hz), 6.89-6.85 (m, 3H), 5.12 (dd, 1H, J 1.9, 10.0 Hz), 4.25 (d, 2H, 5.4 Hz), 3.67-3.55 (m, 2H), 3.20-3.06 (m, 2H), 3.06-2.90 (m, 1H), 2.80-2.65 (m, 1H), 2.23-2.12 (m, 1H), 2.10-1.85 (m, 5H).

Using the same procedure as described above for *N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]-2-pyrrolidin-1-yl acetamide but replacing 2-chloro-*N*-[6-(2-

phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-2-pyrrolidin-1-yl acetamide,

N-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-pyrrolidin-1-yl acetamide,

N-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-pyrrolidin-1-yl acetamide

N-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-pyrrolidin-1-yl acetamide,

N-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}-2- pyrrolidin-1-yl acetamide,

N-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-2-pyrrolidin-1-yl acetamide,

N-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-pyrrolidin-1-yl acetamide,

N-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-pyrrolidin-1-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]-2-pyrrolidin-1-yl acetamide,

N-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}- pyrrolidin-1-yl acetamide,

N-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]-2- pyrrolidin-1-yl acetamide,

N-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]-2- pyrrolidin-1-yl acetamide, respectively.

Example 69:

2-(2,5-Dimethylpyrrolidin-1-yl)-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and 2,5-dimethylpyrrolidine (81 µl). The mixture was stirred at room temperature. Water was

added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. The product was purified by column chromatography using gradient elution with methanol –dichloromethane (2 %-> 5 %). ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 9.66 (s, 1H), 8.35 (d, 1H, J 2.7 Hz), 8.06 (dd, 1H, J 2.7, 8.8 Hz), 7.47-7.32 (m, 5H), 6.93 (d, 1H, J 8.8 Hz), 6.88-6.84 (m, 3H), 5.12 (dd, 1H, J 2.1, 9.9 Hz), 3.22 (s, 2H), 3.05-2.88 (m, 1H), 2.78-2.66 (m, 3H), 2.22-2.12 (m, 1H), 2.08-1.92 (m, 1H), 1.90-1.79 (m, 2H), 1.43-1.34 (m, 2H), 1.06 (d, 6H, J 6.1 Hz).

Using the same procedure as described above for 2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)pyridin-3-yl]acetamide

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]-oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]-pyridin-3-yl}acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-(2,5-dimethylpyrrolidin-1-yl)-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide, respectively, as mixture of *cis*- and *trans*- isomers.

Example 70:

N-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) piperidine (60 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with dichloromethane. Organic extract was dried and evaporated. *N*-[6-(2-Phenylchroman-6-yloxy)-pyridin-3-yl]-2-(4-piperin-1-yl)acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 11.0 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.03 (dd, 1H, J 2.7, 8.8 Hz), 7.46-7.32 (m, 5H), 7.00 (d, 1H, J 8.8 Hz), 6.89-6.85 (m, 3H), 5.12 (dd, 1H, J 1.9, 10.0 Hz), 4.13 (d, 2H, J 4.9 Hz), 3.52-3.41 (m, 2H), 3.15-2.90 (m, 3H), 2.79-2.67 (m, 1H), 2.24-2.12 (m, 1H), 2.07-1.92 (m, 1H), 1.85-1.33 (m, 6H).

Using the same procedure as described above for *N*-[6-(2-Phenylchroman-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

N-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}-2-piperidin-1-yl acetamide,

N-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide,

N-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]-2-piperidin-1-yl acetamide, respectively.

Example 71:

2-(4-Hydroxypiperidin-1-yl)-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and 4-hydroxypiperidine (62 mg). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. Product was purified by column chromatography using 10% methanol in methylenechloride as eluant. 2-(4-Hydroxypiperidin-1-yl)-*N*-[6-(2-phenyl-chroman-6-yloxy)-pyridin-3-yl]-acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_4-MeOH) δ: 8.41 (s, 1H), 8.06 (dd, 1H, J 2.7, 9.0 Hz), 7.45-7.28 (m, 5H), 6.95-6.85 (m, 4H), 5.10 (dd, 1H, J 2.1, 10.0 Hz), 4.13 (s, 2H), 3.72-3.68 (m, 1H), 3.48-3.43 (m, 3H), 3.25-3.10 (m, 1H), 3.02-2.97 (m, 1H), 2.81-2.75 (m, 1H), 2.26-1.76 (m, 6H). $(M)^+$ = 459 (5.8%), 360 (7.4%), 114 (100%).

Using the same procedure as described above for 2-(4-hydroxypiperidin-1-yl)-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-(4-hydroxypiperidin-1-yl)-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide, respectively.

Example 72:

1-{[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) piperidine-4-carboxylic acid ethyl ester (94 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. Product was purified by

column chromatography using 10% methanol in methylenechloride as eluant. 1-{[6-(2-Phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_4-MeOH) δ: 8.48 (s, 1H), 8.10 (dd, 1H, J 2.2, 9.0 Hz), 7.45-7.29 (m, 5H), 6.99-6.88 (m, 4H), 5.10 (dd, 1H, J 2.0, 10.0 Hz), 4.23-4.15 (m, 4H), 3.76-3.72 (m, 2H), 3.22-3.15 (m, 2H), 3.05-2.98 (m, 1H), 2.82-2.75 (m, 2H), 2.27-1.97 (m, 6H), 1.27 (t, 3H, J 7.2 Hz). $(M)^+$ = 515 (2.9%), 470 (4.3%), 360 (8.5%), 170 (100%).

Using the same procedure as described above for 1-{[6-(2-phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide derivative listed in Example 60, there can be obtained:

1-{[6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-(2-phenylchroman-7-yloxy)-pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-ylcarbamoyl]-methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-ylcarba-moyl]methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-ylcarba-moyl]methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-ylcarba-moyl]methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-(3-phenylchroman-7-yloxy)pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester,

1-{[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-ylcarbamoyl]methyl}-piperidine-4-carboxylic acid ethyl ester,

1-{[6-(2-phenylindan-5-yloxy)pyridin-3-ylcarbamoyl]methyl}piperidine-4-carboxylic acid ethyl ester, respectively.

Example 73:

2-Diethylamino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide (200 mg) in acetonitrile was added potassium carbonate (133 mg) and diethyl amine (63 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. Product was purified by column chromatography using 10% methanol in methylenechloride as eluant. 2-Diethylamino-*N*-[6-(2-phenyl-chroman-6-yloxy)pyridin-3-yl]acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 11.1 (s, 1H), 8.38 (d, 1H, J 2.7 Hz), 8.04 (dd, 1H, J 2.7, 8.9 Hz), 7.47-7.32 (m, 5H), 7.01 (d, 1H, J 8.9 Hz), 6.89-6.85 (m, 3H), 5.12 (dd, 1H, J 2.0, 10.0 Hz), 4.14 (d, 2H, J 4.9 Hz), 3.24 (k, 4H, J 7.2 Hz), 3.01-2.92 (m, 1H), 2.76-2.70 (m, 1H), 2.19-2.15 (m, 1H), 2.04-1.94 (m, 1H), 1.24 (t, 6H, J 7.2 Hz).

Using the same procedure as described above for 2-diethylamino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60 (ORM-10786), there can be obtained:

2-diethylamino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-diethylamino-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)-pyridin-3-yl]acetamide,

2-diethylamino-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}-acetamide,

2-diethylamino-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-diethylamino-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide,

respectively.

Example 74:

2-Dimethylamino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-Chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]-acetamide (177 mg) in acetonitrile was added potassium carbonate (118 mg) and 33 % dimethylamine in ethanol (480 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. 2-Dimethylamino-*N*-[6-(2-phenyl-chroman-6-yloxy)-pyridin-3-yl]acetamide was isolated as its hydrochloride salt. ^{1}H-NMR (300 MHz; d_6-DMSO) δ: 11.3 (s, 1H), 8.41 (d, 1H, J 2.3 Hz), 8.07 (dd, 1H, J 2.3, 8.8 Hz), 7.47-7.33 (m, 5H), 7.00 (d, 1H, J 8.8 Hz), 6.88-6.85 (m, 3H), 5.12 (d, 1H, J 8.5 Hz), 4.20 (s, 2H), 3.01-2.69 (m, 8H), 2.20-1.91 (m, 2H).

Using the same procedure as described above for 2-dimethylamino-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide-derivative listed in Example 60, there can be obtained:

2-dimethylamino-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-dimethylamino-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)-pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)-pyridin-3-yl]acetamide,

2-dimethylamino-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]pyridin-3-yl}acetamide,

2-dimethylamino-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-dimethylamino-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide,

respectively.

Example 75:

2-[Bis(-2-hydroxyethyl)amino]-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide

To a solution of 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide (177 mg) in acetonitrile was added potassium carbonate (118 mg) and diethanolamine (65 µl). The mixture was stirred at room temperature. Water was added to the reaction mixture. Solution was extracted with ethyl acetate. Organic extract was dried and evaporated. 2-[Bis(2-hydroxyethyl)amino]-N-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide was purified by column chromatography using 10% methanol in methylenechloride as eluant. ^{1}H-NMR (400 MHz; d_6-DMSO) δ: 10.1 (s, 1H), 8.31 (d, 1H, J 2.7 Hz), 8.07 (dd, 1H, J 2.7, 8.8 Hz), 7.46-7.31 (m, 5H), 6.95 (d, 1H, J 8.8 Hz), 6.86-6.84 (m, 3H), 5.11 (dd, 1H, J 2.1, 10.0 Hz); 4.71 (t,

2H, J 5.4 Hz), 3.50 (q, 4H, J 5.4 Hz), 2.97-2.92 (m, 1H), 2.74-2.70 (m, 1H), 2.67 (t, 4H, J 5.4 Hz), 2.18-2.14 (m, 1H), 2.02-1.97 (m, 1H).

Using the same procedure as described above for 2-[bis(2-hydroxyethyl)-amino]-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide but replacing 2-chloro-*N*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide by an appropriate 2-chloro-*N*-(pyridin-3-yl)acetamide derivative listed in Example 60, there can be obtained:

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3-bromophenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(3-methyl-2-phenylchroman-6-yloxy)-pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(2-phenylchroman-7-yloxy)-pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydro-naphthalen-2-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-{6-[3-(3-fluorophenyl)chroman-7-yloxy]-pyridin-3-yl}acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(3-phenylchroman-7-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(4-oxo-2-phenylchromen-6-yloxy)pyridin-3-yl]acetamide,

2-[bis(2-hydroxyethyl)amino]-*N*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]acetamide, respectively.

Example 76:

2-[2-(3-(5-Nitropyridin-2-yloxy)phenyl)chroman-6-yloxy]-5-nitropyridine

a) 6-Hydroxy-2-(3-hydroxyphenyl)chroman-4-one

6-Hydroxy-2-(3-hydroxyphenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a) starting from 3-hydroxybenzaldehyde. The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.50 (bs, 1H), 9.41 (bs, 1H), 7.22-7.17 (m, 1H), 7.11 (d, 1H, J 3.0 Hz), 7.03 (dd, 1H J 3.0, 8.9 Hz), 6.64 (d, 1H, J 8.9 Hz), 6.92-6.90 (m, 2H), 6.76-6.73 (m, 1H), 5.46 (dd, 1H J 2.9, 12.7 Hz), 3.09 (dd, 1H, J 12.7, 16.9 Hz), 2.75 (dd, 1H, J 2.9, 16.9 Hz).

b) 2-(3-Hydroxyphenyl)chroman-4,6-diol

2-(3-Hydroxyphenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 6-hydroxy-2-(3-hydroxyphenyl)chroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.43 (bs, 1H), 8.88 (bs, 1H), 7.19-7.15 (m, 1H), 6.87 (d, 1H, J 2.7 Hz), 6.84-6.82 (m, 2H), 6.72-6.69 (m, 1H), 6.58 (d, 1H, J 8.7 Hz), 6.53 (dd, 1H, J 2.7, 8.7), 5.01 (d, 1H, J 11.3 Hz), 4.86 (dd, 1H, J 6.2, 10.8 Hz), 2.25-2.19 (m, 1H), 1.88-1.75 (m, 1H).

c) 2-(3-Hydroxyphenyl)chroman-6-ol

2-(3-Hydroxyphenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 2-(3-hydroxyphenyl)-chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.38 (s, 1H), 8.77 (s, 1H), 7.17-7.13 (m, 1H), 6.82-6.79 (m, 2H), 6.70-6.67 (m, 1H), 6.62 (d, 1H, J 8.6 Hz), 6.52-6.47 (m, 2H), 4.89 (dd, 1H, J 2.1, 9.9 Hz), 2.86-2.82 (m, 1H), 2.65-2.59 (m, 1H), 2.09-2.04 (m, 1H), 1.91-1.85 (m, 1H).

d) 2-[2-(3-(5-Nitropyridin-2-yloxy)phenyl)chroman-6-yloxy]-5-nitropyridine

2-[2-(3-(5-Nitropyridin-2-yloxy)phenyl)chroman-6-yloxy]-5-nitropyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in

Example 1 (b) starting from 2-(3-hydroxyphenyl)chroman-6-ol and using 210 mol-% of 2-chloro-5-nitropyridine. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.05 (d, 1H, J 2.9 Hz), 9.03 (d, 1H, J 2.9 Hz), 8.64 (dd, 1H, J 2.9, 9.1 Hz), 8.60 (dd, 1H, J 2.9, 9.1 Hz), 7.52 (t, 1H, J 7.8 Hz), 7.41 (d, 1H, J 7.8 Hz), 7.33-7.31 (m, 1H), 7.28 (d, 1H, J 7.8 Hz), 7.23-7.18 (m, 2H) 7.01-6.90 (m, 3H), 5.20 (dd, 1H, J 2.1, 10.1 Hz), 3.07-2.92 (m, 1H), 2.80-2.70 (m, 1H), 2.30-2.18 (m, 1H), 2.10-1.98 (m, 1H).

Example 77:

6-[2-(3-(5-Aminopyridin-2-yloxy)phenyl)chroman-6-yloxy]-pyridin-3-ylamine

6-[2-(3-(5-Aminopyridin-2-yloxy)phenyl)chroman-6-yloxy]-pyridin-3-yl-amine was prepared as described for 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in Example 35 starting from 2-[2-(3-(5-nitropyridin-2-yloxy)phenyl)chroman-6-yloxy]-5-nitropyridine. Product was isolated as its dihydrochloride salt. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.12 (m, 2H), 7.78 (m, 1H), 7.45 (t, 1H, J 7.8 Hz), 7.31 (d, 1H, J 7.2 Hz), 7.21 (s, 1H), 7.13-7.04 (m, 3H), 6.91-6.87 (m, 3H), 5.15 (d, 1H, J 9.8 Hz), 3.02-2.91 (m, 1H), 2.76-2.70 (m, 1H), 2.23-2.17 (m, 1H), 2.05-1.93 (m, 1H).

Example 78:

N-{6-[2-(3-(N-methanesulfonyl(5-aminopyridin-6-yloxy-))phenyl)chroman-6-yloxy]-pyridin-3-yl}-methanesulfonamide

Pyridine (620 µl) and methanesufonyl chloride (260 µl) were added into a cooled solution of 6-[2-(3-(5-aminopyridin-2-yloxy)phenyl)chroman-6-yloxy]-pyridin-3-ylamine (650 mg) in dry THF (11 ml). After stirring resulting mixture at room temperature for additional 2 hours 1 M hydrochloric acid was added. Solution was extracted with ethyl acetate. Combined organic layers were washed with water, dried with Na_2SO_4 and evaporated. *N*-{6-[2-(3-(*N*-methanesulfonyl(5-aminopyridin-6-yloxy-))phenyl)-chroman-6-yloxy]-pyridin-3-yl}methanesulfonamide was recrystallised from mixture of methanol and diethyl ether. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.74 (s, 1H), 9.67 (s, 1H), 8.02 (d, 1H, 2.7 Hz), 7.98 (d, 1H, J 2.7 Hz), 7.72 (dd, 1H, J 2.7, 8.8 Hz), 7.67 (dd, 1H, J 2.7, 8.8 Hz), 7.44 (t, 1H, J 7.8 Hz), 7.30 (d, 1H, 7.8 Hz), 7.20 (s, 1H), 7.09-7.05 (m, 2H), 6.97 (d, 1H, J 8.8 Hz), 6.89-6.85 (m, 3H), 5.14 (d, 1H J 8.5 Hz), 3.00 (s, 3H), 2.98 (m, 3H), 2.98-2.91 (m, 1H), 2.75-2.70 (m, 1H), 2.21-2.17 (m, 1H), 2.02-1.97 (m, 1H).

Example 79:

N-{6-[2-(3-(*N*-Acyl(5-aminopyridin-6-yloxy-))phenyl)chroman-6-yloxy]pyridin-3-yl}-acetamide

6-[2-(3-(5-Aminopyridin-2-yloxy)phenyl)chroman-6-yloxy]pyridin-3-ylamine of Example 77 (289 mg) was dissolved in 3 ml of dry pyridine under nitrogen. DMAP (16 mg) was added. AcCl (240 µl) was added at room temperature into the reaction solution dropwise because of vigorous and exothermic reaction. The reaction was stirred for 4.5 hours at room temperature and quenched with slow addition of few drops of H_2O. 50 ml of toluene was added and evaporated to dryness. Toluene evaporation was repeated twice. Brownish product mixture was purified with column chromatography (10% methanol in dichloromethane) to give of crystalline slightly yellowish product. The product was further purified with recrystallization from methanol/diethyl ether ^{1}H-NMR (400 MHz; $CDCl_3$) δ: 8.12-8.03 (m, 4H), 7.42-736 (m, 2H), 7.26-7.21 (m, 2H), 7.15 (s, 1H), 7.06 (dd, 1H, J 1.7, 8.0 Hz), 6.91-6.82 (m, 5H), 5.08 (dd, 1H, J 9.6, 2.3 Hz), 3.02-2.90 (m, 1H), 2.80-2.70 (m, 1H), 2.28-2.14 (m, 7H), 2.14-2.01 (m, 1H).

Example 80:

6-(5-Nitropyridin-2-yloxy)-2-[3-(5-nitropyridin-2-yloxy)phenyl]chroman-4-ol

6-(5-Nitropyridin-2-yloxy)-2-[3-(5-nitropyridin-2-yloxy)phenyl]chroman-4-ol was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1 (b) starting from 2-(3-hydroxyphenyl)chroman-4,6-diol and using 210 mol-% of 2-chloro-5-nitropyridine. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.06 (d, 1H, J 2.8 Hz), 9.03 (d, 1H, J 2.8 Hz), 8.64 (dd, 1H, J 2.8, 9.1 Hz), 8.61 (dd, 1H, J 2.8, 9.1 Hz), 7.54 (t, 1H, J 7.9 Hz), 7.43 (d, 1H, J 7.9 Hz), 7.36 (s, 1H), 7.30 (d, 1H, J 9.1 Hz), 7.25-7.21 (m, 3H) 7.01 (dd, 1H, J 2.9, 8.7 Hz), 6.89 (d, 1H, J 8.7 Hz), 5.67 (d, 1H, J 6.4 Hz), 5.36 (d, 1H, J 10.8 Hz), 5.01-4.95 (m, 1H), 2.41-2.36 (m, 1H), 2.02-1.92 (m, 1H).

Example 81:

6-(5-Aminopyridin-2-yloxy)-2-[3-(5-aminopyridin-2-yloxy)phenyl]chroman-4-ol

6-(5-Aminopyridin-2-yloxy)-2-[3-(5-aminopyridin-2-yloxy) phenyl]chroman-4-ol was prepared as described for 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in Example 35 starting from 6-(5-nitropyridin-2-yloxy)-2-[3-(5-nitropyridin-2-yloxy) phenyl]chroman-4-ol. Product was isolated as its dihydrochloride salt. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.15 (d, 2H, J 2.6 Hz), 7.82 (dd, 2H, J 2.6, 8.8 Hz), 7.47 (t, 1H, 7.9 Hz), 7.35 (d, 1H, J 7.9 Hz), 7.24 (s, 1H), 7.19-7.08 (m, 4H), 6.94 (dd, 1H, 2.8, 8.8 Hz), 6.84 (d, 1H, 8.8 Hz), 5.30 (d, 1H, J 10.9 Hz), 4.96 (dd, 1H, J 6.1, 10.7 Hz), 2.38-2.32 (m, 1H), 1.98-1.88 (m, 1H).

Example 82:

6-[(*N*-methanesulfonyl(5-aminopyridin-6-yloxy-)]-2-{3-[*N*-methanesulfonyl-(5-aminopyridin-6-yloxy-)]phenyl}chroman-4-ol

Pyridine (310 µl) and methanesulfonyl chloride (130 µl) were added into a cooled solution of 6-(5-aminopyridin-2-yloxy)-2-[3-(5-aminopyridin-2-yloxy) phenyl]-chroman-4-ol (342 mg) in dry THF (6 ml). After stirring resulting mixture at room temperature for an additional hour 1 M hydrochloric acid was added. Solution was extracted with ethyl acetate. Combined organic layers were dried with Na_2SO_4 and evaporated. 6-[(*N*-Methanesulfonyl(5-aminopyridin-6-yloxy-)]-2-{3-[*N*-methanesulfonyl(5-aminopyridin-6-yloxy-)]phenyl}chroman-4-ol was purified by column chromatography using 5% methanol in dichloromethane as eluant. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.73 (s, 1H), 9.66 (s, 1H), 8.03 (d, 1H, J 2.6 Hz), 7.99 (d, 1H, J 2.6 Hz), 7.71-7.66 (m, 2H), 7.45 (t, 1H, J 7.8 Hz), 7.32 (d, 1H, J 7.8 Hz), 7.22-6.80 (m, 7H), 5.29 (d, 1H J 11.5 Hz), 4.95 (dd, 1H, J 6.1, 10.5 Hz), 3.00 (s, 3H), 2.99 (s, 3H), 2.38-2.31 (m, 1H), 1.99-1.91 (m, 1H).

Example 83:

6-(5-Nitropyridin-2-yloxy)-2-[4-(5-nitropyridin-2-yloxy)phenyl]chroman-4-ol

a) 6-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one

6-Hydroxy-2-(4-hydroxyphenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 3(a) starting from 4-hydroxybenzaldehyde. The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.54 (bs, 1H), 9.38 (bs, 1H), 7.34-7.31 (m, 2H), 7.10 (d, 1H, J

3.0 Hz), 7.02 (dd, 1H J 3.0, 8.8 Hz), 6.91 (d, 1H, J 8.8 Hz), 6.80-6.77 (m, 2H), 5.40 (dd, 1H J 2.7, 13.1 Hz), 3.17 (dd, 1H, J 13.2, 16.9 Hz), 2.68 (dd, 1H, J 2.7, 16.9 Hz).

b) 2-(4-Hydroxyphenyl)chroman-4,6-diol

2-(4-Hydroxyphenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-diol in Example 2(b) starting from 6-hydroxy-2-(4-hydroxyphenyl)chroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.41 (bs, 1H), 8.79 (bs, 1H), 7.23-7.21 (m, 2H), 6.87 (s, 1H), 6.77-6.74 (m, 2H), 6.53 (m, 2H), 5.37 (d, 1H, J 7.0 Hz), 4.97 (d, 1H, J 11.6 Hz), 4.85-4.82 (m, 1H), 2.20-2.15 (m, 1H), 1.95-1.85 (m, 1H).

c) 6-(5-Nitropyridin-2-yloxy)-2-[4-(5-nitropyridin-2-yloxy)phenyl]chroman-4-ol

6-(5-Nitropyridin-2-yloxy)-2-[4-(5-nitropyridin-2-yloxy) phenyl]-chroman-4-ol was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1 (b) starting from 2-(4-hydroxyphenyl)chroman-4,6-diol and using 210 mol-% of 2-chloro-5-nitropyridine. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.05-9.04 (m, 2H, major & minor), 8.66-8.60 (m, 2H, major & minor), 7.61-7.58 (m, 2H, major & minor), 7.31-7.21 (m, 5H, major & minor), 7.10 (dd, 1 H, J 2.9, 8.8 Hz, minor), 7.03 (dd, 1H, J 3, 8.8 Hz, major), 6.97 (d, 1H, J 8.8 Hz, minor) 6.89 (d, 1H, J 8.8 Hz, major), 5.68 (d, 1H, J 6.4 Hz, major), 5.63 (d, 1H, J 4.7 Hz, minor), 5.37-5.30 (m, 1H, major & minor), 5.04-4.97 (m, 1H, major), 4.69-4.65 (m, 1H, minor), 2.41-2.36 (m, 1H, major), 2.21-2.15 (m, 2H, major&minor), 2.07-1.98 (m, 1H, major).

Example 84:

2-{2-[4-(5-Nitropyridin-2-yloxy)phenyl]chroman-6-yloxy}-5-nitropyridine

2-{2-[4-(5-Nitropyridin-2-yloxy)-phenyl]-chroman-6-yloxy}-5-nitropyridine was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 6-(5-nitropyridin-2-yloxy)-2-[4-(5-nitropyridin-2-yloxy) phenyl]-chroman-4-ol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.05 (d, 2H, J 2.9 Hz), 8.65-8.58 (m, 2H), 7.58-7.55 (m, 2H), 7.30-7.26 (m, 3H), 7.20 (d, 1H, J 9.1 Hz), 7.03-6.91 (m, 3H) 5.20 (dd, 1H, J 2.0, 10.1 Hz), 3.06-2.97 (m, 1H), 2.81-2.75 (m, 1H), 2.26-2.21 (m, 1H), 2.11-2.02 (m, 1H).

Example 85:

N-(6-{2-[3-(5-Nitropyridin-2-yloxy)phenyl]chroman-6-yloxy}pyridin-3-yl)-methanesulfonamide

a) 6-Hydroxy-2-(3-benzyloxyphenyl)chroman-4-one

6-Hydroxy-2-(3-benzyloxyphenyl)chroman-4-one was prepared as described for 6-hydroxy-2-(4-fluorophenyl)chroman-4-one in Example 2(a) starting from 3-benzyloxybenzaldehyde. The product was recrystallised from ethanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.41 (bs, 1H), 7.50-7.30 (m, 6H), 7.20 (s, 1H), 7.12-7.08 (m, 2H), 7.05-7.00 (m, 2H), 6.95 (d, 1H, J 8.9 Hz), 5.52 (dd, 1H J 2.9, 12.9 Hz), 5.12 (s, 2H), 3.16 (dd, 1H, J 12.9, 16.9 Hz), 2.78(dd, 1H, J 2.9, 16.9 Hz).

b) 2-(3-Benzyloxyphenyl)chroman-4,6-diol

2-(3-Benzyloxyphenyl)chroman-4,6-diol was prepared as described for 2-(4-fluorophenyl)chroman-4,6-iol in Example 2(b) starting from 6-hydroxy-2-(3-benzyloxyphenyl)chroman-4-one. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.81 (bs, 1H), 7.47-7.28 (m, 6H), 7.09 (s, 1H), 7.02 (d, 1H, J 7.9 Hz), 6.97 (dd, 1H, J 2.4, 7.9 Hz), 6.88 (d, 1H, J 2.8 Hz), 6.59 (d, 1H, J 8.7 Hz), 6.54 (dd, 1H, J 2.8, 8.7 Hz), 5.40 (d, 1H, J 6.2 Hz), 5.12 (s, 2H), 5.08 (d, 1H, J 10.9 Hz), 4.88-4.85 (m, 1H), 2.28-2.23 (m, 1H), 1.92-1.77 (m, 1H).

c) 2-(3-Benzyloxyphenyl)chroman-6-ol

2-(3-Benzyloxyphenyl)chroman-6-ol was prepared as described for 2-(4-fluorophenyl)chroman-6-ol in Example 2(c) starting from 2-(3-Benzyloxyphenyl)-chroman-4,6-diol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.77 (s, 1H), 7.46-7.26 (m, 6H), 7.06 (s, 1H), 7.00-6.93 (m, 2H), 6.63 (d, 1H, J 8.5 Hz), 6.52-6.47 (m, 2H), 5.10 (s, 2H), 4.96 (dd, 1H, J 1.8, 9.8 Hz), 2.91-2.82 (m, 1H), 2.67-2.59 (m, 1H), 2.12-2.07 (m, 1H), 1.99-1.87 (m, 1H).

d) 5-Nitro-2-[2-(3-benzyloxyphenyl)chroman-6-yloxy]pyridine

5-Nitro-2-[2-(3-benzyloxyphenyl)chroman-6-yloxy]pyridine was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine in Example 1 (b) starting from 2-(3-benzyloxyphenyl)chroman-6-ol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.03 (d, 1H, J 2.9 Hz), 8.59 (dd, 1H, J 2.9, 9.1 Hz), 7.47-7.29 (m, 6H), 7.19 (d, 1H, J 9.1 Hz), 7.10 (s, 1H), 7.05-6.92 (m, 5H), 5.14-5.10 (m, 3H), 3.00-2.88 (m, 1H), 2.75-2.69 (m, 1H), 2.20-2.14 (m, 1H), 2.07-1.95 (m, 1H).

e) 3-[6-(5-Aminopyridin-2-yloxy)chroman-2-yl]phenol

2.15 g of 5-nitro-2-[2-(3-benzyloxyphenyl)chroman-6-yloxy]pyridine was dissolved to 600 ml of ethanol and 430 mg g of 10% palladium on charcoal was added under inert atmosphere. Starting material was hydrogenated at room temperature to give quantitative yield of 3-[6-(5-aminopyridin-2-yloxy)chroman-2-yl]phenol ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.50 (bs, 1H), 7.52 (d, 1H, J 3.0 Hz), 7.17 (t, 1H, J 8.1 Hz), 7.05 (dd, 1H, J 3.0, 8.6 Hz), 6.84-6.68 (m, 7H), 5.01-4.99 (m, 3H), 2.91-2.86 (m, 1H), 2.70-2.63 (m, 1H), 2.14-2.08 (m, 1H), 1.96-1.89 (m, 1H).

f) *N*-{6-[2-(3-Hydroxyphenyl)chroman-6-yloxy]pyridin-3-yl}methanesulfonamide

Pyridine (310 µl) and methanesufonyl chloride (130 µl) were added into a cooled solution of 3-[6-(5-Aminopyridin-2-yloxy)chroman-2-yl]phenol (520 mg) in dry THF (21 ml). After stirring resulting mixture at room temperature for additional 4 hours 1 M hydrochloric acid was added. Solution was extracted with ethyl acetate. Combined organic layers were dried with Na_2SO_4 and evaporated. *N*-{6-[2-(3-Hydroxyphenyl) chroman-6-yloxy]pyridin-3-yl}methanesulfonamide was purified by column chromatography using 5% methanol in methylene chloride. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.42 (s, 1H), 7.98 (d, 1H, J 2.8 Hz), 7.66 (dd, 1H, J 2.8, 8.8 Hz), 7.18 (t, 1H, J 8.0 Hz), 6.97 (d, 1H, J 8.8 Hz), 6.88-6.83 (m, 5H), 6.73-6.69 (m, 1H), 5.03 (dd, 1H J 2.1, 9.9 Hz), 2.98 (s, 3H), 2.98-2.90 (m, 1H), 2.72-2.67 (m, 1H), 2.16-2.11 (m, 1H), 1.98-1.91 (m, 1H).

g) *N*-(6-{2-[3-(5-Nitropyridin-2-yloxy)phenyl]chroman-6-yloxy}pyridin-3-yl)-methanesulfonamide

Potassium fluoride (42 mg) was added into a solution of *N*-{6-[2-(3-hydroxyphenyl)chroman-6-yloxy]pyridin-3-yl}methanesulfonamide (100 mg) in dry DMF (1 ml). After stirring the resulting mixture at 120°C for 30 minutes 2-chloro-5-nitropyridine (40 mg) was added. The reaction mixture was stirred for a further 30 minutes at 120°C. After cooling into room temperature 1 M HCl-solution was added and formed precipitate was filtered. *N*-(6-{2-[3-(5-Nitropyridin-2-yloxy)phenyl]-chroman-6-yloxy}pyridin-3-yl) methanesulfonamide was purified by column chromatography using 1:1 mixture of ethyl acetate and heptane as eluant. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.64 (s, 1H), 9.04 (d, 1H, J 2.9 Hz), 8.63 (dd, 1H, J 2.9, 9.1 Hz), 7.98 (d, 1H, J 2.7 Hz), 7.66 (dd, 1H, J 2.7, 8.8 Hz), 7.52 (t, 1H, J 7.7 Hz), 7.39 (d, 1H, J 7.7 Hz), 7.31 (s, 1H), 7.27 (d, 1H, J 9.1 Hz), 7.22-7.19 (m, 1H), 6.96 (d, 1H, J 8.8 Hz), 6.89-6.85 (m, 3H), 5.17 (d, 1H, J 7.8 Hz), 2.97 (s, 3H), 2.98-2.92 (m, 1H), 2.76-2.69 (m, 1H) 2.28-2.19 (m, 1H), 2.02-1.97 (m, 1H).

Example 86:

N-{6-[2-(3-Benzyloxyphenyl)chroman-6-yloxy]pyridin-3-yl}methanesulfonamide

a) 6-[2-(3-Benzyloxyphenyl)chroman-6-yloxy]pyridin-3-ylamine

6-[2-(3-Benzyloxyphenyl)chroman-6-yloxy]pyridin-3-ylamine was prepared as described for 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in Example 35 starting from 5-nitro-2-[2-(3-benzyloxyphenyl)chroman-6-yloxy]pyridine. Product was isolated as its hydrochloride salt. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 7.85 (s, 1H), 7.47-7.29 (m, 6H), 7.09 (s, 1H), 7.02 (d, 1H, J 7.4 Hz), 6.98 (dd, 1H, J 2.3, 8.2 Hz), 6.91 (d, 1H, J 8.7 Hz), 6.85-6.81 (m, 4H), 5.12 (s, 2H), 5.09 (d, 1H, J 9.5 Hz), 2.96-2.89 (m, 1H), 2.72-2.67 (m, 1H) 2.20-2.14 (m, 1H), 2.03-1.97 (m, 1H).

b) *N*-{6-[2-(3-Benzyloxyphenyl)chroman-6-yloxy]pyridin-3-yl}methanesulfonamide

N-{6-[2-(3-Benzyloxyphenyl)chroman-6-yloxy]pyridin-3-yl}methanesulfonamide was prepared as described for *N*-{6-[2-(3-hydroxyphenyl)chroman-6-yloxy]-pyridin-3-yl}methanesulfonamide in Example 85 (f) starting from 6-[2-(3-benzyloxyphenyl)chroman-6-yloxy]pyridin-3-ylamine. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 9.64 (s, 1H), 7.98 (d, 1H, J 2.8 Hz), 7.66 (dd, 1H, J 2.8, 8.9 Hz), 7.47-7.28 (m, 6H), 7.09

(s, 1H), 7.04-6.94 (m, 3H), 6.89-6.85 (m, 3H), 5.12 (s, 2H), 5.09 (dd, 1H, J 2.1, 12.0 Hz), 2.98 (s, 3H), 2.98-2.89 (m, 1H), 2.73-2.67 (m, 1H) 2.20-2.14 (m, 1H), 2.02-1.96 (m, 1H).

Example 87:

N-Methyl-*N'*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]guanidine

a) 1-Methyl-3-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]thiourea

Solution of 6-(2-phenylchroman-6-yloxy)pyridin-3-ylamine (150 mg) and methyl isothiocyanate (94 µl) in ethanol was refluxed for 10 hours. After cooling solvents were evaporated. Crude product of 1-methyl-3-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]thiourea was purified by column chromatography (5% methanol in dichloromethane). ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.45 (bs, 1H), 8.02 (d, 1H, J 2.7 Hz), 7.81 (dd, 1H, J 2.7, 8.8 Hz), 7.70 (bs, 1H), 7.47-7.38 (m, 4H), 7.36-7.32 (m, 1H), 6.94-6.86 (m, 4H), 5.12 (dd, 1H J 2.3, 10.1 Hz), 2.98-2.93 (m, 1H), 2.90 (d, 3H, J 4.3 Hz), 2.76-2.71 (m, 1H), 2.19-2.15 (m, 1H), 2.15-1.99 (m, 1H).

b) *N*-Methyl-*N'*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]guanidine

Solution of 1-methyl-3-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]thiourea (150 mg), methyliodide (36 µl) and acetone (15 ml) was refluxed for 90 minutes. Solvent was evaporated and residue was dissolved to 4 ml of methanol saturated with NH_3. Mixture was heated under preasure at 100°C for 16 hours. Solvent was evaporated and residue was purified by column chromatography using 10% methanol in dichloromethane as eluant. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 9.35 (bs, 1H), 8.04 (d, 1H, J 2.7 Hz), 7.71 (dd, 1H, J 2.7, 8.8 Hz), 7.65 (bs, 1H), 7.47-7.34 (m, 5H), 7.05 (d, 1H, J 8.8 Hz), 6.90-6.88 (m, 3H), 5.13 (d, 1H J 7.9 Hz), 3.01-2.98 (m, 1H), 2.80 (d, 3H, J 4.4 Hz), 2.75-2.71 (m, 1H), 2.19-2.15 (m, 1H), 2.02-1.98 (m, 1H).

Using the same procedure as described above for *N*-Methyl-*N'*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]guanidine in steps a) and b) but replacing 5-amino-2-(2-phenylchroman-6-yloxy)pyridine in step a) by an appropriate pyridin-3-ylamine-derivative listed in Example 53, there can be obtained:

N-Methyl-*N'*-{6-[2-(4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2,3-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2,6-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(3,4-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(3,5-difluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(3-chlorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(3-bromophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-{6-[2-(4-ethylphenyl)chroman-6-yloxy]pyridin-3-yl}succinamic acid,

N-Methyl-*N'*-{6-[2-(3-methoxyphenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid,

N-Methyl-*N'*-[6-(3-methyl-2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(2-phenylchroman-7-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(4-oxo-2-phenylchroman-7-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(3-methyl-4-oxo-2-phenylchroman-6-yloxy)pyridin-3-yl]-succinamic acid,

N-Methyl-*N'*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(5-oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)-pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-{6-[2-(3-fluorophenyl)chroman-6-yloxy]pyridin-3-yl}-succinamic acid

N-Methyl-*N'*-[6-(2-phenylchroman-6-yloxy)pyridin-3-yl]succinamic acid,

N-Methyl-*N'*-[6-(4-oxo-2-phenyl-4*H*-chromen-6-yloxy)pyridin-3-yl]-succinamic acid,

N-Methyl-*N'*-[6-(2-phenylindan-5-yloxy)pyridin-3-yl]succinamic acid, respectively.

Example 88:

5-Chloro-2-(2-phenylchroman-6-yloxy)pyridine

2-Phenylchroman-6-ol (500 mg) was dissolved in dry DMF (5 ml) under nitrogen. Potassium *tert*-butoxide (270 mg) was added in to a sloution and the resulting mixture was stirred for 30 minutes. 2,5-Dichloropyridine was added and the mixture was stirred at 120°C for 2,5 hours. The reaction mixture was allowed to cool to room temperature and 1 M HCl-solution was added and it was extracted with ethyl acetate. The combined organic phases were washed with water and saturated NaCl-solution and dried. The raw product was passed silica gel column using heptane-ethyl acetate (3:1) as an eluant and then recrystallised 2-propanol. ^{1}H NMR (300 MHz, d_6-DMSO) δ: 8.19 (d, 1H, J 2.6 Hz), 7.92 (dd, 1H, 8.8, 2.6 Hz), 7.47-7.34 (m,

5H), 7.02 (d, 1H, J 8.8 Hz) 6.92-6.87 (m, 3H), 5.12 (dd, 1H, J 10.0, 2.1 Hz), 2.97 (m, 1H), 2.73 (m, 1H), 2.17 (m, 1H), 2.01 (m, 1H).

Using the same procedure as described above for 5-Chloro-2-(2-phenyl-chroman-6-yloxy)pyridine, but replacing 2-phenylchroman-6-ol by:

2-(4-Fluorophenyl)chroman-6-ol,
2-(3-fluorophenyl)chroman-6-ol,
2-(2-Fluorophenyl)chroman-6-ol,
2-(2,3-Difluorophenyl)chroman-6-ol,
2-(2,4-Difluorophenyl)chroman-6-ol,
2-(2,5-Difluorophenyl)chroman-6-ol,
2-(2,6-Difluorophenyl)chroman-6-ol,
2-(3,4-Difluorophenyl)chroman-6-ol,
2-(3,5-Difluorophenyl)chroman-6-ol,
2-(2-Trifluoromethylphenyl)chroman-6-ol,
2-(4-Trifluoromethylphenyl)chroman-6-ol,
2-(3-Chloro-4-fluorophenyl)chroman-6-ol,
2-(2-Chlorophenyl)chroman-6-ol,
2-(3-Chlorophenyl)chroman-6-ol,
2-(2,4-Dichlorophenyl)chroman-6-ol,
2-(3-Bromophenyl)chroman-6-ol,
2-(4-Ethylphenyl)chroman-6-ol,
2-(3-Methoxyphenyl)chroman-6-ol,
3-Methyl-2-phenylchroman-6-ol,
2-phenylchroman-7-ol,
6-hydroxyflavanone,
7-hydroxyflavanone,
6-Hydroxy-3-methyl-2-phenylchroman-4-one,
2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-ol,
6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-ol,
6-Hydroxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one,
2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-ol,
3-(3-Fluorophenyl)chroman-7-ol,
3-Phenylchroman-7-ol,
6-Hydroxyflavone,
2-Phenylindan-5-ol,

2-(3-hydroxyphenyl)chroman-6-ol,
there can be obtained

5-Chloro-2-[2-(4-fluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3-fluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2-fluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2,3-difluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2,4-difluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2,5-difluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2,6-difluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3,4-difluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3,5-difluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2-trifluoromethylphenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(4-trifluoromethylphenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2-chlorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3-chlorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(2,4-dichlorophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3-bromophenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(4-ethylphenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-[2-(3-methoxyphenyl)chroman-6-yloxy]pyridine,
5-Chloro-2-(3-methyl-2-phenylchroman-6-yloxy)pyridine,
5-Chloro-2-(2-phenylchroman-7-yloxy)pyridine,
6-(5-Chloropyridin-2-yloxy)-2-phenylchroman-4-one,
7-(5-Chloropyridin-2-yloxy)-2-phenylchroman-4-one,
6-(5-Chloropyridin-2-yloxy)-3-methyl-2-phenylchroman-4-one,
5-Chloro-2-(2-phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)pyridine,
5-Chloro-2-(6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)pyridine,
6-(5-Chloropyridin-2-yloxy)-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one,
5-Chloro-2-(2-phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)pyridine,
5-Chloro-2-[3-(3-fluorophenyl)chroman-7-yloxy]pyridine,
5-Chloro-2-(3-phenylchroman-7-yloxy)pyridine,
6-(5-Chloropyridin-2-yloxy)-2-phenylchromen-4-one,
5-Chloro-2-(2-phenylindan-5-yloxy)pyridine,
2-[2-(3-(5-Chloropyridin-2-yloxy)-phenyl)chroman-6-yloxy]-5 chloropyridine, respectively.

Example 89:

6-(2-Phenylchroman-6-yloxy)nicotinonitrile

6-(2-Phenylchroman-6-yloxy)nicotinonitrile was prepared as described for 5-nitro-2-(2-phenylchroman-6-yloxy)pyridine using 500 mg of 2-phenylchroman-6-ol and replacing 2-chloro-5-nitropyridine by 337 mg of 6-chloronicotinonitrile. The product was purified by column chromatography using heptane-ethyl acetate as an eluant and then crystallised from 2-propanol. ^{1}H NMR (400 MHz, d_6-DMSO) δ: 8.65 (d, 1H, J 2.4 Hz), 8.28 (dd, 1H, 8.8, 2.4 Hz), 7.47-7.34 (m, 5H), 7.17 (d, 1H, J 8.8 Hz) 6.96-6.87 (m, 3H), 5.14 (dd, 1H, J 10.1, 2.2 Hz), 2.99 (m, 1H), 2.73 (m, 1H), 2.18 (m, 1H), 2.00 (m, 1H).

Using the same procedure as described above for 6-(2-Phenylchroman-6-yloxy)nicotinonitrile, but replacing 2-phenylchroman-6-ol by:

2-(4-Fluorophenyl)chroman-6-ol,
2-(3-fluorophenyl)chroman-6-ol,
2-(2-Fluorophenyl)chroman-6-ol,
2-(2,3-Difluorophenyl)chroman-6-ol,
2-(2,4-Difluorophenyl)chroman-6-ol,
2-(2,5-Difluorophenyl)chroman-6-ol,
2-(2,6-Difluorophenyl)chroman-6-ol,
2-(3,4-Difluorophenyl)chroman-6-ol,
2-(3,5-Difluorophenyl)chroman-6-ol,
2-(2-Trifluoromethylphenyl)chroman-6-ol,
2-(4-Trifluoromethylphenyl)chroman-6-ol,
2-(3-Chloro-4-fluorophenyl)chroman-6-ol,
2-(2-Chlorophenyl)chroman-6-ol,
2-(3-Chlorophenyl)chroman-6-ol,
2-(2,4-Dichlorophenyl)chroman-6-ol,
2-(3-Bromophenyl)chroman-6-ol,
2-(4-Ethylphenyl)chroman-6-ol,
2-(3-Methoxyphenyl)chroman-6-ol,
3-Methyl-2-phenylchroman-6-ol,
2-phenylchroman-7-ol,
6-hydroxyflavanone,

7-hydroxyflavanone,
6-Hydroxy-3-methyl-2-phenylchroman-4-one,
2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-ol,
6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-ol,
6-Hydroxy-2-phenyl-3,4-dihydro-2*H*-naphthalen-1-one,
2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-ol,
3-(3-Fluorophenyl)chroman-7-ol,
3-Phenylchroman-7-ol,
6-Hydroxyflavone,
2-Phenylindan-5-ol,
2-(3-Hydroxyphenyl)chroman-6-ol,
2-(3-Hydroxyphenyl)chroman-4,6-diol,
2-(4-Hydroxyphenyl)chroman-4,6-diol,

there can be obtained

6-[2-(4-Fluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3-Fluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2-Fluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2,3-Difluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2,4-Difluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2,5-Difluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2,6-Difluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3,4-Difluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3,5-Difluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2-Trifluoromethylphenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(4-Trifluoromethylphenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3-chloro-4-fluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2-chlorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3-chlorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(2,4-dichlorophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3-bromophenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(4-ethylphenyl)chroman-6-yloxy]nicotinonitrile,
6-[2-(3-methoxyphenyl)chroman-6-yloxy]nicotinonitrile,
6-(3-Methyl-2-phenylchroman-6-yloxy]nicotinonitrile,
6-(2-phenylchroman-7-yloxy)nicotinonitrile,
6-(4-Oxo-2-phenylchroman-6-yloxy)nicotinonitrile,

6-(4-Oxo-2-phenylchroman-7-yloxy)nicotinonitrile,
6-(3-Methyl-4-oxo-2-phenylchroman-6-yloxy)nicotinonitrile,
6-(2-Phenyl-2,3-dihydrobenzo[1,4]dioxin-6-yloxy)nicotinonitrile,
6-(6-Phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)nicotinonitrile,
6-(5-Oxo-6-phenyl-5,6,7,8-tetrahydronaphthalen-2-yloxy)nicotinonitrile,
6-(2-Phenyl-2,3-dihydrobenzo[1,4]oxathiin-6-yloxy)nicotinonitrile,
6-[2-(3-Fluorophenyl)chroman-6-yloxy]nicotinonitrile,
6-(2-Phenylchroman-6-yloxy)nicotinonitrile,
6-(4-Oxo-2-phenyl-4*H*-chromen-6-yloxy)nicotinonitrile,
6-(2-Phenylindan-5-yloxy)nicotinonitrile,
2-[2-(3-(5-Cyanopyridin-2-yloxy)phenyl)chroman-6-yloxy]-5-cyanopyridine,
6-(5-Cyanopyridin-2-yloxy)-2-[3-(5-cyanopyridin-2-yloxy)phenyl]chroman-4-ol,
6-(5-Cyanopyridin-2-yloxy)-2-[4-(5-cyanopyridin-2-yloxy)phenyl]chroman-4-ol, respectively.

Claims

1. Compounds of formula (I) or (II):



(I)



(II)

wherein

X is -O-, $-CH_2-$ or -C(O)-;

Z is $-CHR_{12}-$ or valence bond;

Y is $-CH_2-$, -C(O)-, $CH(OR_{13})-$, -O-, -S-;

provided that in case Z is a valence bond, Y is not C(O);

the dashed line represents an optional double bond in which case Z is $-CR_{12}-$ and Y is

$-CH_2-$, -C(O)- or $CH(OR_{10})-$ (in formula II) or

-CH- (in formula I);

R_2 and R_3 are independently H, lower alkyl, lower alkoxy, $-NO_2$, halogen, $-CF_3$, -OH, benzyloxy or a group of formula (IIIa)



(IIIa)

R_1 is H, CN, halogen, $-CONH_2$, -COOH, $-CH_2NH_2$, $NHC(O)R_5$, $NHC(NH)NHCH_3$ or, in case the compound is of formula (II) wherein the optional double bond exists or in case R_2 or R_3 is benzyloxy or a group of formula (IIIa), R_1 can also be $-NO_2$ or $NR_{16}R_{17}$;

R_4 is H, $-NO_2$, CN, halogen, $-CONH_2$, -COOH, $-CH_2NH_2$, $-NR_{16}R_{17}$, $-NHC(O)R_5$ or $-NHC(NH)NHCH_3$;

R_5 is lower halogenalkyl, lower carboxylalkyl, $-CHR_6NR_7R_8$, or one of the following groups



W is N or CH;

Q is CHR_{14}, NR_9, S or O;

R_6 is H or lower alkyl;

R_7 and R_8 are independently H, acyl, lower alkyl or lower hydroxyalkyl;

R_9 is H, lower alkyl or phenyl;

R_{10} and R_{11} are independently H or lower alkyl;

R_{12} is H or lower alkyl;

R_{13} is H, alkylsulfonyl or acyl;

R_{14} is H, -OH, $-COOR_{15}$;

R_{15} is H or lower alkyl;

R_{16} and R_{17} are independently H, acyl, alkylsulfonyl, $-C(S)NHR_{18}$ or $-C(O)NHR_{18}$;

R_{18} is H or lower alkyl

and pharmaceutically acceptable salts and esters thereof.

2. A compound according to claim 1 wherein R_1 is $-NHC(O)R_5$, X is O, Y is CH_2 and Z is CHR_{12}.

3. A compound according to claim 2 wherein Z is CH_2 and R_5 is $-CHR_6NR_7R_8$ or one of the following groups:



4. A compound according to claim 1 wherein R_2 or R_3 is a benzyloxy or a group of formula (IIIa)



(IIIa)

5. A compound according to claim 4 wherein R_4 is NO_2.

6. A compound according to claim 4 or 5 wherein R_1 is NO_2

7. A pharmaceutical composition comprising a compound of claim 1 together with a pharmaceutically acceptable carrier.

8. A method for inhibiting Na^+/Ca^{2+} exchange mechanism in a cell, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

9. A method for treating arrhythmias, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

ABSTRACT

Therapeutically active compounds of formula (I) or (II):



(I)



(II)

wherein X is -O-, $-CH_2-$ or -C(O)-; Z is $-CHR_{12}-$ or a valence bond; Y is $-CH_2-$, -C(O)-, $CH(OR_{13})-$, -O-, -S-; provided that in case Z is a valence bond, Y is not C(O); the dashed line representing an optional double bond in which case Z is $-CR_{12}-$ and Y is $-CH_2-$, -C(O)- or $-CH(OR_{10})-$ (in formula II) or -CH- (in formula I); R_2 and R_3 are independently H, lower alkyl, lower alkoxy, $-NO_2$, halogen, $-CF_3$, -OH, benzyloxy or a group of formula (IIIa)



(IIIa)

R_1 is H, CN, halogen, $-CONH_2$, -COOH, $-CH_2NH_2$, $-NHC(O)R_5$, $-NHC(NH)NHCH_3$ or, in case the compound is of formula (II) wherein the optional double bond exists or in case R_2 or R_3 is benzyloxy or a group of formula (IIIa), R_1 can also be $-NO_2$ or $-NR_{16}R_{17}$; R_4 is H, $-NO_2$, CN, halogen, $-CONH_2$, -COOH, $-CH_2NH_2$, $-NR_{16}R_{17}$, $-NHC(O)R_5$ or $-NHC(NH)NHCH_3$; R_5 is lower halogenalkyl, lower carboxylalkyl, $-CHR_6NR_7R_8$, or one of the following groups



W is N or CH; Q is CHR_{14}, NR_9, S or O; R_6 is H or lower alkyl; R_7 and R_8 are independently H, acyl, lower alkyl or lower hydroxyalkyl; R_9 is H, lower alkyl or phenyl; R_{10} and R_{11} are independently H or lower alkyl; R_{12} is H or lower alkyl; R_{13} is H, alkylsulfonyl or acyl; R_{14} is H, -OH, $-COOR_{15}$; R_{15} is H or lower alkyl; R_{16} and R_{17} are independently H, acyl, alkylsulfonyl, $-C(S)NHR_{18}$ or $-C(O)NHR_{18}$;

R_{18} is H or lower alkyl and pharmaceutically acceptable salts and esters thereof. The compounds are potent inhibitors of Na^+/Ca^{2+} exchange mechanism.

L7


Vehicle
Example 76
Example 61
Example 80
Example 83
Start of Fast Rise in ACs, min
40
30
20
10
0
INHIBITED COMPLETELY
AC1
AC2
Aftercontraction

Fig. 1


Vehicle
Example 76
Example 61
Example 80
Example 83
Maximum height, mg
150
125
100
75
50
25
0
INHIBITED COMPLETELY
AC1
AC2
Aftercontraction

Fig. 2


Vehicle
Example 76
Example 61
Example 80
Example 83
Time to Maximum Height of ACs, min
50
40
30
20
10
0
INHIBITED COMPLETELY
AC1
AC2
Aftercontraction

Fig. 3

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- [x] BLACK BORDERS
- [ ] IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- [ ] FADED TEXT OR DRAWING
- [x] BLURED OR ILLEGIBLE TEXT OR DRAWING
- [x] SKEWED/SLANTED IMAGES
- [ ] COLORED OR BLACK AND WHITE PHOTOGRAPHS
- [ ] GRAY SCALE DOCUMENTS
- [ ] LINES OR MARKS ON ORIGINAL DOCUMENT
- [x] REPERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- [ ] OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning documents *will not* correct images problems checked, please do not report the problems to the IFW Image Problem Mailbox